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Gliomas are extremely heterogeneous, both morphologically and biologically, 
which contributes to a very poor prognosis. Current imaging of glioma is insufficient 
for a thorough diagnosis, therapy assessment and prognosis prediction. Moreover, 
refined and more sophisticated imaging technique could help in furthering our 
knowledge of gliomas. 
In order to facilitate proliferation, cancer cells undergo a change in structure 
and an increase in metabolism that results in distortion and disruption of tissue 
architecture. Gliomas are characterised by an increase in cells of variable sizes, as 
well as changes in the tissue microstructure. Diffusion-Weighted Imaging (DWI) and 
the apparent diffusion coefficient (ADC), have been extensively studied as potential 
imaging biomarkers for cellularity and tissue architecture. However, several studies 
have shown partial overlap in the measured values between tumour subtypes. 
Moreover, ADC is influenced by several factors and does not provide detailed 
information on the tissue microstructure. The Vascular, Extracellular and Restricted 
Diffusion for Cytometry in Tumours (VERDICT) is a novel diffusion model that infers 
tissue microstructure compartment from conventional DWI measurements. This 
model derives metrics for the intracellular, intravascular and extracellular–
extravascular spaces providing a more detailed interpretation of the tissue 
microstructure. To date, VERDICT has been applied to xenograft models of colorectal 
cancer, patient studies of prostate cancer and recently its feasibility in glioma has 
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to image intratumoral and intertumoral heterogeneity in glioma. The results have 
also been validated with histology as part of a prospective study. 
Gliomas also exhibit a significant increase in mitotic activity within the 
tumour. The increased number of mitosis alters cell density which, in turn, affects 
the total concentration of tissue sodium as the concentration of tissue sodium is 
approximately ten-fold higher in the extracellular compared to the intracellular 
space. In addition, there is a decrease in Na+/K+-ATPase activity in tumours due to 
ATP depletion, which contributes to disturb sodium homeostasis. Non-invasive 
detection of 23Na with MRI has the potential to quantify sodium concentration and 
therefore could be an imaging probe of cell morphology and membrane function 
within the tumour microenvironment, as well as a method of probing tissue 
heterogeneity. During my PhD, a novel 23Na-MRI technique has been used to 
evaluate sodium distribution within glioma and in the surrounding tissue. 
Metabolic reprogramming is one of the major driving forces for determining 
glioma growth and invasion. Therefore, the non-invasive characterization of 
metabolic intratumoral, peritumoral and intertumoral heterogeneity in vivo could 
help to better stratify patients and to develop novel therapeutic strategies targeting 
cancer-specific metabolic pathways. 13C magnetic resonance imaging (MRI) using 
dynamic nuclear polarization (DNP) is a novel technique that allows non-invasive 
assessment of the metabolism of hyperpolarized (HP) 13C-labelled molecules in vivo, 
such as the exchange of [1-13C]pyruvate to [1-13C]lactate in tumours (Warburg 
effect). Part of my PhD has focused on developing and translating HP [1-13C]pyruvate 
MRI to explore metabolic reprogramming in glioma and the surrounding 
microenvironment. 
The overall aim of my PhD has been to develop novel approaches to imaging 
glioma with MRI to probe both the architectural and metabolic changes of Glioma. 
The preliminary evidence suggests that these tools can more deeply phenotype 
tumours than conventional imaging approaches. Although the main focus of this 
work has been gliomas, the techniques developed and presented here may be 
applied to study other pathological conditions within the brain, which raises the 
possibility of other potential clinical applications for this work. 
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Tumours have traditionally been defined as abnormal masses of tissue 
that begin when cells in a part of the body proliferate uncontrollably or fail to 
undergo normal cell death and become immortalised (American Cancer 
Society, 2011). The uncontrolled proliferation of abnormal cells is one of the 
commonest shared feature of all tumours and has been considered a hallmark 
of cancer (Hanahan and Weinberg, 2000).  
The simplest tumour classification systems are based on histological 
aggressiveness. Tumours can be benign (non-cancerous), pre-malignant 
(pre-cancerous), or malignant (cancerous). Tumours are also commonly 
labelled as neoplasms: this word derives from the Ancient Greek words neo, 
that means "new", and plasma, that means "formation”, expressing the 
concept that a tumour is a new formation, which is usually aberrant. Similarly, 
the word “cancer” derives from the crab-like nature of cancer that was 
described by the Greeks around 200 B.C. (David and Zimmerman, 2010). 
Hippocrates, the “Father of Medicine”, used the words carcinos (crab) and 
carcinoma in the Hippocratic Corpus to describe a range of swelling that 
represented tumours. Recent evidence has demonstrated the presence of 
cancer lesions in mummies, fossils and preserved bodies over a period of 
several millennia. As an example, a recent CT scan of a Ptolemaic mummy 
demonstrated osteoblastic metastatic disease (figure 1.1) secondary to 
prostate cancer (Prates et al., 2011). 
Today the most common tumours are lung, breast, prostate and 
colorectal cancers (Stewart and Wild, 2014). Cancer survival is continuing to 
increase over the past few decades. However, there are worldwide disparities 
in cancer incidence and survival which are still significant even within high-
income countries (Arnold et al., 2019). Overall, cancer is the major cause of 




morbidity and mortality with approximately 8 million cancer-related deaths 
worldwide in 2012 according to the last cancer report produced by the World 
Health Organization (WHO) in 2014 (Stewart and Wild, 2014). Interestingly, 
although the report also highlighted a remarkable difference in cancer 
distribution across the globe, the differences in mortality are less marked 
(Stewart and Wild, 2014). This heterogeneity in cancer prevalence and 
	
 
Figure 1.1: Egyptian Ptolemaic mummy. 
Left: X-ray digital extended-view of the upper body, showing the crossed 
arms mummification position and extensive post-mortem bone fractures.  
Right: MDCT MPR (sagittal) of the lumbar spine, showing sclerotic 
vertebral bone lesions. 
From: Prates et al., 2011.  
	
100 C. Prates et al. / International Journal of Paleopathology 1 (2011) 98– 103
Fig. 3. X-ray digital extended-view of the upper body, showing the crossed arms
mummification position and extensive post-mortem bone fractures.
pelvic skeleton both iliac wings showed similar ense areas (Fig. 7 ),
slightly larger (right wing 2.8 cm,  and left 2.3  cm), and with a more
irregular pattern. The main lesion at the right iliac wing shows slight
cortical thickening and focal erosion, with a lamellated adjacent
reaction. The medullary areas of both clavicles, the left scapula,
three ribs, both ischia (Fig. 2), and all humeral and femoral heads
(Fig. 7 ) were punctuated by dense spots or small nodules, measur-
ing between 1 and 4  mm.
Fig. 4. MDCT MPR  (sagittal) of the lumbar spine, showing sclerotic vertebral bone
lesions.
Some other small, ill-defined and less dense, bone focal changes
identified at other parts of the skeleton (frontal skull, mandible, and
odontoid process), are not characteristic of any sole disease.
In the related analysis of the preserved pelvic soft tissue, we
could identify the inferior bladder wall, the prostate fossa filled
with debris and collapsed seminal vesicles embedded in resin accu-
mulated in the rectovesical space (Fig. 8).
Some of the preserved muscles, particularly at the limbs,
showed several small oval areas of low density, some of which
have dense or calcified centers. It is unclear if these are due to
taphonomic changes or a parasitic disease: trichinosis.
4. Discussion
Despite the large number of st di d human remains, from
antiquity to modern ages, evidence of primary or metastatic malig-
nancy is rare but not unknown (Capasso, 2005; Pahl, 1986; Torre
et al., 1980). Destructive (osteolytic) or bone forming (osteoblastic)
ancient bone lesions are rarely identified. Even if this scarcity of
bone cancer findings could be partially reduced by careful physical
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mortality emphasises the wide spectrum of processes that fall under the 
umbrella of cancer and the importance of understanding the basic principles 
of cancer biology to determine causation and develop new treatments. 
1.1 The Warburg effect 
Otto Warburg is one of the most renowned cancer scientists of the past 
century. Warburg was awarded the Nobel Prize in Physiology or Medicine in 
1932 for his doctoral research into oxidation in cancer that led to the so-called 
Warburg effect which is recognised as a metabolic pathway in most cancer 
cells (Warburg, 1925; Brand, 2010). The Warburg effect is the conversion of 
glucose to lactate, even in the presence of ample oxygen (Warburg, 1956). 
Cancer cells have a predilection for aerobic glycolysis despite the fact that this 
process is an inefficient way to generate adenosine 5´-triphosphate (ATP), 
compared to conventional mitochondrial oxidative phosphorylation. This 
switch towards a less-efficient ATP production may be due to the advantages 
it confers in facilitating the formation of reducing equivalents and the uptake 
and incorporation of nutrients into the tumour that are required for proliferation 
e.g., nucleotides, amino acids, and lipids (Vander et al., 2015). Moreover, the 
metabolites required to support anabolic growth can themselves be 
oncogenic, by altering cell signalling and blocking cellular differentiation (Ward 
and Thompson, 2012). Therefore, aerobic glycolysis is not only a necessary 
consequence of tumour formation but it also is a driver that promotes 
proliferation and resistance to cell death (Vander et al., 2015). 
1.2 Hallmarks of cancer 
In a seminal paper published in Cell in 2000, Hanahan and Weinberg 
addressed the so-called hallmarks of cancer, i.e. essential alterations in cell 
biology which result in malignant transformation (Hanahan and Weinberg, 
2000). The six original hallmarks were: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless 
replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis (Hanahan and Weinberg, 2000). Those characteristics are 
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common to all cancers. Following on from that initial publication, in 2011 the 
same authors proposed the 2nd generation of these hallmarks which includes 
two enabling characteristics - genome instability and inflammatory state - and 
two emerging hallmarks - reprogramming the cellular metabolism and 
avoiding immunological destruction (Hanahan and Weinberg, 2011). The 
identification of those characteristics has had a pivotal role in shaping cancer 
research over the past 15 years. Indeed, the hallmarks became the targets of 
new drugs as well as new imaging techniques.  
The evolution of a normal cell to a neoplastic one is a multistep 
process that involves these cancer hallmarks with the support of the tumour 
microenvironment. Cancer is a mixture of complex tissues in which 
transformed cells exercise their influence over normal cells and the latter 
contribute to the development and expression of some of the hallmarks. Most 
of the characteristics of this heterogeneous environment, such as 
angiogenesis, hypoxia and proliferation, can be assessed with imaging 
techniques such as Magnetic Resonance Imaging (MRI) or Positron Emission 
Tomography (PET). Imaging the hallmarks may increase knowledge on 
cancer biology, which is necessary in order to refine treatment and, 
eventually, personalise it. In this regard, imaging plays a pivotal role allowing 
non-invasive detection and evaluation of cancer.  
1.3 Brain tumours 
Although brain tumours are quite rare, accounting for less than 2% of 
all cancers, they cause significant morbidity and their prognosis is poor 
(Walker et al., 2011; Stewart and Wild, 2014). Brain tumours can be both 
primary and secondary. During the last century, the classification of brain 
tumours has been largely based upon histopathological features or phenotype 
with different putative cells of origin. However, the most recent 2016 World 
Health Organization classification of tumours of the central nervous system 
takes into account both phenotypic and genotypic parameters (Louis et al., 
2016). Markers such as isocitrate dehydrogenase (IDH) mutations, mutations 
of the alpha-thalassemia/mental retardation syndrome X-linked (ATRX) gene, 
expression or codeletion of chromosome arms 1p and 19q are now essential 
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in classifying central nervous system (CNS) tumours. Oligoastrocytoma is, 
according to the consensus document which defined the updated 
classification, the best example of how the genotypic characterisation can 
change lesion classification. Combining genotype (i.e. IDH mutation and 
1p/19q codeletion status) and phenotype (combination of astrocytic and 
oligodendroglial cells population) we can classify most tumours as either 
astrocytomas or oligodendrogliomas with only a small percentage of tumours 
defined as not otherwise specified (NOS) (Louis et al., 2016). 
 Nevertheless, despite numerous primary CNS tumours, gliomas are 
still the most common, accounting for nearly 70% of central nervous cancers. 
They arise from glial cells, which form the supporting architecture of the brain, 
and glioblastoma (GBM) is the most frequent and malignant histologic type 
among gliomas (Ohgaki, 2009). 
1.4 Glioma 
Gliomas are a heterogeneous group of tumours that originate from 
central nervous system precursor epithelial cells (Bigner, 1981; Heppner, 
1984). Traditionally, they have been classified according to the prevailing cell 
lineage as: astrocytic tumours, oligodendroglial tumours or glioblastoma when 
poorly differentiated (Arevalo et al., 2017). According to the WHO 
classification, gliomas are given a grade between I and IV; Grade I being the 
least aggressive and Grade IV the most aggressive anaplastic tumours (Louis 
et al., 2007a, b, 2016). The incorporation of molecular markers has also 
contributed to define more homogenous diagnostic categories for treatment 
purpose based on those biomarkers. Indeed, while in the past the definition of 
low-grade glioma (LGG) referred to WHO grade II gliomas, the new definition 
of lower-grade glioma (LrGG) is based upon the presence of the IDH mutation 
(figure 1.2) as this has been shown to predict survival (Pouratian and Schiff, 
2010; Arevalo et al., 2017) This classification determines correct patient 
management. However, even within the lower-grade gliomas, the 
management is dramatically different, with some lesions being amenable to 
surgical resection while the role of surgery in some is still debatable 




The overall incidence rate of central nervous cancers in the UK is 12.4 
per 100,000 people (CRUK, 2019). Despite some controversy regarding a 
possible increase in incidence during the 1980s and 1990s (Preston-Martin et 
al., 1993; Muir et al., 1994), probably due to the introduction of high-resolution 
imaging modalities which could better detect brain tumours (Ohgaki, 2009), 
these figures remained stable during the last three decades (CRUK, 2019). 
1.4.2 IDH Mutations and gliomagenesis 
Isocitrate dehydrogenase (IDH) has become one of the key biomarkers 
of underlying glioma biology and a cornerstone of the WHO brain tumour 
classification (Louis et al., 2016). There are three IDH isoforms named IDH1, 
IDH2 and IDH3, of which the first two are of particular interest in gliomas. IDH 
converts isocitrate to a-ketoglutarate in the cytosol (IDH1) and in the 
mitochondria (IDH2) generating reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) from NADP+ which has a key role in controlling cellular 
	
 
Figure 1.2: Classification of adult gliomas according to histology and IDH status. 
Oligoastrocytoma is not included because it is very rare. 
From: Arevalo et al., 2017 
	
trocytomas display alterations in the ATRX (loss) and
TP53 (mutation) genes with high frequency, and,
when present, those anomalies are almost invariably
associated with a mutation in the IDH gene. Although
alterations in the ATRX and TP53 are very common
in astrocytomas, they are not considered as diagnostic
criteria. IDH mutant astrocytomas can be subdivided
into 2 groups: positive and negative for ATRX (Fig 3).
It is noteworthy that an ATRX alteration is not ex-
pected to be present in pediatric astrocytomas.6,20
2. Diffuse glioma grade II or III, IDH wild type: It is an
uncommon tumor presentation of a diffuse astrocy-
toma. IDH wild type tumors are considered to have a
worse prognosis compared with the IDH-mutated coun-
terpart because they progress to glioblastoma faster. It is
important to point out that oligodendrogliomas IDH
wild type are virtually nonexistent.1 Therefore, if a dif-
fuse glioma grade II or III presents as IDH wild type, it is
classified as an astrocytoma, disregarding the possible
histologic suggestion of an oligodendroglioma (Fig 4).
Knowing that IDH-wild type diffuse astrocytomas are
uncommon tumors, it is important to rule out a lower
grade lesion like ganglioglioma (I) or a higher grade
lesion such as glioblastoma (IV) by focusing on benign
or malignant histologic features.1
3. Diffuse glioma II or III, NOS: This group includes tu-
mors in which neither the IDH mutant nor IDH wild
type could be identified (negative immunohistochemis-
try and subsequent negative sequencing for mutation in
codons IDH1 132 and IDH2 172 by direct study of
DNA).1 Tumors that, for whatever reason, cannot
undergo genetic study (because they are anatomically lo-
cated in deep and eloquent structures where tissue avail-
ability is limited or because the institution does not have an
adequate laboratory, etc) are also classified as NOS.
GLIOBLASTOMA
The latest update of the WHO classification for tumors of
the CNS recommends that the term “glioblastoma multi-
forme” should be replaced by “glioblastoma.” It is classi-
fied according to its IDH status into 3 types:
1. Glioblastoma, IDH wild type: This is the most common
type of glioblastoma (95%) and corresponds to the
so-called primary or de novo glioblastoma.34 This
type of glioblastoma occurs in patients ! 55 years old,
has an aggressive clinical course, and its genotype and
presentation are both heterogeneous and variable.
Common genetic alterations include mutations of epi-
dermal growth factor receptor, MGMT, the phospha-
Chart 2. Classification of adult gliomas according to histology and IDH status. Oligoastrocytoma is not included because it is very rare; if there
is a tumor with astrocytic/oligodendroglial mixed histology, in most cases you can make a proper classification with the genetic study. DDx !
Differential diagnosis.
338 ! Neurographics 2017 September/October; 7(5):334–343; www.neurographics.org
	
 22 
oxidative damage. In 2008, a seminal paper featured in Science identified 
IDH1 mutation as un unexpected genetic alteration in patients with 
glioblastoma (Parsons et al., 2008). The authors extensively sequenced the 
protein coding genes of a cohort of 22 glioblastomas. In that cohort, all the 
IDH mutated glioblastomas exhibited the same mutation: a replacement of an 
arginine with a histidine at amino acid residue 132 (R132H). This site is critical 
for isocitrate binding to IDH, therefore, a mutation at this level inactivates 
completely the ability of the protein to bind isocitrate de facto completely 
arresting its catalytic activity. This results in reduced production of a-
ketoglutarate and NADPH. Moreover, the mutated enzyme acquires the new 
capability of catalysing the reduction of a-ketoglutarate to 2-hydroxyglutarate 
(2HG), an oncometabolite (Dang et al., 2009). The latter has been associated 
with increased risk of brain tumours in patients with 2HG dehydrogenase 
deficiency and its concentration level has been correlated with an increase in 
reactive oxygen species which in turn contributes to cancer risk (Dang et al., 
2009). Moreover, 2HG is also directly toxic by inhibiting enzymes that use 
glutamate and or a-ketoglutarate. Interestingly, Parsons et al. associated this 
mutation with secondary glioblastomas, younger age of diagnosis and a better 
prognosis lying the basis for a better understanding of gliomagenesis 
(Parsons et al., 2008). IDH mutation is also sufficient in establishing glioma 
CpG island methylator phenotype (G-CIMP) which determines tumour 
pathogenicity (Turcan et al., 2012).  
Further analysis of the presence of IDH mutation in different 
histological types highlighted that this mutation is an early event in 
gliomagenesis. Watanabe et al. (Watanabe et al., 2009) demonstrated that 
low grade diffuse astrocytomas, oligodendrogliomas and oligoastrocytomas 
share IDH1 mutations as frequent genetic alterations. Interestingly, low grade 
diffuse astrocytomas usually show TP53 mutations but rarely show loss of 
1p/19q. On the contrary, oligodendrogliomas often show loss of 1p/19q but 
rarely TP53 mutations. Lastly, oligoastrocytomas either have TP53 mutations 
or 1p/19q codeletion. The heterogeneity in mutation profile bar the presence 
of IDH1 mutations support the hypothesis that the latter is an earlier event in 
the gliomagenesis, likely happening in a common precursor, and further 
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mutations determine the final histological type (Watanabe et al., 2009). The 
early occurrence of IDH mutations in a common precursor was also confirmed 
in a large cohort of 939 tumour samples by Yan et al. (Yan et al., 2009). 
Indeed, they demonstrated that astrocytomas and oligodendrogliomas share 
IDH mutations, but not other genetic alterations, implying that IDH mutations 
occur relatively early during gliomagenesis. Further supporting evidence is the 
rarity of IDH mutations in primary glioblastoma (Yan et al., 2009). Some 
authors therefore have proposed the existence of three separate pathways for 
gliomagenesis (Cohen et al., 2013). A first pathway would see an early IDH 
mutation followed by TP53 mutation leading to astrocytic lineage tumours.  If 
the second mutation is the codeletion 1p/19q the resulting lineage would be 
oligodendrogliomas with the capability of progression to anaplastic 
oligodendrogliomas if further mutations occur. Lastly, the third pathway leads 
to IDH wild-type glioblastoma through multiple genetic alterations acquired 
over a very short time span.  
The discovery of the key importance of IDH in glioma tumorigenesis 
and aggressiveness determined an effort in non-invasive detection of the 
presence of the mutation. As mutation in IDH results in increased 
concentration of 2HG, measuring the concentration of this metabolite has 
been proposed as a way to predict IDH mutation. 2HG can be detected with 
magnetic resonance spectroscopy and dedicated acquisition protocols; its 
concentration correlates with IDH mutation status (Andronesi et al., 2012; 
Choi et al., 2012; Pope et al., 2012). The capability of in vivo assessment of 
2HG concentration has a significant diagnostic and prognostic role. In addition 
to the possibility of non-invasively determining the presence of the mutation 
without a biopsy, monitoring the 2HG concentration during treatment can 
predict therapy response earlier than other morphological techniques (Choi et 
al., 2012). Over the past few years several IDH inhibitors have been proposed 
with promising results in vitro and in animal models (Rohle et al., 2013; Zheng 
et al., 2013; Turkalp et al., 2014). In particular, Rohle and colleagues 
developed an IDH1 (R132H) mutation-specific inhibitor that caused a 
reduction in glioma volume in murine xenografts due to inhibition of 
proliferating cancer cells (Rohle et al., 2013). More recently, Popovici-Muller 
et al. (Popovici-Muller et al., 2018) developed an inhibitor of the IDH1 mutant 
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enzyme - AG-120 (ivosidenib) - that lowers the concentration of 2HG without 
showing any effect on wild-type or mutant isoforms of IDH2. Pre-clinical data 
in an orthotopic mouse xenograft model of human IDH-mutant glioma 
demonstrated the capability of ivosidenib to dramatically inhibit the production 
of 2HG and tumour growth (Nicolay et al., 2017). Ivosidenib was approved by 
the FDA in 2018 for treatment of acute myeloid leukaemia with IDH1 mutation 
paving the way to further applications in other malignancies harbouring similar 
mutations (Dhillon, 2018). A recently concluded open-label multicentre phase 
1 study in patients with solid tumours including cholangiocarcinoma and 
glioma demonstrated promising clinical activity of ivosidenib in those patients 
with an acceptable toxicity profile (Fan et al., 2020). However, brain 
penetrance of ivosidenib was low, therefore potentially limiting the efficacy of 
the drug in patients with glioma. To overcome this limitation, a novel IDH 
inhibitor (AG-881, vorasidenib) with improved brain penetration and dual 
efficacy on both IDH1 and IDH2 mutations has been developed (Konteatis et 
al., 2020). Vorasidenib demonstrated a dramatic inhibition of 2HG production 
(> 97%) in an orthotopic glioma mouse model (Konteatis et al., 2020). A 
dedicated phase-1 multi-centre study is currently undergoing in patients with 
recurrent non-enhancing gliomas with IDH1 mutation (NCT03343197) 
comparing the concentration of 2HG following treatment with either ivosidenib 
or vorasidenib with the concentration of 2HG in untreated tumours. 
1.4.3 Treatment  
Glioma grade is strongly associated with prognosis, thus dictates 
treatment. MRI is routinely used for the diagnosis and estimation of glioma 
grade due to its non-invasive nature. Even though it has a high accuracy, in 
most cases a definite histological diagnosis is required to confirm the 
suspected diagnosis and evaluate the treatment options. 
1.4.3.1 Lower-grade glioma 
At present, there is not a common consensus about treatment 
strategies for LrGG. Indeed a recent Cochrane review underlined the lack of 
systematic randomised controlled clinical trials on which to base the clinical 
decision about the clinical management of these patients (Veeravagu et al., 
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2013). Although common guidelines are still needed, surgical management is 
widely recognized as a viable treatment strategy, especially for grade II 
tumours, and the cancer is often resected with or without subsequent 
fractionated radiotherapy (RT) and chemotherapy using nitrosourea or 
temozolomide (Nitta et al., 2015; Schucht et al., 2015). Moreover, surgery is 
also indicated in patients with large lesions or with neurologic symptoms 
(Carabenciov and Buckner, 2019). After surgery, patients are followed up 
using serial MRIs in order to detect recurrence and/or progression. 
Beside surgery, conventional radiation therapy is a well-established 
treatment strategy for lower-grade gliomas. A combination of radiation and 
chemotherapy is currently supported as therapy in post-surgical patients as 
soon as there is a risk for tumour recurrence (Carabenciov and Buckner, 
2019). Early radiotherapy is especially warranted in patients with histology 
suggestive of astrocytoma and subtotal resection after surgery. However, the 
timing of radiotherapy is still very controversial especially in patients with 
lower risk of transformation due to the potential significant side effects. A 
potential new avenue for treatment of low-grade glioma are IDH inhibitors 
such as ivosidenib and vorasidenib described in paragraph 1.4.2. A phase 1 
study comparing those two compounds is currently ongoing. 
It is important to highlight that even grade II gliomas are an incurable 
chronic disease with malignant progression toward a high-grade glioma being 
almost granted at some stage of follow-up. 
1.4.3.2 High-grade glioma 
The role of surgery in HGG is less debatable. Although some older 
studies failed to demonstrate a survival benefit for resection, this was 
probably due to the inadequate assessment of the tumour boundaries and the 
extent of resection (Schucht et al., 2015). Several current guidelines, including 
the NICE guidelines, advocate maximal resection as a primary target in the 
management of patients with HGG (Sanai, 2012; Talibi et al., 2014; NICE, 
2015). The optimal extent of resection depends on several characteristics, 
including the tumour size and location, general and neurological status, and 
the experience of the surgeon. However, to achieve a gross-total resection it 
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is mandatory to understand the exact location and extent of tumour, which is 
often challenging with currently available methods.  
Since the introduction of neuronavigation based on pre-surgical 
imaging, there has been a significant improvement in surgical accuracy, and 
this is now standard-of-care. New techniques such as 5-aminolevulinic acid 
(5-ALA)-guided surgery and intraoperative MRI (iMRI) have been developed 
in order to overcome these limitations. Indeed, a recently published review, 
confirmed that these new techniques have an individual benefit in terms of 
extent of resection (Barone et al., 2014). In particular, the introduction of 5-
ALA in the clinical setting has had a striking effect in achieving gross total 
resection; patients in which the resection was carried out using 5-ALA 
experienced a longer progression-free survival and less enhancement in the 
tumour bed after resection, when compared with white light alone (Tonn and 
Stummer, 2008; Stummer et al., 2014). From a biological point of view, 5-ALA 
is an amino acid that is normally present in the human body being a 
metabolite of heme. Its production is strictly regulated by a negative feedback 
inhibition of the heme on the enzyme 5-ALA synthase. When exogenous 5-
ALA is administered the feedback is bypassed and it starts to accumulate. 5-
ALA elicits the synthesis of the protoporphyrin IX which is fluorescent if 
exposed to the appropriate wavelengths of light and is usually converted in 
heme. The uncontrolled increase in protoporphyrin IX due to the 5-ALA 
therefore results in a build-up of fluorescence inside malignant cells. The 
tumour can be then better visualised using a surgical microscope equipped 
with dedicated optical filters (Stummer et al., 1998; Tonn and Stummer, 
2008). This characteristic helps neurosurgeons in identifying malignant tissue 
and, combined with neuronavigation, may significantly improve gross total 
resection (Tonn and Stummer, 2008; Barone et al., 2014). Nevertheless, a 
complete resection is very often unachievable either due to unfavourable 
lesion characteristics or an underestimation of the tumour spread. 
Radiotherapy is an integral component in the treatment of HGG 
(Ludmir et al., 2019). It confers a survival advantage in patients with 
glioblastoma (Cabrera et al., 2016a). Although the specific approach depends 
on characteristics specific to tumour and patient (such as age and 
performance status) radiotherapy is recommended for patients with 
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glioblastoma both after the initial surgery/biopsy and at recurrence in 
the American Society for Radiation Oncology (ASTRO) guidelines (Cabrera et 
al., 2016b).  Moreover, thanks to recent technological advantages such 
as intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy 
(IGRT), it is possible to reduce the dose delivery to normal tissues without 
sacrificing the treatment of the glioblastoma (Burnet et al., 2014). Therefore, 
the combination of these technologies is the state-of-the-art of radiotherapy 
for patients with glioblastoma. 
1.4.4 Treatment evaluation 
Whilst neurosurgery is focused on obtaining the so-called maximum-
achievable resection in order to boost the prognosis, there is a compelling 
need for proper treatment evaluation. Currently, this evaluation relies either on 
the duration of patient survival or on the radiographic response rate or 
progression-free survival (PFS). In order to improve the assessment of the 
radiographic response, the RANO Working Group (an international panel 
consisting of neuro-oncologists, neurosurgeons, radiation oncologists, 
neuroradiologists, neuropsychologists, and experts in QoL measures) 
proposed in 2010 a set of criteria that do not rely anymore only on two-
dimensional measurements of the enhancing tumour area but on a more 
elaborate set of characteristics that takes into account multiple sequences 
and parameters (table 1.1) (Wen et al., 2010). Although the RANO criteria 
perform significantly better compared to traditional response assessment 
strategies, they fall short of definitively distinguishing tumour progression, 
pseudoresponse, and pseudoprogression (Huang et al., 2015).  
RANO criteria defined pseudoprogression as an increase in contrast 
enhancement which is evident at the first post radiation MRI and subsequently 
subsides without any change in therapy at the following scan (Wen et al., 
2010). This phenomenon usually occurs within 12 weeks after the completion 
of radiotherapy in 20-30% of patients (Wen et al., 2010). To partially mitigate 
the risk of misinterpreting an enhancing area and labelling it as progression 
within 12 weeks from radiotherapy, the criteria define as true progression only 
contrast enhancing areas that are outside the radiation field, unless a sample 
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is obtained from the enhancing area to confirm the presence of viable tissue 
(Wen et al., 2010). A similar solution has been proposed for pseudoresponse: 
antiangiogenic agents may produce a significant decrease in contrast 
enhancement as early as 2 days after initiation of therapy therefore potentially 
resulting in overcalling of radiological response; RANO criteria only claim 
response if the radiological appearance persists for at least 4 weeks to 
overcome this (Wen et al., 2010). It is evident that the approach taken by the 
RANO panel has been quite conservative, resulting in uncertainties for up to 
12 weeks after therapy.  
In the past few years, a number of advanced techniques, such as 
perfusion MRI or spectroscopy have been proposed to help with this, however 
a consensus is still to be reached (Huang et al., 2015). Dynamic susceptibility 
contrast-magnetic resonance imaging (DSC-MRI) has been proposed as a 
quantitative tool to assess pseudoprogression: using the relative cerebral 
blood volume, a sensitivity of 90% and a specificity of 60% have been 
reported whilst perfusion maps demonstrated slightly lower figures with 
sensitivity of 85.7% and a specificity of 89.2% (Huang et al., 2015). Despite 
the good performance of DSC-MRI, this technique has important limitations. 
Its characteristic sensitivity to susceptibility for instance, leads to a low signal-
to-noise level in areas near bone surfaces, air interface or blood products (as 
in case of haemorrhage) and the disruption of the blood-brain barrier resulting 
in vascular leakage. Some studies have demonstrated that dynamic contrast 
enhanced- magnetic resonance imaging (DCE-MRI) could effectively detect 
 CR PR SD PD 
T1 post Gadolinium None ≥ 50%ê < 50% ê 
< 25% é 
≥ 25% é* 
T2/FLAIR Stable or ê Stable or ê Stable or ê é* 
New lesion None None None Present* 
Corticosteroids None Stable or ê Stable or ê NA ** 
Clinical Status Stable or é Stable or é Stable or é ê* 
Requirement for response All All All Any ** 
 
Table 1.1: The RANO criteria used to assess treatment response in gliomas. 
Abbreviations are as follow: CR = complete response; PR = partial response; SD = stable 
disease; PD = progressive disease. 
* Progression occurs when any of these criteria is present. ** NA = Not applicable. 
Despite the other criteria, an increase in steroid dose alone is not sufficient to classify a 





pseudo response with a sensitivity of approximately 100% and specificity of 
around 80%, but the pharmacokinetic models are complex to use leading to 
difficulty in standardization (Huang et al., 2015).  
Magnetic resonance spectroscopy (MRS) is a promising technique for 
pseudo progression evaluation: a higher choline-to-creatine and choline-to-
NAA ratios are observed in tumour progression compared to normal 
parenchyma or treatment necrosis; in particular, using the choline-to-NAA 
ratio the sensitivity and specificity are 88% and 86% (Huang et al., 2015). 
However, MRS requires an operator to properly select the region in which the 
ratio has to be computed and to set the saturation bands; this results in low 
reproducibility of results and high inter-operator variability. Reproducibility is 
also jeopardised by the equipment, pulse sequences, parameters, and post-
processing methods used in different sites.  
Despite the potential utility of these techniques in helping 
characterising pseudo progression from true progression their adoption into 
the routine clinical environment faces many challenges due to issues with 
acquisition, post-processing and analysis. Many are still considered research 
techniques rather than clinical tools. Nevertheless, a prompt assessment of 
therapy would be desirable to better define management at the earliest stage 
possible. Therefore, it is necessary to develop more advanced imaging 
techniques to allow a better understanding of tumour physiology which will 
improve primary detection and tumour characterisation, as well as early 
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Gliomas may present clinically with neurological disturbance such as 
headaches, seizures or focal neurological deficits depending on the location 
of the tumour. Despite the routine clinical use of conventional proton Magnetic 
Resonance Imaging (1H-MRI) in the assessment of glioma, the technique 
cannot fully assess infiltrative growth or response to therapy (Villanueva-
Meyer et al., 2017). Therefore, anatomic imaging of gliomas can be 
complemented by more advanced techniques to assess tumour biology 
(Brindle et al., 2017). For example, the use of diffusion-weighted imaging 
(DWI) to evaluate tissue water movement has been extensively applied to 
imaging cancer and has found a wide range of routine applications. DWI is 
frequently used in glioma imaging and recently an advanced form of DWI, 
diffusion kurtosis imaging (DKI), has emerged as a new potential tool to 
demonstrate tumour heterogeneity (Van Cauter et al., 2012, 2014).  
MRI largely measures the signal from hydrogen nuclei (or protons 1H) 
in water or to a lesser extent in fat given the natural abundance of these 
molecules. MRI can also be used to detect other nuclei, the so-called X-
nuclei: these nuclei can be used to explore metabolic processes in vivo and 
include sodium (23Na) (Maudsley and Hilal, 1984; Madelin, 2013; Madelin and 
Regatte, 2013) or carbon (13C) containing compounds (Gallagher et al., 2008, 
2011a). Research in multi-nuclei MRI has increased over the last decade due 
to the potential of these approaches to unlock new biology. However, the 
signal from nuclei such as 23Na, 13C or 31P is much lower compared to protons 
due to their lower concentration, different gyromagnetic ratio and nuclear 
polarisation and therefore until recently, multi-nuclei imaging with conventional 
MRI systems has been a great challenge. Nevertheless, with the widespread 
adoption of higher-field magnets and the improvement in coil technology and 
Chapter 2   
Imaging of glioma 
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acquisition sequences, these nuclei can now be successfully imaged at high 
resolution within a clinically practical timescale. These techniques may 
provide useful data to complement conventional multi-parametric MRI 
protocols comprising standard morphological and dynamic contrast enhanced 
sequences, to better stratify tumours and response to treatment. 
2.1 Conventional proton MRI 
The current standard of practice in Europe for glioma imaging is based 
on conventional proton MRI. The standard protocol includes T2W, FLAIR, DWI 
and pre- and post- gadolinium-based contrast agent T1W with 80% of centres 
using 3D imaging (Thust et al., 2018). This simple protocol is in line with the 
recommendation of the Response Assessment in Neuro-Oncology (RANO) 
Criteria for glioma, based on changes in tumour size and blood-brain barrier 
breakdown seen on post-contrast imaging (Wen et al., 2010). However, 
conventional imaging has significant limitations in assessing tumour response 
in the first 3 months after treatment. During this time window, contrast 
enhancement can increase for many reasons, such as therapy induced 
damage to normal brain tissue or simulated tumour progression (pseudo 
progression). Therefore, during these 3 months there is a significant delay in 
accurately assessing the response of the tumour which could result in missing 
the optimal treatment window for these patients with a dismal prognosis. 
2.1.1 Morphologic imaging 
MRI is the modality of choice to investigate patients with sudden 
presentation of neurological disturbances and has a high sensitivity for 
detecting brain tumours. Routine MRI of brain tumours typically involves T2-
weighted images (T2WI), T2 fluid-attenuated inversion recovery (FLAIR), T1-
weighted images (T1WI), acquired pre- and post- gadolinium-based contrast 
agent administration and Diffusion Weighted Imaging (DWI) (Brindle et al., 
2017). Often a post-contrast high-resolution T1 isovolumetric sequence is 
performed preoperatively for use with intraoperative navigational software (i.e. 
Stealth System and Brainlab) (Elhawary et al., 2011; Khoshnevisan and 
Allahabadi, 2012). Together these sequences have a role in detection and 
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localisation of the lesion, identification of mass effect on the brain parenchyma 
and distant spread, assessment of the ventricular system and vasculature, 
and to some extent can be used to characterize the lesion according to its 
imaging phenotype. Certain features, such as contrast enhancement, signs of 
mass effect and significant peri-tumoral oedema, strongly suggest a high-
grade tumour, whilst others, such as a poorly defined mass, are more in 
keeping with lower-grade tumours. However, making a diagnosis of a specific 
tumour type is challenging due to the fact that some characteristics 
associated with high grade tumours may be expressed by low grade tumours 
and vice versa (Mabray et al., 2015). In these cases, MRI cannot be specific.  
Another limitation of conventional imaging is the evaluation of peri-
tumoral oedema: high grade gliomas spread through oedema with tumour 
cells infiltrating regions of non-enhancing T2WI/FLAIR signal hyperintensity as 
well as in regions of up to 2.5 cm beyond the area of T2WI/FLAIR signal 
change (Watanabe et al., 1992; Price and Gillard, 2011). This leads to a sub-
optimal resection with potential residual tumour and risk of recurrence (Lu et 
al., 2003; Cha, 2006; Barajas et al., 2013). 
2.1.2 Proton nuclear magnetic resonance spectroscopy 
Both benign and malignant tumours show an increased metabolism 
compared to the normal surrounding tissue and produce high levels of lactate. 
Proton MR spectroscopy (1H-MRS) can non-invasively measure brain 
metabolites in vivo, including the steady-state concentration of lactate. 
Several biological processes can be measured using 1H-MRS, such as 
glucose consumption, variation in membrane turnover and proliferation (Price 
and Gillard, 2011; Zhang et al., 2014). Proton spectroscopy is current in use 
for many clinical applications in neurological, cardiac, and oncological imaging 
(Constantine et al., 2004; Sahraian and Eshaghi, 2010; Radbruch and 
Bendszus, 2015). 
MRS has been used to differentiate brain tumours of different grades 
and secondary from primary lesions using metabolite concentrations; however 
clear cut-off values to discriminate tumour grades have not been identified. In 
addition, there is also an overlap of some metabolites between different 
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lesions: for example, Cho/Cr values are similar in grade IV astrocytoma and 
metastatic deposits (Möller-Hartmann et al., 2002). Despite the lack of 
accuracy in grading brain tumours, some researchers have demonstrated 
benefits in adding spectroscopic imaging to conventional MR techniques for 
target selection in brain biopsies (Martin et al., 2001). To date, most of the 
studies are single centre with variations in scan qualities. Different inpatient 
populations and study designs may produce heterogeneity in the results. 
Although 1H-MRS may be a non-invasive method for assessing brain 
tumours, it has to be interpreted by an experienced reader and has not to date 
been shown to clearly discriminate between high and low grade tumours 
(Wang et al., 2014). 
2.2 Diffusion weighted imaging 
Diffusion-Weighted Imaging (DWI) is an MRI technique based on the 
Brownian motion of water within tissue. Any molecule in a fluid is displaced as 
the molecule is agitated by thermal energy into random motion. In normal 
tissue the motion of water molecules is relatively free and random - it is limited 
only by the boundaries of the tissue itself; the effect of this erratic motion has 
been termed displacement distribution. Analysing this distribution at two time-
points using diffusion-sensitive gradients, information can be obtained about 
the medium in which water molecules are moving. DWI is the general term 
given for such sequences and can be seen as the unprocessed result of the 
application of a pulsed gradient spin echo sequence (Stejskal and Tanner, 
1965; Hagmann et al., 2006).  
The degree of diffusion weighting of the pulsed gradient spin echo 
sequence is termed the b-factor, and is determined through manipulation of 
the gradients (Stejskal and Tanner, 1965; McRobbie et al., 2017). The b-
factor is given by the equation: 
! = #!$!%!(∆ −	"
#
) [1] 
where G is the amplitude of the gradients, δ is the time of applied gradients 
and Δ duration between the paired gradients. Having defined the b-factor, the 
diffusion signal strength can be defined according to the following equation: 
+(!) = 	+$	exp	(−!/) [2] 
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where S(b) is the diffusion signal at a specific b value and D is the self-
diffusion constant of the specific tissue. To simplify DWI evaluation, a map 
which depicts the magnitude of diffusion is generated using at least two DWI 
acquisitions with different b-values; this map is called the apparent diffusion 
coefficient (ADC) map. The apparent diffusion coefficient is calculated 
according to the following equation: 





where the T2W signal is provided by the images acquired with b set to 0. The 
ADC map will also eliminate any interpretation uncertainties deriving from the 
so-called T2 shine through effect which is due to the long TE used for DWI 
acquisitions and the subsequent T2W signal. A high ADC value reflects 
 
Figure 2.1: Diffusion signal intensity curve. 
Log signal intensity versus b-values, the apparent diffusion coefficient (ADC) is the 
absolute value of the slope of the curves. The theoretical curve of signal decay for the 
mono-exponential model is represented in blue. This is based on the assumption that the 
water molecules within a voxel diffuse in the same way. However, this is not true in reality 
as more than one tissue will be present within a voxel represented by a biexponential 
curve (represented in red).  At low b-values (< 150 s/mm2), the signal is dominated by the 
blood microcirculation with a resulting higher signal than expected. This perfusion 
component is exploited with the intravoxel incoherent motion imaging (IVIM – see 
paragraph 2.2.1). At high b values the signal is dominated by hindrance effects (notably 
from water/membranes interaction). The heterogeneity of the signal due to the different 
interactions, results in the so-called diffusion kurtosis (DKI) with a large deviation of the 
measured signal compared to the expected signal. As IVIM informs on perfusion, DKI has 
greater sensitivity to tissue features.  




unrestricted random motion, and it will result in a hyperintense region on the 
map; conversely, in the presence of restricted motion, it will appear 
hypointense, such as an acute stroke or in the presence of a cellular tumour. 
DWI is a very powerful sequence routinely used in the assessment of 
many disease processes, such as acute stroke and solid cancers. Several 
papers have addressed the importance of DWI and ADC in evaluation of 
gliomas. As tumour proliferation increases cellularity, it is expected that higher 
grade malignant tumours should exhibit lower ADC values due to reduction of 
the extracellular matrix and consequent hindrance to water diffusion (Chen et 
al., 2013). Indeed, higher grade gliomas tend to have lower ADC values 
compared to lower grade gliomas (Bulakbasi et al., 2004). Moreover, a worse 
prognosis is associated with lower ADC values (Hilario et al., 2014). However, 
the ADC values of certain gliomas types, such as grade II astrocytoma and 
glioblastoma, overlap significantly and therefore a clear cut-off for 
discriminating higher grade and lower grade tumours is still undefined (Kono 
et al., 2001). Interestingly, ADC values have also been reported to be higher 
in the infiltrative peri-tumoral oedema seen in glioblastoma, although this has 
not been found consistently in all studies (Kono et al., 2001; Oh et al., 2005; 
Server et al., 2009; Lee et al., 2011; Hilario et al., 2014). 
ADC has also been proven capable of subtyping lower grade gliomas. 
Astrocytomas and oligodendrogliomas exhibit characteristic features on 
pathology: astrocytomas have low to moderate cell density with variable 
cellular morphology, whilst oligodendroglioma are more hypercellular with 
more uniform cellular morphology. Therefore, astrocytomas tend to have 
higher ADC values compared to oligodendroglioma due to greater diffusion of 
the molecules of water within the extracellular matrix (Tozer et al., 2007). 
Interestingly although, both astrocytomas and oligodendrogliomas are more 
cellular than normal brain parenchyma, the ADC values are higher than 
normal brain. This hints to the possibility that the presence of macromolecules 
in the extracellular matrix of those tumours may have a significant effect in 
reducing the diffusion of molecule of waters. The extracellular matrix of 
astrocytomas and oligodendrogliomas is known to contain a high 
concentration of glycosaminoglycans, in particular hyaluronan, which 
positively correlates with ADC (Tozer et al., 2007). 
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Nevertheless, despite the potential applications in neuro-oncology and 
the vast body of published literature, clear cut-offs for quantitative assessment 
of ADC are still lacking, mostly due to the high variability of ADC values 
reported in the literature. This variability on ADC can be related both to 
biological and technical factors. For instance, some ADC values have been 
calculated without taking into account the IVIM affect, therefore resulting in a 
higher value than expected, especially using clinical protocols including b 
values of 0 and 1000 s/mm2. Moreover, the diffusion of molecules of water in 
tissues can be influenced by several biological factors such as cell density, 
cell size, cell shape, membrane permeability and subcellular architecture 
(Panagiotaki et al., 2014). Diffusion weighted imaging is also highly sensitive 
to technical parameters. As per equation 1 and 2, it is clear that the gradients 
and field strength have a significant effect on the b values. Moreover, different 
coils and magnets will have different technical characteristics resulting in 
lower reproducibility between different vendors (Chen et al., 2013). The b 
value is a key determiner of the ADC values, but there is no consensus on 
which b value should be used and despite the fact that a b value of 1000 
s/mm2 is the most used in neuro applications, this is not a standardized 
approach. 
2.2.1 Diffusion Tensor Imaging 
The assumption that water diffusion is the same in every direction 
(isotropic) inside the brain parenchyma is an oversimplification. The brain 
parenchyma is highly structured, and the axonal bundles present a specific 
orientation; therefore, the diffusion of water between these will follow those 
paths having different diffusion coefficients along different directions 
(anisotropic diffusion). Anisotropic diffusion is described using a 3x3 matrix 
which is called a diffusion tensor (DT): 





In this matrix, Dxx, Dyy and Dzz represent the diffusion along the reference axis 
(x, y and z) while the six off-diagonal elements represent the correlation of 
random motions between each pair of principal directions. Assuming that 
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diffusion in the directions x à y and y àx is the same, the mirror elements of 
the matrix should be identical and therefore only 6 unique elements are 
needed to fill the matrix. This means that to calculate the tensor, 7 
measurements are needed: one baseline value (b0) and 6 data sets oriented 
in 6 different directions. The technique that has been developed to probe this 
directionality is named Diffusion Tensor Imaging (DTI) (Moseley et al., 1990; 
Basser et al., 1994; Le Bihan, 1995; Poupon et al., 2000). DTI can provide 
information on anisotropic diffusion characterized by eigenvectors (direction – 
expressed as fractional anisotropy [FA]) and eigenvalues (magnitude – 
expressed as mean diffusivity [MD]). The fractional anisotropy is of particular 










where l represent the principal eigenvalues. The mean diffusivity (MD) is 




Gliomas tend to spread along white matter tracts, therefore they cause a 
significant disruption of white matter regions that can be visualized using DTI 
(Price and Gillard, 2011). The visualisation of these changes can be used to 
improve surgical planning by giving neurosurgeons a better understanding of 
tumour location, proliferation and surrounding normal axonal bundles (Price et 
al., 2004). Lastly, DTI has been demonstrated to predict recurrence in GBM 
patients thanks to a deeper insight into tumour pattern of infiltration (Price et 
al., 2007). 
2.2.2 Intravoxel incoherent motion diffusion imaging 
In the 1980s, Le Bihan introduced the concept that the movement of 
protons caused by blood flow within capillaries (namely microperfusion) can 
mimic a random walk (namely pseudo-diffusion) (Le Bihan et al., 1986). This 
can be observed at low b values and can influence the signal of diffusion 
weighted imaging (Le Bihan et al., 1986; Higaki et al., 2018; Le Bihan, 2019). 
Shortly after describing this phenomenon, Le Bihan also introduced a method 
to assess tissue perfusion and diffusion using specific b values, also due to 
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the fact that the blood microcirculation component decays 10 times faster than 
the diffusion component (Le Bihan et al., 1986; Le Bihan, 2019). The overall 
signal intensity from the combination of the tissue diffusion and the blood flow 
component, is described as: 
+
+$C = D9:9; exp[−!	(/
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where fIVIM is the blood flow fraction, Dblood is the diffusion coefficient in the 
blood and Dtissue is the diffusion coefficient in the tissue. Performing a diffusion 
acquisition with multiple b values of which at least half are below the IVIM 
effect threshold (believed to be 250 s/mm²) allows for estimating both the 
perfusion and diffusion using the equation above. Theoretically, as few as 3 
low b values are sufficient to derive the IVIM signal (i.e. b = 0, 100 and 200 
s/mm²), however, the long acquisition time and the subsequent sensibility to 
motion artifacts jeopardized the adoption of IVIM until echo planar imaging 
was coupled with echo-planar imaging (Le Bihan et al., 1988; Turner et al., 
1990; Yamada et al., 1999). 
The capability of informing on perfusion without the need of a 
gadolinium-based contrast agent and almost with no penalties in terms of 
acquisition time, sparked significant interest in the potential application of IVIM 
imaging in neuro-oncology. Over the past few years, several reports 
demonstrated that IVIM imaging can improve glioma grading providing 
information on perfusion (assessed at low b values) and tissue diffusion 
(assessed at high b values). Bisdas et al. for example (Bisdas et al., 2013) 
observed higher diffusion values in high-grade glioma and increased 
perfusion fraction in keeping with perfusion studies of gliomas. Those results 
were also confirmed by other reports (Federau et al., 2014; Shen et al., 2016). 
Response to therapy has also been evaluated with IVIM diffusion imaging. 
Gadolinium-based contrast agent enhanced perfusion imaging is routinely 
used to assess pseudo-progression by the use of cerebral blood volume 
maps. However, this requires injection of a gadolinium-based contrast agent 
which is now recognized as potentially harmful due to dose-dependent 
gadolinium deposition in the brain (Kanda et al., 2014). Moreover, contrast 
agents are known to leak through the disrupted blood-brain barrier potentially 
limiting the accuracy of conventional contrast enhanced perfusion techniques. 
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IVIM diffusion imaging exploits the intrinsic properties of the tissue providing, 
at the same time, information on perfusion and structural architecture of the 
tissue. Kim et al. (Kim et al., 2014) demonstrated that the evaluation of the 
heterogeneity of the IVIM-derived parameters can differentiate between 
pseudo-progression and true progression with higher accuracy than 
conventional perfusion imaging.  Interestingly, Puig et al. (Puig et al., 2016) 
demonstrated that the perfusion fraction and the pseudo-diffusion component 
of the contrast enhancing regions of glioblastomas can significantly predict 
survival at 6-months in newly diagnosed glioblastomas.    
2.2.3 Non-Gaussian Diffusion Models 
DWI and the derived ADC have been shown to be useful in evaluating 
the cellularity of gliomas and Diffusion Tensor Imaging (described in 
paragraph 2.2.1) is a valuable tool to evaluate tumour invasiveness. However, 
DWI and DTI both approximate the Brownian motion of water using a 
Gaussian distribution. This model is an over-simplification: the brain is a 
complex microenvironment structurally, in which movements are restricted by 
the parenchymal architecture which is highly heterogeneous. The non-
Gaussian diffusion effects are particular evident at high b values (Iima and Le 
Bihan, 2016) where the ADC simplified model reaches its limits. To overcome 
these limitations, over the last two decades several models have been 
proposed. 
The first model proposed to handle the non-Gaussian behaviour of the 
diffusion signal was the bi-exponential model (Niendorf et al., 1996). However, 
this model is simplistic and assumes that the signal was due to two different 
pools of water molecules which demonstrate Gaussian diffusion. Despite the 
simplistic nature of this model, the idea of employing non-monoexponential 
models to analyse diffusion data to fully harness the potentiality of the 
technique lead to the development of several models based on the non-
Gaussian distribution of water movement (Mulkern et al., 2009). One of the 
most popular model is Diffusional Kurtosis Imaging (DKI) (Jensen and 
Helpern, 2003, 2010; Jensen et al., 2005; Rosenkrantz et al., 2015)  
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Originally introduced by Jensen and Helpern in 2003 (Jensen and 
Helpern, 2003), this technique was proposed to estimate the excess of 
kurtosis of water diffusion using pulsed-field gradient sequences and b values 
up to 2000 s/mm2. Subsequent formulation of the technique was based on the 
following equation: 
ln	[+(!)] = ln[+(0)] − !/,CC +	
%
D
!!/,CC! J,CC + K(!#) [8] 
where S(b) is the signal intensity at a given echo time, Dapp is the apparent 
diffusion coefficient in the direction parallel to the diffusion sensitizing 
gradients, and Kapp is the apparent diffusional kurtosis in the same direction 
(Jensen et al., 2005). The parameter b is function of the gradient strength 
(defined as g) and the time parameters d and D according to the following 
equation: 
! = (#%5)!	(∆ − "
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) [9] 
Equation 7 defines diffusional kurtosis as dependent on the direction of the 
diffusion sensitizing gradients. As the directional dependence of the 
conventional diffusion coefficient is described by a diffusion tensor with 6 
components (see equation 4, paragraph 2.2.1), the directional dependence of 
the diffusional kurtosis can be defined by a diffusional kurtosis tensor with 15 





where si is a component of the displacement vector s. 
DKI could be a more accurate tool to assess water diffusion in vivo 
enabling a better evaluation of structural architecture and heterogeneity. In 
comparison with conventional DWI, DKI has shown improved performance for 
discriminating between high-grade and low-grade gliomas, hence being a 
potential non-invasive biomarker in the grading of gliomas (Raab et al., 2010; 
Van Cauter et al., 2012, 2014). In 2010 Raab et al. demonstrated that DKI 
could have a role in glioma grading (Raab et al., 2010). They used a diffusion 
sequence with six non-zero b values and calculated the mean kurtosis (MK) 
as the average of the apparent kurtosis coefficient over all the directions they 
acquired. In the 34 patients which completed the study, MK was significantly 
different between lower grade and higher-grade gliomas. Van Cauter et al. 
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used a different acquisition technique based on 3 non-zero b values from 
which they derived axial, radial and mean kurtosis (Van Cauter et al., 2012, 
2014). They confirmed the findings of Raab and proposed a decision path 
based on mean kurtosis which used the most significant values derived from 
diffusion kurtosis. Although those studies successfully highlighted the utility of 
diffusion kurtosis in glioma imaging, more refined methods to estimate the 
diffusion kurtosis tensor that were proposed by Tabesh et al. in 2011 have not 
yet been applied to gliomas (Tabesh et al., 2011); this model should increase 
the robustness of diffusion kurtosis reducing noise, motion and imaging 
artifacts. Moreover, this approach allows the estimation of more parameters 
derived from the kurtosis tensor including fractional anisotropy of diffusion 
kurtosis. Tabesh et al. derived a tensor equation to estimate the mean 
kurtosis moving away from the directional averaging used in the previously 
published papers. 	
2.2.3.1 Vascular, extracellular and restricted diffusion for cytometry in tumours  
 The different approaches to diffusion imaging described above are 
mostly based on different ways of modelling the diffusion signal without any 
assumption related to the biological properties of the tissue that determine 
that signal. To explore tissue architecture and functioning, biophysical 
modelling is necessary (Novikov et al., 2018). Several methods have been 
proposed to disentangle the effect of the different structures contained in each 
voxel in order to harness the full potential of diffusion MRI (Panagiotaki et al., 
2012). Some of those models were built on the geometry and architecture of 
the structures contained within the target tissue, other models are built around 
the different tissue compartments and the exchange of molecules between 
them. The Neurite Orientation Dispersion and Density Imaging is an example 
of a model based on the geometric characteristics of the target tissue (Zhang 
et al., 2012). In this model, Zhang et al adapted the previously proposed 
orientation-dispersed cylinder model (Zhang et al., 2011) to estimate neurite 
density and orientation dispersion. 
A more recent and potentially relevant model for assessing brain 
tumours is the Vascular, Extracellular and Restricted Diffusion for Cytometry 
in Tumours (VERDICT). This novel advanced model-based diffusion-weighted 
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MRI technique can quantify microstructural features of tumours in vivo. As 
previously mentioned, ADC is the most commonly used metric to summarize 
the water mobility under the assumption that low ADC values correspond to 
increased cellularity. However, ADC is a composite biomarker that conflates 
several biological parameters in a single metric. Cell density, size, shape, 
permeability, subcellular architecture and perfusion all influence the ADC 
measurement making them difficult to separate (Panagiotaki et al., 2014). 
Biophysical models such as VERDICT can estimate the effects of specific 
histologic features through the implementation of complex algorithms, and 
could potentially disentangle the effects of the different components and 
provide more accurate metrics.  
VERDICT MRI has been developed for prostate cancer, with the 
objective of providing information on the size of the cancer cells, the vascular 
compartment, the extracellular and the intracellular volume (Panagiotaki et al., 
2014). The model was proposed by Panagiotaki et al. in 2014 as a way to 
obtain as assessment of the microstructure of the whole-tumour as opposed 
to conventional histology that is limited in sample number and, therefore, 
limited in assessing the structural heterogeneity of cancer. Technically, the 
model is actually the sum of three models characterising diffusion in the 
intracellular compartment (S1), extracellular compartment (S2), and arising 
from the microcirculation (S3). The overall model does not account for any 
potential exchange between the three compartment and is represented by the 
following equation: 
+ = 	∑ D*+*#*J%  [11] 
where fi is the signal at b = 0 from water molecules in population i, 0 ≤ 	D* ≤ 1, 
∑ D*#*J% = 1. Over the past few years, this technique has been successfully 
translated into human and applied to patients with prostate cancer with 
brilliant results in terms of differentiating tumour from benign areas and 
assessing therapy response to cytotoxic drugs (Panagiotaki et al., 2015; 
Bonet-Carne et al., 2018). 
Previous data obtained with conventional ADC and IVIM imaging 
proveides some evidence that grade correlates with extracellular space 
volume and cell density (Vargová et al., 2003; Bisdas et al., 2013). Moreover, 
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as mentioned in paragraph 2.2.1, tissue perfusion measured with IVIM 
imaging was shown to be significantly different between glioma grade (Bisdas 
et al., 2013), in line with a significant body of literature based on perfusion 
MRI. The capability of VERDICT MRI to probe intracellular, extracellular and 
vascular compartments in prostatic cancer suggests that this technique could 
also be used in glioma. Our group has recently translated this technique to 
brain imaging, albeit with some modifications as detailed in chapter 3, and 
published the first proof-of-concept study on the use of VERDICT in patients 
with glioma. The results of that study are presenting in this thesis, chapter 3. 
2.3 Sodium MRI 
An increase in cell metabolic activity is also associated with changes in 
Na+/K+-ATPase activity. In particular, when the consumption of ATP for 
proliferation is higher, the function of the sodium pump may be reduced and, 
as a consequence of this, changes in the extracellular and intracellular 
concentration of these ions will be affected (Madelin and Regatte, 2013). 
Malignant tumours show an increase in intracellular sodium concentration that 
if detectable and could be used to distinguish low-grade and high-grade 
gliomas (Ouwerkerk et al., 2003). Gliomas are characterized by angiogenesis 
and cell proliferation as well as increased lactate formation; these factors, in 
addition to the changes in Na+/K+ transport, produce an acidic extracellular 
environment. Therefore, Sodium MRI (23Na MRI) could also be a surrogate for 
non-invasive assessment of pH.  
Sodium is a quadrupolar nucleus with spin 3/2 that yields the second 
strongest nuclear magnetic resonance signal from biological tissues, after 
protons (Madelin and Regatte, 2013). Although natural abundance sodium is 
detectable with 23Na-MRI, the sensitivity for sodium is 9.2% of the proton 
sensitivity and therefore sodium MRI (23Na-MRI) has an average signal-to-
noise ratio (SNR) which is up to 20,000 times lower than that for protons. 
However, with the advent of high-field scanners, improved radiofrequency 
coils, as well as optimized sequences, 23Na-MRI is now feasible with a 
temporal and spatial resolution that is clinically useful (Konstandin and Nagel, 
2014). Several 23Na-MRI studies have already been performed in the brain to 
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evaluate its possible use for assessing tumours or neurodegenerative 
diseases both qualitatively and quantitatively (Ouwerkerk et al., 2003; Mellon 
et al., 2009; Thulborn et al., 2009; Inglese et al., 2010, 2013; Nagel et al., 
2011; Reetz et al., 2012; Zaaraoui et al., 2012; Yushmanov et al., 2013; 
Haneder et al., 2015). MRI is able to detect and quantify both intracellular and 
extracellular sodium, thus providing a powerful tool to assess tumour 
metabolism and homeostasis (Ouwerkerk et al., 2003; Thulborn et al., 2009; 
Zaaraoui et al., 2012). 
Historically, brain tumours have been of primary interest as a potential 
application for sodium imaging. In the paper that established this field, 
Maudsley postulated why sodium MRI could detect the different components 
within gliomas but was able only to show images of an animal model of stroke 
(Maudsley and Hilal, 1984). The interest in glioma imaging was revamped in 
the nineties by Schuierer et al. and Thulborn et al. (Schuierer et al., 1991; 
Thulborn et al., 1999). Despite the growing interest and the potential utility of 
sodium MRI in primary brain tumours, at present less than 15 studies have 
evaluated this technique in patients with gliomas. This may in part be 
attributed to the technical challenges both in terms of acquisition and post-
processing.  
Sodium Imaging has been performed on patients with gliomas using a 
resolution of up to 4 mm3 isotropic at both 1.5  T (Ouwerkerk et al., 2003) and 
3 T (Haneder et al., 2015), 5.5 mm3 isotropic at 7 T (Nagel et al., 2011) and 3 
mm3 isotropic at 9.4 T (Mirkes et al., 2014). We have developed within the 
group some high-resolution sequences with a nominal resolution of 2 x 2 x 4 
mm3 and 3 mm3 isotropic which are feasible on a clinical 3 T scanner in 
approximately 10 minutes. The higher resolution we have achieved allows a 
more accurate localization of areas expressing alteration in sodium 
concentration. Moreover, we may have a more accurate sodium map that may 
improve biopsy accuracy, therapeutic planning and may assist with better 
tumour stratification. Ouwerkerk et al. in 2003 demonstrated that sodium 
concentration could differentiate normal parenchyma from malignant tissue; 
however, their study was a proof–of-concept study and did not correlate 
sodium concentration with different pathological subtypes (Ouwerkerk et al., 
2003). Acquiring sodium-targeted biopsies would allow a deeper 
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understanding of tumour heterogeneity with the possibility to correlate an 
increase in sodium concentration with other biomarkers such as IDH1 or 
ATRX. 
2.4 Hyperpolarized 13C MRSI 
Tumours metabolise glucose very differently from normal tissue, 
generating lactate even in the presence of oxygen, a process known as the 
Warburg effect (Warburg, 1956). Other metabolic pathways, such as amino 
acid utilisation and fatty acid synthesis, are also reprogrammed in tumours 
compared to normal tissue (Yoshimoto et al., 2001; Kuhajda, 2006; Menendez 
and Lupu, 2007). A number of non-invasive imaging methods have been used 
to probe these alterations in cancer metabolism. A novel technique for 
studying this metabolism is currently under development and has been 
termed hyperpolarized carbon-13 Magnetic Resonance Spectroscopic 
Imaging (MRSI) (Weissleder and Mahmood, 2001). 
Positron Emission Tomography (PET) is an extremely sensitive 
technique for studying molecular processes without disrupting normal 
physiology, with tracer detection in the nano- to picomolar range (Culver et al., 
2008; Kurhanewicz et al., 2011). PET imaging in conjunction with [18F]2-
fluoro-2-deoxy-D-glucose (18F-FDG), is an established clinical tool to probe 
altered glucose metabolism in cancer patients (Czernin et al., 2013). Whole 
body 18F-FDG PET is superior to standard Computed Tomography for the 
assessment of tumour stage in many malignancies (Hicks, 2012), however it 
is limited by a relatively low clinical spatial resolution (of the order of 5 mm), 
poor soft tissue contrast, exposure of patients to ionizing radiation and the 
inability to discriminate between different metabolites or the compartment 
from which the signal arises e.g. extracellular vs intracellular (Gallagher et al., 
2011b; Ehman et al., 2017). 
Magnetic Resonance Spectroscopy (MRS) may also play a useful role 
in probing cancer metabolism by detecting the resonant frequencies of nuclei 
within distinct molecules (such as that of hydrogen, 1H, or protons), therefore 
it can be used to non-invasively discriminate between metabolites (Kwock et 
al., 2006; García-Figueiras et al., 2016). However, in comparison to PET, MRI 
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is a very insensitive technique utilising only a small number of the available 
nuclei to generate an image or spectrum. At clinical field strengths, only a few 
of the available hydrogen nuclei in every million are used to generate these 
images (Kurhanewicz and Vigneron, 2008; Van Der Graaf, 2010). This low 
sensitivity is due to the low polarisation of the nuclei at thermal equilibrium 
and consequently, only molecules at relatively high concentration can be 
probed with MRS. Despite the great potential of MRS as a tool to study 
biochemistry in vivo, it is not used routinely in the clinic due to both the low 
spatial and molecular sensitivity of the technique, and difficulty in subsequent 
data interpretation (Kwock et al., 2006; Gallagher et al., 2011b). 
Dynamic Nuclear Polarisation (DNP) is a technique based in solid state 
physics which greatly increases the signal-to-noise ratio (SNR) achieved on 
MR by significantly increasing the polarisation of nuclear spins and therefore 
enabling a much larger proportion of them to be utilised for imaging 
(Overhauser, 1953). In 2003 DNP was combined with an efficient method to 
transfer the substrate from the solid (~1 K) to liquid (~300 K) state, a process 
which is now known as ‘Dissolution DNP’.  This technique opened up new 
possibilities for the method to be translated into biological systems such as 
cell studies and in vivo animal imaging (Ardenkjaer-Larsen et al., 2003). The 
technique, termed Hyperpolarized Carbon-13 Magnetic Resonance 
Spectroscopic Imaging (HP 13C-MRSI), has now been translated into humans 
(Nelson et al., 2013). This paragraph provides a brief overview of the 
technique, its applications in pre-clinical imaging, an outline of the current 
human trials that are ongoing as well as future potential applications.  
2.4.1 The benefits of metabolic imaging with MRI 
An alternative approach to the steady state measurement of tissue 
metabolites, is to probe dynamic changes in metabolites during enzymatic 
reactions, which can be assessed through the exogenous administration of 
labelled metabolites. A physiologically-active substrate labelled with a nucleus 
that can be detected with MRI, allows spectral discrimination between the 
substrate and its subsequent downstream metabolic products; when applied 
to imaging it allows the spatial distribution of both the substrate and the 
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product to be detected. However, MRS requires long acquisition times which 
in turn makes it difficult to discriminate rapid changes in real-time metabolism 
in vivo.  13C is ideal for labelling endogenous metabolic molecules which are 
mostly carbon based, as its low natural abundance (1.1%) results in a low 
level of background noise. 13C-MRS acquisition from either a single voxel or a 
small number of voxels has been used to successfully analyse many 
	
 
Figure 2.2: Diagram showing the metabolic fate of glucose and pyruvate. 
Abbreviations: LDH - lactate dehydrogenase, ALT - alanine transaminase, PDH - pyruvate 
dehydrogenase, CA - carbonic anhydrase, PC - pyruvate carboxylase, CAT - carnitine 
acyltransferase, CS - citrate synthase, IDH - isocitrate dehydrogenase, GLDH - glutamate 
dehydrogenase, OGDC – oxoglutarate (a-ketoglutarate) dehydrogenase complex, SCS - 
succinyl coenzyme A synthetase, SDH – succinate dehydrogenase (part of succinate-





physiological processes in organs such as in the brain, as well as pathological 
processes including cancer (Neeman et al., 1990; Morris and Bachelard, 
2003; Abrantes et al., 2014). Although 13C-MRS has been used to detect early 
changes in cancer metabolism as a biomarker for response to treatment 
(Neeman et al., 1990),  its utility is limited by very low SNR as well as poor 
temporal and spatial resolution. Therefore the increase in SNR afforded by 
DNP has opened up the possibility of applying 13C-MRS in new ways, allowing 
for rapid acquisition of imaging to probe real-time metabolism (Ardenkjaer-
Larsen et al., 2003; Hurd et al., 2012). 
There are several methods that have been described for increasing 
nuclear polarisation and generically they are termed hyperpolarisation 
techniques; for example, there are a number of approaches for the 
hyperpolarisation of gases used in ventilation imaging (Couch et al., 2015; 
Kruger et al., 2016; Ebner et al., 2017). DNP was first postulated as a 
hyperpolarisation method by Overhauser in 1953 (Overhauser, 1953), and 
has now been applied to 13C-labelled physiologically substrates which are 
rapidly transported and metabolised by the cells. To facilitate the process, 
labelled molecules are mixed with a free-radical containing agent, frozen in a 
glass state, and then cooled to approximately 1 Kelvin in a magnetic field e.g. 
3.35 T or 5 T. At these extreme physical conditions, the electron pool in the 
free radical becomes fully polarised and the transfer of polarisation from the 
electron pool to the nuclear pool is facilitated by microwave irradiation. 
Increasing the polarisation to levels required for in vivo imaging takes 
approximately two hours and following this the sample is removed from the 
field and quickly dissolved with superheated water (Ardenkjaer-Larsen et al., 
2011; Jähnig et al., 2016). This hyperpolarized sample has an increase in 
signal of 10,000 to 100,000-fold and can be used to probe the real-time 
dynamics of enzymatic activity in vitro in cell culture or in vivo in animal 
models, using rapid spectroscopy or imaging (Day et al., 2007; Merritt et al., 
2007; Lerche et al., 2010; Nielsen et al., 2017). The term spectroscopic 
imaging is used where spectra are acquired from multiple voxels to generate 
an image of the metabolic distribution across the tissue.  
One of the challenges of the technique is that the signal from the 
hyperpolarized carbon is very transient and decays with a half-life that is 
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commonly 20-30 s in vivo; therefore perfusion, transport and metabolism must 
occur during approximately 5 half-lives or 2-3 mins. This limits the number of 
in vivo molecules and reactions that can be probed with the technique and 
necessitates very rapid and efficient imaging strategies. 
2.4.1.1 Preclinical imaging 
To date, [1-13C]pyruvate has been the most widely used metabolite for 
hyperpolarized 13C MRSI, due to its relatively long polarisation half-life (the 
time it takes for a compound to lose half of its initial hyperpolarized signal), 
rapid distribution and uptake, and the central role it plays in many metabolic 
pathways (figure 2.1) (Brindle et al., 2011; Lumata et al., 2015). Pyruvate is at 
an important metabolic crossroad between the formation of lactate on one 
hand, and entry into the tricarboxylic acid cycle (TCA) with the formation of 
carbon dioxide on the other. 
In cancer, the 13C label on [1-13C]pyruvate is predominantly exchanged 
to [1-13C]lactate via the enzyme lactate dehydrogenase (LDH) but some will 
also be exchanged to [1-13C]alanine via alanine aminotransferase (ALT), or 
irreversibly converted to 13CO2 via pyruvate dehydrogenase (PDH) (Merritt et 
al., 2007). The production of lactate in tumour tissue, even in the presence of 
oxygen, is termed the ‘Warburg effect’ and has been observed using HP 13C-
MRSI in a variety of preclinical cancer models. There is evidence that the 
labelling of lactate correlates with tumour grade, with higher lactate labelling 
present in more aggressive tumours (Warburg, 1956; Albers et al., 2008). HP  
13C-MRSI has also been used to demonstrate a consistent decrease in the 
13C exchange between [1-13C]pyruvate and [1-13C]lactate during tumour 
responses, regardless of treatment type in various in vitro and in vivo models, 
with changes seen as early as 24 hours after the initiation of therapy, and 
sometimes earlier than conventional imaging modalities such as diffusion-
weighted imaging (Day et al., 2007, 2011; Witney et al., 2009, 2010; Ward et 
al., 2010; Bohndiek et al., 2012). HP 13C-MRSI may also have a role in the 
early detection of preneoplastic changes, as demonstrated in a pancreatic 
model evaluating LDH activity with increased HP 13C label exchange between 
13C-pyruvate and endogenous lactate present with the onset of neoplastic 
transformation (Serrao et al., 2016). 
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2.4.2 Translation into human imaging  
The first human study using HP 13C-MRSI was completed in 2013 at the 
University of California San Francisco (UCSF) (Nelson et al., 2013). This 
study demonstrated the safety and feasibility of HP 13C-MRSI with [1-
13C]pyruvate in thirty one male subjects with biopsy-proven prostate cancer. 
Patients were injected with hyperpolarized 13C-pyruvate. Signals from 
pyruvate and lactate were observed in the vasculature, tumour and normal 
prostate at the 3 dose levels considered (0.14, 0.28 and 0.43 mL/kg actual 
body weight of 230 mM pyruvate solution) and uptake in the prostate was 
observed approximately 20 seconds after injection.   
A few mild adverse events such as dysgeusia (5/31 patients) were 
reported but none of them were considered to be dose-limiting toxicities. Two 
single events of dizziness and grade 2 diarrhoea reported in the phase 2 
component, were attributed to concomitant medications. The highest dose 
tested, 0.43 mL/kg of 13C-pyruvate solution, showed the highest SNR for 13C-
pyruvate as expected. The study also demonstrated an elevated 13C-
lactate/13C-pyruvate ratio on HP 13C-MRSI in one patient where no 
abnormality was detectable on conventional 1H-MRI; this patient was 
subsequently shown to have a biopsy-proven low-grade tumour (figure 2.2). 
The study concluded that the data confirmed both the safety of the agent and 
	
 
Figure 2.3: Hyperpolarized pyruvate metabolism in human prostate cancer. 
Images from a patient with bilateral biopsy-proven Gleason grade 3+3 prostate cancer. (a) 
Axial T2 weighted image and (b) apparent diffusion coefficient map showing a peripheral 
zone tumour (red arrows). (c) False colour metabolic map superimposed over the the 
proton image showing voxels with an elevated ratio of hyperpolarized [1-13C]lactate/[1-
13C]pyruvate bilaterally in the prostate and highlighted in pink, obtained after 
administration of hyperpolarized [1-13C]pyruvate. Adapted from Nelson et al 2013. 
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Figure 2. Hyperpolarized pyruvate metabolism in human prostate cancer. Images from a patient with bilateral biopsy-proven 
Gleason Grade 3 + 3 pr state cancer. (a) Axial T2 weighted image and (b) pparent diffusion coefficient (ADC) m p sho ing a 
peripheral zone tumour ( arrows). (c) False colour metabolic map superimposed over the proton image showing voxels with an 
elevated ratio of hyperpolarized (1-13C)lactate/(1-13C)pyruvate bilaterally in the prostate and highlighted in pink, obtained after 
administration of hyperpolarized (1-13C)pyruvate. Adapted from Nelson et al18 with permission.
abnormality was detectable on conventional 1H-MRI; this patient 
was subsequently shown to have a biopsy-proven low-grade 
tumour (Figure 2). The study co cluded that the d ta confirmed 
both the safety of the agent and that an elevated 13C-lactate/13C-py-
ruvate may be seen in regions that were otherwise undetectable 
with standard methods, opening up the possibility of using meta-
bolic imaging to detect occult tumours.
This initial study required a sterile room for the production and 
hyperpolarization of the 13C pyruvate prior to dissolution and 
injection. Wider application of the technology was made possible 
by the design of  new plat orm which utilizes an integral, dispos-
able and sterile fluid path or pharmacy kit (Figure 3).29 The SPINlab 
hyperpolarizer, produced by GE Healthcare, uses a closed-cycle 
cryogenic system and has ultisample capability (Figure 4). The 
pharmacy kit is prefilled and sealed in a sterile environment, before 
being transferred to the clinical hyperpolarizer, thus enabling the 
hyperpolarization of a pyruvate sample within a routine clinical 
environment such as a radiology department, whilst maintaining 
the sample sterility. Filled pharmacy kits can either be used on the 
day of production or stored frozen depending on the method that 
is used.
Clinical imaging studies
There are currently six sites that have undertaken clinical 
imaging with the technique, although several other facilities 
will commence human imaging in the near future. Current 
studies in human HP 13C-MRSI research are exploring pyru-
vate metabolism in a number of organs such as the brain, 
heart, liver and breast and in a variety of disease processes. 
Several of these studies are evaluating HP 13C-MRSI derived 
biomarkers in addition to tissue samples in order to under-
stand and validate the biophysical nature of signal generation 
with HP 13C-MRSI. Another important aim is to establish the 
reproducibility and repeatability of the technique.
A significant objective of the current clinical studies is to 
investigate HP 13C-MRSI as an imaging biomarker of early 
treatment response. Many of these studies are being run in 
parallel with other conventional imaging tests for measuring 
treatment response, as well as functional MR imaging tech-
niques, such as dynamic contrast-enhanced MRI. Changes in 
tumour metabolism in response t  therapy have been shown 
to occur before anatomical changes can be detected and 
potentially could be earlier than functional imaging alter-
ations. The use of the technique as a response biomarker has 
been demonstrated in several animal studies and is now being 
translated to humans (Figure 5).34,39,42,44 An exciting area for 
future research is how changes in metabolism measured by HP 
13C-MRSI following treatment relate to circulating tumour 
biomarkers such as cell-free DNA,45,46  as this would increase 
the ability to non-invasively int rrogate tumour activity and 
responses to therapies, and spare patients the complications 
associated with serial biopsies. Potentially, HP 13C-MRSI may 
provide a specific pharmacodynamic downstream imaging
biomarker of both conventional and novel agents, and could 
also be used to detect early changes following therapy which 
are predictive of long-term response. This could therefore 
provide a novel non-invasive precision medicine approach to 
drug development, permitting early cessation of ineffective 
drugs and providing a cost saving in terms of patient time and 
toxicities.
THE FUTURE OF THE TECHNIQUE
MRI hardware developments for hyperpolarization
Despite the large increase in SNR that is generated by DNP, both 
the hardware and acquisition sequences required have to be opti-
mized to avail of this i creased signal. Dedicated 13C coils are
needed for the technology: current research being undertaken aims 
to optimize coil design and pulse sequences to maximize the signal 
acquired. For example, the use of multiple-channel coil arrays can 
enable parallel imaging techniques to accelerate acquisition while 
retaining sensitivity.47  Calibrationless methods have been shown to 
overcome the limitations of the short-lived hyperpolarized species 
in this context.48
There have been several different imaging schemes proposed 
for the acquisition of hyperpolarized 13C data.49–51 A key 
component of most sequences is the use of single shot, multiple 
time point acquisition to acquire dynamic, 0-specific data.51 
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that an elevated 13C-lactate/13C-pyruvate may be seen in regions that were 
otherwise undetectable with standard methods, opening up the possibility of 
using metabolic imaging to detect occult tumours. 
This initial study required a sterile room for the production and 
hyperpolarisation of the 13C pyruvate prior to dissolution and injection. Wider 
application of the technology was made possible by the design of a new 
platform which utilises an integral, disposable and sterile fluid path or 
pharmacy kit (figure 2.3) (Ardenkjaer-Larsen et al., 2011). The SPINlab 
hyperpolarizer, produced by GE Healthcare, uses a closed-cycle cryogenic 
system and has multi-sample capability (figure 2.4). The pharmacy kit is 
prefilled and sealed in a sterile environment, before being transferred to the 
clinical hyperpolarizer, thus enabling the hyperpolarisation of a pyruvate 
sample within a routine clinical environment such as a radiology department, 
	
 
Figure 2.4: Pharmacy kit for clinical polarisation. 
The kit contains pyruvate sealed within a closed sterile environment. The kit includes: a 
sample vial, the concentric tube assembly, the multi-position inlet/outlet valve, a syringe 




whilst maintaining the sample sterility. Filled pharmacy kits can either be used 
on the day of production or stored frozen depending on the method that is 
used.   
2.4.3 Clinical imaging studies 
There are currently six sites that have undertaken clinical imaging with 
the technique, although several other facilities will commence human imaging 
in the near future. Current studies in human HP 13C-MRSI research are 
exploring pyruvate metabolism in a number of organs such as the brain, heart, 
liver and breast and in a variety of disease processes. Several of these 
studies are evaluating HP 13C-MRSI derived biomarkers in addition to tissue 
samples in order to understand and validate the biophysical nature of signal 
generation with HP 13C-MRSI. Another important aim is to establish the 
reproducibility and repeatability of the technique.  
	
 
Figure 2.5: Schematic of cryostat, magnet and sorption pump; GE SPINlab Diamond 
Polariser. 
(a) Schematic of cryostat, magnet and sorption pump. The 3.35 T magnet is located within 
a helium-filled cryostat and suspended within an external vacuum vessel. Reproduced 
from Ardenkjaer-Larsen et al37 with permission. (b) Photograph of the SPINlab Diamond 
Polariser for clinical use in Cambridge (GE Healthcare). This clinical SPINlab uses a 5T 
magnet. 
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Figure 4. (a) Schematic of cryostat, magnet and sorption pump. The 3.35 T magnet is located within a helium-filled cryostat and 
suspended within an external vacuum vessel. Reproduced from Ardenkjaer-Larsen et al29 with permission. (b) Photograph of the 
SPINlab Diamond Polarizer for clinical use in Cambridge (GE Healthcare). This clinical SPINlab uses a 5T magnet.
Figure 5. 13C spectroscopic imaging of a murine lymphoma tumour before and after drug treatment. Colour maps representing 
(1-13C)lactate and (1-13C)pyruvate peak intensities obtained from 13C chemical-shift imaging i  the same mouse before and after 
treatment with the chemotherapeutic agent etoposide. The proton greyscale images define the tumour margins (indicated in 
white). Reproduced from Day et al34 with permission.
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A significant objective of the current clinical studies is to investigate HP 
13C-MRSI as an imaging biomarker of early treatment response. Many of 
these studies are being run in parallel with other conventional imaging tests 
for measuring treatment response, as well as functional MR imaging 
techniques, such as dynamic contrast-enhanced (DCE) MRI. Changes in 
tumour metabolism in response to therapy have been shown to occur before 
anatomical changes can be detected and potentially could be earlier than 
functional imaging alterations. The use of the technique as a response 
biomarker has been demonstrated in several animal studies and is now being 
translated into humans (Day et al., 2007, 2011; Witney et al., 2009; Aggarwal 
et al., 2017). An exciting area for future research is how changes in 
metabolism measured by HP 13C-MRSI following treatment relate to 
circulating tumour biomarkers such as cell-free DNA (Dawson et al., 2013; 
Bettegowda et al., 2014), as this would increase the ability to non-invasively 
interrogate tumour activity and responses to therapies, and spare patients the 
complications associated with serial biopsies. Potentially, HP 13C-MRSI may 
provide a specific pharmacodynamic downstream imaging biomarker of both 
conventional and novel agents, and could also be used to detect early 
changes following therapy which are predictive of long-term response. This 
could therefore provide a novel non-invasive precision medicine approach to 
drug development, permitting early cessation of ineffective drugs and 
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Gliomas are primary brain tumours characterised by diffuse infiltration 
and a poor prognosis (Paulus and Peiffer, 1989; Louis et al., 2016). Genetic 
and phenotypic heterogeneity contribute to both poor therapy response and 
tumour recurrence (Anjum et al., 2017; Daher and de Groot, 2018). Magnetic 
Resonance Imaging (MRI) is the imaging modality of choice but is limited in 
assessing tumour subtypes and intratumoral heterogeneity (Sottoriva et al., 
2013; Mabray et al., 2015; Ceccarelli et al., 2016; Aihara et al., 2017). In 
addition, conventional imaging is ineffective in evaluating the spread of 
tumour into the peritumoral region which may lead to sub-optimal resection 
and recurrence (Langen et al., 2017). Consequently, new imaging biomarkers 
are required to improve the assessment of glioma. 
Several studies have addressed the importance of Diffusion-Weighted 
Imaging (DWI) and the apparent diffusion coefficient (ADC) in evaluating 
gliomas but have shown partial overlap in the measured values between 
subtypes (Kono et al., 2001; Bulakbasi et al., 2004; Hilario et al., 2014). The 
ADC may have a role in differentiating high grade glioma from metastases 
and in assessing peritumoral oedema, but it cannot accurately differentiate 
primary brain tumour subtypes (Kono et al., 2001; Oh et al., 2005; Server et 
al., 2009; Lee et al., 2011; Hilario et al., 2014).  
The Vascular, Extracellular and Restricted Diffusion for Cytometry in 
Tumours (VERDICT) is a model that infers tissue microstructure from DWI 
measurements (Panagiotaki et al., 2014). This model derives multiple 
compartments (intracellular, intravascular and extracellular–extravascular 
Chapter 3   
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spaces) and has been applied to xenograft models of colorectal cancer, 
patient studies of prostate cancer and has recently been shown to be feasible 
in glioma (Panagiotaki et al., 2014, 2015a; Bailey et al., 2018; Roberts et al., 
2018). Here we have applied this method to image intratumoral and 
intertumoral heterogeneity in glioma and validated with histology as part of a 
prospective study. The primary aims of this prospective study were to 
demonstrate the use of the technique in the human brain for the first time and 
to show feasibility in a clinical environment. The secondary aim was to 
validate VERDICT parameters with histopathologic analysis on a patient-by-
patient basis. Exploratory aims of this study were to evaluate the potential 
utility of the modelled parameters as biomarkers of glioma heterogeneity and 
subtype as well as the presence of tumour in the peritumoral environment.   
3.1 Methods and materials 
3.1.1 Patient selection 
Fourteen consecutive treatment-naïve patients (6 men, 8 women; age 
43.5 ± 15.1 years) were recruited into this prospective ethically-approved 
study (East of England, Cambridge South Research Ethics Committee, REC 
reference number 16/EE/0184) from a neuro-oncology multidisciplinary team 
meeting or clinic. Subjects were scheduled for for image-guided biopsy or 
resection and gave written informed consent.  
3.1.2 MRI acquisition 
MRI examinations were performed using a 3.0 T clinical scanner and a 12-
channel head coil (Discovery MR750; GE Healthcare). Imaging included: 3D 
T2-weighted imaging (T2W; repetition time/echo time [TR/TE] 2500/79 ms; 248 
slices; slice thickness 1.2 mm; acquisition matrix 320x320; field of view [FOV] 
240x240 mm), 2D T2W fluid-attenuated inversion recovery (FLAIR; TR/TE 
8000/126ms; inversion time [TI] 2128 ms; slice thickness 6 mm; acquisition 
matrix 384x224; FOV 240x240 mm) and DWI (TR/TE 2841-3867/83.3-87.4 
ms; slice thickness 5mm; b-values 0,1000 s/mm2; matrix 128x128; FOV 
240x240 mm). 3D T1-weighted Fast SPoiled GRadient echo (T1W FSPGR; 
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252 slices; 0.94x0.94x1.5 mm reconstructed to 0.94x0.94x1 mm; TR/TE 
8.2/3.2; slice thickness 1.5 mm; matrix 256x256; FOV 240x240 mm) was 
performed before and after injection of a gadolinium-based contrast agent 
(Gadobutrol 1.0 mmol/mL; Schering). ADC maps were generated as per 
clinical standard.  
3.1.3 VERDICT acquisition and post-processing 
VERDICT is a model-based diffusion MRI proposed in 2014 to quantify 
tumour microstructure (Panagiotaki et al., 2014). The model assumes that a 
wide range of tumours can be characterised by assessing three different 
compartments: the vascular compartment, the extracellular-extravascular 
space and the intracellular space.  Technically, as also described in chapter 2, 
the model is the sum of three models characterising diffusion in the 
intracellular compartment (S1), extracellular compartment (S2), and arising 
from the microcirculation (S3). The overall model does not account for any 
potential exchange between the three compartments and is represented by 
the following equation: 
+ = 	∑ D*+*#*J%  [11] 
where fi is the signal at b = 0 from water molecules in population i, 0 ≤ 	D* ≤ 1, 
∑ D*#*J% = 1.  
The parameters for DWI and VERDICT modelling used in this study 
are shown in table 3.1, the spatial resolution was 2 mm isotropic (Panagiotaki 
et al., 2015a). For each b-value, a separate b=0 image was acquired to 
compensate for varying T2-weighting. To assess the robustness of the 5 b-
value abbreviated acquisition, an extended protocol using 40 b-values was 
undertaken in one patient within the limits of the clinical gradient system 
(Gmax, 45 mT/m; slew rate, 200 mT/m/s). The echo time (TE) scaled as a 
consequence of an increase of the diffusion time (the time between the 
diffusion sensitising gradients, expressed as ∆ in table 3.1), thus in turn 
increasing the total time between excitation and refocussing leading to longer 
echo times. Each scan was normalised with their respective own unweighted 






∆ /∂(ms) Echo Time 
(ms) 








90 23.5/4.7 49.3 49.4 8 2 200000 
500 31.3/12.2 64.3 41.5 8 2 200000 
1500 43.4/25.8 91.4 30.1 8 2 200000 
2000 32.1/16.5 72.7 75.8 8 2 200000 
3000 43.8/24.8 89.4 43.9 8 2 200000 
	
Table 3.1: Diffusion MRI parameters for the abbreviated VERDICT model. 
Parameters used for the shortened protocol: ∆ is the time separation between the gradient 
pulses; ∂ Is the duration of the pulses; |G| is the combined gradient strength of the diffusion 
encoding.  
	
The tumours were located on T2W and then 16 axial DWI slices were 
acquired over the region-of-interest (ROI) for VERDICT modelling. The 
acquisition time for each b-value was 66 s, with a total time of 330 s. Tumour 
cell radius, intracellular (IC) and combined extracellular/vascular volume (EC) 
were calculated (MATLAB 2016b, the MathWorks) using a framework based 
on linearization and convex optimization which provides an acceleration factor 
of 1500 (Daducci et al., 2015; Bonet-Carne et al., 2016). Intracellular and 
extracellular spaces were modelled separately and therefore the sum of both 
compartments was only approximately 100%. Parameter maps were 
registered to 3D T1W obtained after gadolinium-based contrast agent injection 
and 3D T2W sequences (SPM12, UCL).  
3.1.4 MRI analysis 
A neuroradiologist with 6 years of experience in neuro-imaging outlined 
ROIs on axial T2W and axial 3D-T1W post-contrast sequences using OsiriX 
(V.8.5.2, Pixmeo SARL). To assess the reproducibility of the ROI definition, a 
second observer with 3 years of experience in neuro-imaging, blind to the 
clinical data, performed a second analysis using the same software. ROIs 
were drawn around the entire lesion including the surrounding oedema using 
a combined evaluation of T1W and T2W imaging. The 3D-T1W images 
obtained after injection of a gadolinium-based contrast agent were used to 
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better define the enhancing tissue and the necrosis (if present) whilst the 
T2WI were used to better highlight the oedema boundaries. ADC and 
VERDICT maps were co-registered to the anatomical imaging to calculate the 
microstructural parameters.   
3.1.5 Pathological analysis 
All enrolled patients underwent image-guided biopsy or resection using 
the 3D-T1W imaging obtained after injection of a gadolinium-based contrast 
agent as per clinical routine and to facilitate retrospective correlation with 
imaging. Screenshots of the neuro-navigation system were saved during the 
procedure to guide pathological analysis. Histopathology was used to 
determine the tumour grade and type using WHO-2016 classification (Louis et 
al., 2016). A neuropathologist with 7 years of experience evaluated tumour 
photomicrographs from a x600 FOV and a fixed matrix of 184x138 µm to 
assess cellularity and cell size using semi-automated software (Image-Pro 
Insight). Average tumour cell size was assessed by measuring the short and 
long axes of 20 cancer cells in each FOV for patient-by-patient correlation 
with the cell size obtained processing the VERDICT data. To determine if 
shrinkage post fixation affected these measurement, red blood cell size was 
compared between a blood smear and a stained section in the same patient 
(Hsu et al., 2007; Tran et al., 2015).  
3.1.6 Statistical Analysis 
Statistical analysis was performed using a mathematical analytical 
software (Matlab Statistics and Machine Learning Toolbox, Matlab 2017a, 
Mathworks). A Kolmogorov–Smirnov test was used as a goodness-of-fit test 
comparing our data to a standard normal distribution to confirm the 
appropriateness of using non-parametric tests for the statistical analysis. 
Comparisons between pathological analysis and VERDICT parameters were 
performed using the Wilcoxon rank-sum test. The same non-parametric 
statistical test was used to assess the difference in cell size and density and 
to compare the results obtained by the two observers. A statistical 
significance of p £ 0.05 was used. The Dice similarity coefficient (DSC) was 
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used to assess the reproducibility of the segmentation performed by the two 
observers (Dice, 1945); a coefficient > 0.70 indicates good overlap between 
the ROIs (Zijdenbos et al., 1994; Zou et al., 2004). 
3.2 Results 
The demographics and tumour characteristics are shown in Table 3.2. 
VERDICT fitting was successfully performed for all patients. The time window 
between imaging and surgery was 17.5 ± 12.3 (median ± standard deviation; 
range: 4 – 46) days in patients with LGG and 5.2 ± 6.4 (1 – 17) days in 
patients with HGG. Patients included: seven low grade gliomas (LGG: four 
diffuse, isocitrate dehydrogenase 1 [IDH1] R132H mutant astrocytomas; three 
IDH1 R132H mutant, 1p19q co-deleted oligodendrogliomas) and seven high 
grade gliomas (HGG: six IDH-wildtype glioblastomas; one IDH-wildtype 
astrocytoma). 
 
 Low Grade Glioma  High Grade Glioma  p 
Age in years 
 
33.2 ± 9.2  
(24 – 45) 
55.3 ± 11.9 
(44 – 78) 
< 0.01 
 
Men, n (%) 2 (28.6%) 4 (57.1%) 0.59 
Lesion size in mm 
 
44.4 ± 19.1 
(23.1 – 68.7) 
27.1 ± 17.2 
(6.4 – 56.4) 
0.13 
 
IDH1 R132H, n (%) 












4.2 ± 3.0 
(1 – 8.8) 
19.2 ± 6.7 




Table 3.2: Demographic data and histopathological characteristics for high grade and low 
grade tumours. 
IDH1 R132H: mutations involving isocitrate dehydrogenase 1. The monoclonal antibody MIB-
1 was used to determine the Ki-67 labelling index as a marker of proliferation. Continuous 
values are expressed as mean ± SD with range in parentheses. 
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3.2.1 Histopathological analysis 
The histopathological measure of cell radius (Figure 3.1) was not 
significantly different in HGG compared to LGG: 5.7 ± 1.4 µm (range: 4.5 – 
8.1) vs. 4.6 ± 1.6 µm (3.1 – 8.1) respectively (p = 0.16). The red blood cell 
size was 5.5 ± 0.7 µm (range 4.4 – 6.9) on fixed sections and 7.6 ± 0.6 µm 
(6.6 – 8) on the cell smear (p < 0.001) demonstrating a reduction in size 
following fixation.  
	
 
Figure 3.1: Cell radius at MRI and pathology. 
(A) Box-and-whisker plot illustrating the cell radius as measured by VERDICT MRI and 
pathology for low grade glioma (LGG) and high grade glioma (HGG). (B) H&E staining from 
a low grade glioma shown in Fig. 2. (C) H&E staining from a high grade glioma also shown 






There was a trend towards a higher histological cell density in HGG 
compared to LGG: 104 ± 43 cells/FOV (range: 67 – 170) vs. 51 ± 66.4 




Figure 3.2: Representative low grade and high grade glioma. 
(A) - (F) Representative images from a low grade glioma: (A) axial post gadolinium 3D T1WI; 
(B) intracellular volume fraction; (C) cell radius maps; (D) axial T2WI; (E) extracellular volume 
fraction; (F) ADC map; scale shown x10-6 mm2/s. Colour maps for B, C and E have been 
superimposed on the grayscale image from A with the colour scale shown for each image. (G) 
- (N) Representative images from a high grade glioma: (G) axial post gadolinium 3D T1WI; (H) 
intracellular volume fraction; (I) cell radius maps; (J) axial T2WI; (K) extracellular volume 
fraction; and (L) ADC map, scale shown x 10-6 mm2/s. Colour maps for H, I and K have been 





3.2.2 VERDICT analysis 
VERDICT parametric maps for LGG and HGG are shown in Figure 3.2. The 
calculated cell radius was similar in both groups: 6.8 ± 2.3 µm for HGG (range 
4.3 – 11) and 6.7 ± 1.2 µm for LGG (4.8 – 7.8); Figure 3.1. There were no 
significant differences between VERDICT radius measurements and those 
from pathological sections for either LGG (p = 0.09) or HGG (p = 0.80). The 
intracellular volume fraction was higher in HGG compared to LGG: 0.13 ± 
0.07 (range 0.08 – 0.27) vs. 0.08 ± 0.02 (0.07 – 0.14) respectively; p = 0.05. 
The extracellular/vascular volume fraction showed the opposite trend with a 
higher EC volume fraction in LGG compared to HGG but this was not 
significant: 0.92 ± 0.04 (range 0.85 – 0.95) vs. 0.88 ± 0.07 (0.75 – 0.92) 
respectively; p = 0.10, Figure 3.3. DWI as per clinical standard was obtained 
in 12/15 patients. The conventional ADC was higher in LGG compared to 
HGG: 1.22 ± 0.13 x 10-3mm2/s (range 1.13 – 1.44) vs. 0.98 ± 0.38 x 10-3mm2/s 
(0.77 – 1.74); however, the difference was not statistically significant (p = 
0.18); Figure 3.4.  
 
	
Figure 3.3: Volume fractions for low grade and high grade glioma. 
Box-and-whisker plot showing intracellular volume fraction (IC) and extracellular volume 
fraction (EC) for both low grade gliomas (LGG) and high grade gliomas (HGG) derived 





3.2.3 Reproducibility analysis 
The assessment of the reproducibility in the ROIs segmentation for the entire 
tumour region performed by the two observers resulted in high reproducibility 
demonstrated by a DSC of 0.89 ± 0.06 (0.80 - 0.99). A sub analysis 
performed according to grading demonstrated similar results with a DSC of 
0.89 ± 0.05 (0.82 - 0.94) for LGG and 0.89 ± 0.08 (0.80 - 0.99) for HGG.  
The results of the analysis performed by the second observer are shown in 
Table 3.3. 
 
 LGG HGG 
 Obs 1 Obs 2 p Obs 1 Obs 2 p 
Cell radius (µm) 6.7±1.2 6.7±1.5 0.53 6.8±2.3 6.1±2.1 1 
IC volume fraction 0.08±0.02 0.11±0.03 0.07 0.13±0.07 0.12±0.06 0.93 
EC volume fraction 0.92±0.04 0.91±0.05 0.60 0.88±0.07 0.89±0.05 0.94 
	
Table 3.3: Comparison between the two observers. 
Comparison between the VERDICT parameters derived by the analysis performed by the two 




Figure 3.4: Apparent diffusion coefficient for low grade and high grade glioma. 
Apparent diffusion coefficient (ADC) values for low grade glioma (LGG) and high grade 





3.3 Discussion  
VERDICT is an advanced diffusion method which has previously been 
applied to pre-clinical models of cancer showing microstructural differences 
between tumours and a decrease in cell volume following chemotherapy 
(Panagiotaki et al., 2014). The method has also been shown to differentiate 
benign prostate tissue from tumour in patients (Panagiotaki et al., 2015a). In 
this study we have compared VERDICT to histopathological findings at 
surgery and correlated with tumour grade. Non-invasive grading of glioma is a 
major challenge for conventional MRI and biopsied tissue is limited by 
sampling error as the tumour is very heterogeneous (Langen et al., 2017). 
Conventional ADC has a sensitivity and specificity for differentiating high and 
low grade tumours of only 85% and 80% respectively and there is a large 
overlap in ADC between grades (Zhang et al., 2017). Therefore, additional 
imaging methods are required to accurately differentiate tumour subtypes and 
to demonstrate tumour heterogeneity (Kono et al., 2001).  
VERDICT parameters showed a higher intracellular volume fraction in 
HGG compared to LGG and a trend towards a smaller extracellular/vascular 
volume fraction. As IC and EC are independently derived, their 
complementarity demonstrates intra-model consistency. Moreover, these 
results were validated with the histological findings where there was a higher 
cell density in HGGs compared to LGGs. Importantly, although the 
conventional ADC was higher in LGG compared to HGG, this was not 
statistically significant. Therefore, VERDICT could provide important 
additional information which is complementary to conventional DWI. 
Moreover, the capability of VERDICT to explore micro-architectural changes 
through assessing the relative volume fraction has a significant potential role 
in evaluating tumour infiltration in the peritumoral region. Indeed, visual 
assessment of the maps revealed significant heterogeneity in the peritumoral 
zone both in LGG and HGG. For instance, in the representative case of LGG 
depicted in Figure 3.2, there were areas of increased intracellular volume 
fraction and increased cell radius not corresponding to areas of suspicion on 
conventional imaging. Similarly, the representative case of HGG showed an 
increased intracellular volume fraction and increased cell radius within the 
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peritumoral region but outside the boundaries of the contrast enhancing 
lesions. However, targeted biopsies were not obtained from these areas, 
warranting future studies to explore the significance of those findings.   
VERDICT-derived maps showed a higher degree of heterogeneity 
compared to the corresponding ADC maps. This phenomenon was 
particularly evident in HGG (Figure 3.2) where regional differences in the 
VERDICT maps were not visible on ADC. The areas of high IC volume largely 
corresponded to the independently-derived areas of low EC volume, which 
again provides evidence that the model is internally consistent. Future studies 
can validate this heterogeneity using multiregional biopsies and the technique 
could be used as a tool to assess changes in this heterogeneity with 
treatment as well as a method to assess the resection cavity following surgery 
(Panagiotaki et al., 2014). 
The range of cell size was larger for HGG compared to LGG on both 
VERDICT and histopathology in keeping with the more heterogeneous nature 
of the higher-grade tumours. The patient-by-patient validation of cell size 
measured with VERDICT against the pathological assessment demonstrated 
no statistically significant difference between the two techniques for both HGG 
(p = 0.80) and LGG (p = 0.09). However, a one-to-one comparison with 
pathology is difficult to achieve due to several limiting factors. Sampling errors 
are a major potential confounding factor given that only a small proportion of 
the tumour was biopsied and this may not represent the whole tumour 
(Panagiotaki et al., 2014). Moreover, brain shift during surgery and the 
different scale of pathology and imaging (µm vs mm) also contribute to 
potential mis-registration. It is also worth noting that the model used in this 
study was optimized for the assessment of gliomas. Indeed, the model 
requires an average expected cell size as input information and has been 
fine-tuned on a specific cell shape. With the aims of assessing the feasibility 
of the technique and obtain preliminary validation data, the model was 
optimized to embrace a wide spread of gliomas, however, different tumours 
have different histological characteristics, therefore it would be desirable to 
optimize a pool of models in order to harness the full potential of the 
technique. For example, astrocytomas have low to moderate cell density with 
variable cellular morphology, whilst oligodendroglioma are more hypercellular 
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with more uniform cellular morphology thus they would be better assessed 
with dedicated models.  
The slight reduction in cell size measurements on histopathology 
compared to the in vivo measurements may be accounted for by shrinkage 
following fixation which is a known phenomenon both at the macroscopic and 
microscopic and level. Shrinkage is accounted for by a combination of 
dehydration and direct effects of formalin. In particular, formalin fixation is a 
two-step process characterised by initial diffusion in the tissue and 
accumulation followed by the binding phase in which chemical bounds 
between protein and nucleic acids are promoted by formalin (Hsu et al., 
2007). Macroscopically, several authors reported shrinkage of the cerebrum, 
cerebellum and brain stem (Quester and Schröder, 1997). More interesting 
and pertinent to this study is that microscopic shrinkage after fixation was 
observed in a plethora of different cancers including breast cancer (Pritt et al., 
2005), non-small cell lung cancer (Hsu et al., 2007; Park et al., 2017), renal 
tumours (Tran et al., 2015), oral squamous cella carcinoma (Umstattd et al., 
2017) and melanoma (Friedman et al., 2019). Therefore, caution must be 
applied when comparing pathological specimens and image-derived 
biomarkers. In this study the comparison between VERDICT-derived 
biomarkers and pathology was aimed at validating the imaging measurements 
as correlative biomarkers to the reference standard. However, direct 
correspondence was not expected due to the effects of fixation. To assess 
this effect, we collected blood smears to assess the magnitude of shrinkage in 
our cohort: we found a good correspondence between image-derived and 
pathological biomarkers, especially taking into account the magnitude of 
shrinkage we observed in the red blood cells. Although there is no ground 
truth for cell size the aim was to correlate relative cell size measurements on 
histology and imaging, rather than to assess absolute cell size. 
Rapid acquisition and data analysis are necessary for clinical 
translation of the method and the abbreviated VERDICT MRI protocol 
proposed by Panagiotaki et al. (Panagiotaki et al., 2015b) was performed in 
5.5 min representing a reduction of 45 min compared to the extended 
protocol. A single case was acquired with both the abbreviated and extended 
protocol (results presented in the supplementary material) to explore the 
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magnitude of change in the imaging biomarker derived with those two 
different approaches. The estimation of the intracellular and extracellular 
volume fractions were similar, although a formal statistical analysis was not 
performed as both protocols were performed on a single case. However, the 
similarity in resulting parameters suggest the abbreviated protocol can be 
successfully applied to explore cellularity in gliomas by adding only few 
minutes to a standard brain protocol. In addition, the data fitting was 
combined with a post-processing algorithm based on linearization and convex 
optimization which reduced the computing by more than 1500-fold to allow the 
analysis to be made available within a clinically applicable timescale: 25.5±5.3 
min for acquisition and post-processing (Daducci et al., 2015; Bonet-Carne et 
al., 2016).  
The primary objective of the work was to assess the feasibility of using 
VERDICT MRI to investigate the tissue microstructure in glioma in a clinical 
setting. The limitations of the study include a small sample size which may 
have reduced the statistical power of the study. Also, the original VERDICT 
model is designed to compute the intracellular, intravascular and 
extracellular–extravascular spaces in an animal model of prostate cancer at a 
pre-clinical field strength of 9.4T which has significantly higher diffusion 
gradient capabilities of ~300 mT/m. The computational modelling can become 
unstable with the noise and time constraints experienced at clinical field 
strength which can compromise the computational fit of the intravascular 
compartment (Panagiotaki et al., 2015a). Correlation between histology and 
imaging is also challenging as 2 mm thick imaging slices were compared to 4 
μm pathological slides which could introduce sampling errors, particularly 
given the heterogeneous nature of glioma. Future larger studies are needed 
to more fully validate the technique against histopathology and to explore its 
potential applications as a routine clinical tool.  
3.4 Conclusion 
In conclusion, VERDICT MRI could be a promising technique to assess 
the tissue microenvironment within glioma using a clinically applicable 
protocol. The derived parameters demonstrated larger cells and a trend 
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towards a smaller extracellular space in high grade tumours compared to low 
grade tumours. This approach may provide additional information compared 
to conventional diffusion weighted imaging.  
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Short vs. extended protocol 
The extended protocol duration was 49.5 min and the post-processing 
required 16 min; the abbreviated protocol was 5.5 min and the post-
processing required 20 ± 5.3 min (Table 4). The computing time to perform 
the fit without linearization and convex optimization was estimated to be more 
than 343 hours for a single patient and was not deemed feasible. The cell 
radius was 4.1 ± 0.6 µm using the extended protocol and 3.4 ± 0.7 µm with 








Scan time (min) 49.5 5.5 
Cell radius (µm) 4.1 ± 0.6 3.4 ± 0.7 
IC volume fraction 0.12 ± 0.02 0.11 ± 0.01 
EC volume fraction 0.88 ± 0.02 0.81 ± 0.02 
	
Table 3.4: Extended VERDICT MRI protocol compared to the abbreviated protocol. 
Comparison between the scanning time and derived metrics for the full and the abbreviated 
protocols for the single patient that underwent both approaches. Values are expressed as 
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Gliomas are tumours that arise from the cells that surround and support 
the neurons termed glial cells which include	 astrocytes (origin of astrocytomas 
and glioblastomas), oligodendrocytes (origin of oligonderoglioma), and 
ependymocytes (origin of ependymomas). Among primary brain tumours, 
gliomas are the most common, accounting for nearly 70% of central nervous 
cancers, of which glioblastoma (GBM) is the most frequent and malignant 
histologic type (Ohgaki, 2009; Dolecek et al., 2013; Ostrom et al., 2015; Tamimi 
and Juweid, 2017). Gliomas are a heterogeneous group (Bigner, 1981; 
Heppner, 1984) and according to the WHO 2016 classification of tumours of the 
central nervous system, are currently classified by integrating phenotypic and 
genotypic parameters into groups with similar prognosis and treatments (Louis 
et al., 2016). In order to determine the malignancy and select the best 
treatment, gliomas are given a grade between I and IV: grade I being the least 
aggressive (virtually non-existent in adults) and grade IV the most aggressive 
anaplastic tumours (Louis et al., 2016). Based on the histological appearances, 
gliomas are divided into: diffuse glioma (grade II or III), also termed lower-grade 
glioma (LrGG); and glioblastoma (Grade IV), also termed high-grade glioma 
(HGG) (Arevalo et al., 2017). There has been a recent shift in classification with 
an increasing role for molecular biomarkers, which highlights the biological 
complexity of gliomas. 
The contribution of ion channel expression and ion imbalance in cancer 
formation and development is increasingly being understood: several ions have 
been shown to be key in a number of fundamental cancer processes 
(Prevarskaya et al., 2010). Among others, sodium is critical for normal cellular 
function and its dysregulation has been observed in several cancers. For 
Chapter 4   
23Na-MRI as a biomarker of tumour 
heterogeneity and survival  
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instance, prostate, breast and ovarian cancers with high metastatic phenotypes 
have increased expression of embryonic forms of voltage-gated sodium 
channels (VGSCs) and a striking increase in sodium concentration within the 
tumours (Diss et al., 2005; Fraser et al., 2005; N Ahmed et al., 2007). Similarly, 
high-grade glioma cells have been shown to overexpress non-voltage-gated 
sodium channels of the degenerin superfamily, which are normally absent in 
astrocytes, and their knockdown inhibits glioma growth and cell migration 
opening up new potential treatment strategies for malignant gliomas (Vila-
Carriles et al., 2006; Kapoor et al., 2009). Moreover, an increase in the tissue 
sodium concentration may also be a consequence of increased extracellular 
interstitial fluid volume: this can be due to several processes including protein 
leakage into the interstitium secondary to permeable blood brain barrier or cell 
death with the sudden release of the intracellular fluid (Leslie et al., 2019).  
Gliomas are typically associated with oedema which is due to an enlarged 
interstitial fluid compartment (Papadopoulos et al., 2004). Furthermore, HGGs 
are characterized by the presence of necrosis, which contributes to the 
expansion of the extracellular fluid compartment and increases the extracellular 
sodium concentration. Despite the mounting evidence that sodium may play a 
significant role in tumours and that its concentration is raised is several 
malignancies, a tool or technique for routine, non-invasive, in vivo 
measurements of sodium concentration in patients is lacking (Leslie et al., 
2019). 
Sodium-23 (23Na) is the only stable sodium isotope. 23Na has a 
quadrupolar nucleus with spin 3/2 that yields the second strongest nuclear 
magnetic resonance signal from biological tissues, after protons (Madelin and 
Regatte, 2013). Although natural abundance sodium is detectable with MRI, the 
sensitivity for sodium is 9.2% of the proton sensitivity and therefore sodium MRI 
(23Na-MRI) has an average signal-to-noise ratio (SNR), which is up to 20,000 
times lower than that for proton. Since the first paper on sodium MRI (Maudsley 
and Hilal, 1984), brain neoplasms have been a topic of great interest for 
potential applications of the technique. Although Maudsley and Hilal (Maudsley 
and Hilal, 1984) showed only images of a healthy cat brain and of a middle 
cerebral artery ischaemic stroke (induced by manual ligation), their postulation 
about the signal changes in neoplasms laid the foundation for the subsequent 
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research in brain tumours. As mentioned above, an increase in cell metabolic 
activity is associated with changes in Na+/K+-ATPase activity: when ATP 
utilisation for cellular proliferation is increased, the function of the sodium pump 
may be reduced and, as a consequence of this, changes in the extracellular and 
intracellular concentration of these ions will be seen (Madelin and Regatte, 
2013). Gliomas are characterized by angiogenesis, cell proliferation and 
increased lactate formation; these factors, in combination with the changes in 
Na+/K+ transport, foster the production of an acidic extracellular environment. 
Therefore, 23Na-MRI could potentially be a surrogate for non-invasive 
assessment of mitochondrial ATP production and pH.  
In 1991 Schuierer and colleagues (Schuierer et al., 1991) reported the 
first application of sodium MRI to study human brain tumours using a 4 T whole-
body MR scanner. Their cohort of 27 patients comprised gliomas (n = 17, both 
low and high grade), meningiomas (n = 4) as well as other supratentorial lesions 
(n = 6). Feasibility and tolerability were confirmed in all patients, however 2 of 
the smallest meningioma were not visible on the sodium MRI due to the lack of 
spatial resolution. Moreover, as compared to conventional proton MRI, Sodium 
MRI failed to show any additional information above that provided by histology, 
grading, size, and differentiation from the surrounding oedema. However, this 
was as a result of the technical limitations of these early studies In 2003 
Ouwerkerk et al. published a seminal paper using improved sodium MRI 
methodology on a 1.5 T clinical scanner (Ouwerkerk et al., 2003). Although the 
study claimed to enrol only malignant brain tumours, 6 of the 20 cases were 
WHO grade II and only 7 were grade IV. Ouwerkerk et al. demonstrated that the 
sodium concentration could differentiate normal parenchyma from malignant 
tissue. Moreover, they were able to observe high sodium concentration in 
FLAIR hyperintense but non-enhancing regions confirming a sodium increase 
both in tumours and oedema. The signal increase was attributed to a 
combination of changes in the extracellular volume fraction and intracellular 
sodium concentration, but the two compartments could not be disentangled 
given the technique used at that time. Interestingly, the signal heterogeneity 
found in the peritumoral region hinted at potential additional information 
provided by sodium MRI as compared to conventional proton MRI. 
	
 92 
In an attempt to disentangle the effect on the sodium signal due to its 
extracellular and intracellular component, Nagel et al. (Nagel et al., 2011) 
explored the use of relaxation-weighted 23Na sequences (23NaR) to quantify the 
intracellular compartment. This sequence used an inversion recovery 
preparation pulse to exploit the T1W differences of sodium ions. In their paper, 
Nagel et al used an inversion time of 41 ms and a repetition time of 185 ms that 
allowed for suppression of the sodium signal arising from compartments with 
longitudinal relaxation times such as the CSF. Therefore, the signal that was 
obtained was supposed to be derived from the intracellular compartment. Their 
cohort was comprised of low- (7) and high- grade primary brain tumours (7) and 
2 metastases. An increased 23NaR signal intensity was observed only in 4 of the 
5 glioblastomas and in 1 of the 2 cerebral metastases. This finding was deemed 
in keeping with the higher proliferation activity seen in high-grade gliomas and 
in metastases, and was also confirmed by a strong correlation between 23NaR 
imaging and MIB-1, a known marker of proliferation rate.  
The following year, Laymon et al. (Laymon et al., 2012) evaluated 
sodium MRI in combination with [18F]FLT-PET, acquired as separate studies, as 
imaging biomarkers for therapy evaluation in patients with glioblastoma. The 
rationale behind this combination is that [18F]FLT-PET is a marker for 
DNA synthesis and consequently cellular proliferation which does not cross the 
blood-brain barrier. In contrast, sodium MRI is also a marker of cellular 
proliferation and viability but as it relies on intrinsic contrast it is not influenced 
by the blood-brain barrier. Therefore, those two techniques may have a 
synergic effect providing complementary information. Laymon and colleagues 
demonstrated that sodium MRI and [18F]FLT-PET imaging biomarkers have 
some similarities and differences in assessing therapy response of glioblastoma 
suggesting that the two modalities are complementary. Indeed, assessing the 
degree of complementarity and overlap of the two modalities in a voxel-wise 
analysis, they showed a significant heterogeneity across the lesion and were 
able to identify 4 clusters: increase in [18F]FLT and increase in sodium, increase 
in [18F]FLT and decrease in sodium, decrease in [18F]FLT and increase in 
sodium and decrease in [18F]FLT and decrease in sodium. The envisaged that 
changes in [18F]FLT can be secondary to blood-brain barrier damage (i.e. an 
increase in [18F]FLT may be due to an increase in breakdown of the blood-brain 
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barrier) whilst the sodium signal has no relation with the blood brain barrier and 
it is only due to biological differences. However, the significance of the clusters 
was deemed to be undetermined.  
Sodium MRI has also been investigated as an indirect biomarker of IDH 
mutation and as a prognostic factor by Biller et al. (Biller et al., 2016). Following 
on from previous work by Nagel et al. (Nagel et al., 2011), in this study the ratio 
between the relaxation-weighted sodium signal (23NaR, deemed to be derived 
from the intracellular sodium) and the total sodium signal (23NaT) was 
investigated. Biller and colleagues demonstrated a strong correlation between 
the proposed ratio and IDH mutation, however they also showed that sodium 
MRI is superior to IDH mutation status in predicting progression-free survival 
and improves the accuracy of brain tumour classification. Thus, they concluded 
that sodium MRI is a promising tool for non-invasive outcome prediction and 
tumour diagnosis, with the potential to improve patient management. 
Neto et al. (Neto et al., 2018) proposed a three-compartment model to 
determine pseudo-intracellular sodium concentration: 1. extracellular volume 
fraction, 2. apparent intracellular sodium concentration, and 3. apparent total 
sodium concentration. As expected the solid components of all the tumours 
showed higher values of apparent total sodium concentration than the normal 
appearing white matter (Madelin and Regatte, 2013; Madelin et al., 2014). 
However, the extracellular volume fraction was consistently increased in all the 
cases and the authors deemed this to be the dominant factor responsible for the 
apparent total sodium concentration increase. The apparent intracellular sodium 
concentration was lower than in the normal-appearing white matter in all the 
cases bar the single glioblastoma recruited (Nagel et al., 2011; Biller et al., 
2016). The model presented in this study clearly showed the ability to 
differentiate between the different compartments; however, as highlighted by 
the authors, the necessity to assume that the water fraction is constant in the 
brain parenchyma despite the known differences between grey and white 
matter, constitutes a significant limitation of this study. 
More recently, Thulborn et al. (Thulborn et al., 2018) assessed the 
potential utility of sodium MRI as early biomarker of therapy response in 
patients with glioblastoma undergoing fractionated chemoradiation. Using a 
two-compartment model they converted what they called tissue sodium 
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concentration (TSC; essentially the 23NaT described by Nigel) maps into Cell 
Volume Fraction maps from which they subsequently derived the Residual 
Tumour Volume and the Tumour Cell Kill. Interestingly, changes in Cell Volume 
Fraction, Residual Tumour Volume and Tumour Cell Kill were seen during the 
course of the 6-week regimen, but they were not correlated with prognosis; over 
the same period of time, there was little biological variation in the normal 
appearing tissue ruling out the possibility of inaccurate measurement. The lack 
of a correlation with prognosis may reflect the heterogeneity of glioblastoma 
with its extremely high response variability to treatments. Nevertheless, the 
capability of sodium imaging to detect changes during treatment, whilst the 
lesion size remains stable in size, highlighted the potential use of sodium 
imaging as an early biomarker for therapy assessment.   
Thanks to the technical advances in scanner technology, in particular the 
wider availability of high-performance ≥ 3 T magnets, and acquisition strategies, 
such as the 3D-cones trajectory (Gurney et al., 2006; Riemer et al., 2014),  over 
the past three decades, sodium MRI is now feasible in a clinical environment 
with 3 T clinical scanners. Moreover, the development of new sequences has 
allowed accurate measurements of sodium in both the intracellular and 
extracellular compartments, enabling a deeper understanding of both the lesion 
and the surrounding microenvironment. Gliomas are known to have an increase 
in cell mitotic activity, this should later the intracellular sodium concentration that 
is detectable with sodium imaging. Furthermore, changes in the 23Na-MRI signal 
in the region surrounding gliomas can be an indirect measure of the presence of 
cancer cells in the peritumoral brain zone, with the possibility of radically 
changing the management of patients with glioma. Therefore, the primary aim 
of this study was to non-invasively measure the distribution of tissue sodium 
concentration and intracellular-weighted sodium concentration within gliomas 
and in the peritumoral brain parenchyma. Additionally, as we hypothesised that 
sodium is a biomarker for cell proliferation, our secondary aim was to assess 




4.1 Methods and materials 
4.1.1 Patient selection 
Patients presented in this work were enrolled under three prospective 
studies approved by our local Research Ethics Committee (East of England, 
Cambridge South Research Ethics Committee; REC reference numbers 
16/EE/0184, 15/EE/0378 and 07/H0308/245) as part of a larger brain tumour 
imaging initiative. Between October 2015 and October 2018 sixty-five 
Inclusion criteria 
- 18 years or older; 
- Be scheduled for biopsy or resection of a presumed glioma of any grade (based on 
imaging features consisting with glioma); 
- Be aware of, and understand the diagnosis; 
- Be able to provide written informed consent according to ICH/GCP, national and local 
regulations; 
- Be willing and able to comply with scheduled visits, laboratory tests, imaging and 
other study procedure; 
- Patients of childbearing potential must have a negative urinary or blood pregnancy 
test prior to enrolment if there is a possibility they could be pregnant. 
 
Exclusion Criteria 
Clinical contraindications to MR imaging will apply to each patient and include, but are 
not limited to: 
- Pacemakers, non-MR compatible heart valves or cardiac stent or other vascular stent; 
- Renal impairment; 
- Known allergic reactions to Gd contrast agent; 
- Intracranial aneurysm clips that are not MR safe; 
- Intracranial programmable shunt; 
- History of intra-orbital metal fragments that have not been removed; 
- Inner ear implants; 
- Artificial joint/limb prosthesis not MR safe; 
- Neuro-stimulator or other under the skin devices; 
- False eye; 
- Claustrophobia; 
- Inability to give informed consent. 
 




treatment-naïve patients (36 males, 29 females; 54.8 ± 16.9 years) with a 
presumed diagnosis of a glioma of any grade were recruited from the weekly 
Multidisciplinary Team (MDT) meeting and/or from the Neuro-oncology clinic. 
Only patients scheduled for stereotactic biopsy or resection of a glioma, based 
on previous imaging featuring a lesion in keeping with a glioma with MDT 
consensus of the likely diagnosis, were screened to assess eligibility by a 
member of the research team. The inclusion and exclusion criteria used to 
assess eligibility are shown in table 4.1. During the Neuro-oncology clinic 
appointment, all the eligible patients received a detailed participant information 
sheet, describing the study rationale and procedure, and had a dedicated 
encounter with a member of the research team to discuss the study rationale, 
potential involvement and expected outcome. Written informed consent was 
signed by all the participants before enrolling in the study and after ample time  
for reflection and questioning. 
4.1.2 1H and 23Na MRI acquisitions 
All the MRI examinations were performed using a 3 T clinical scanner 
(GE Discovery MR750; GE Healthcare, Waukesha, WI, USA) using a dual-
tuned 23Na/1H quadrature transmit/receive head coil (Rapid Biomedical, Rimpar, 
Germany) for the 23Na MRI and a 12-channel head coil for the 1H imaging.  
Sodium imaging was performed using two independent acquisition both 
based on an ultra-short echo time sequence with 3D-Cones readout (Riemer et 
al., 2014); acquisition parameters were as follow: TE = 0.5 ms, TR = 100 ms, 3 
mm nominal isotropic resolution, FOV = 28 cm. The intracellular weighted 
sodium images were obtained with similar parameters using fluid suppression 
by inversion recovery (IR). The two sequences exploit the different T1 effect of 
sodium in the intracellular and extracellular spaces. In particular, the IR 
sequence eliminates the signal from extracellular fluid exploiting the T1 
relaxation differences between CSF and tissues. To achieve fluid suppression, 
the T1 value for CSF was firstly established and then an IR pulse was set 
accordingly. The suppression of the extracellular fluid leads to an estimation of 
the concentration of the sodium contained within the intracellular space. Scan 
duration was between 12 and 16 minutes according to scan coverage and 
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individual specific absorption rate (SAR). To convert the signal intensity into 
apparent sodium concentration, external calibrants with a known concentration 
of sodium are needed. For this study, the calibration phantoms were made from 
a stock of 20 mM and 80 mM sodium chloride (NaCl) in water with 4% agar and 
1% nickel sulphate (NiSO4). Each of the phantoms were cylindrical tubes of 30 
ml capacity filled with the stock solution. During the acquisition, those were 
strapped to the headphones worn by the subjects so they were included in the 
imaging field of view (FOV). Phantoms were changed regularly to exclude the 
possibility of dehydration. Nevertheless, the mathematical method used to 
create the map is independent of the phantom concentration. The formula uses 
the signal intensities of the phantoms as a reference for the signal intensities 
within the body, therefore as long as the phantom concentration is within the 
physiological range there is not a detrimental effect on the quantitative maps. It 
is worth mentioning that there are other potential methods to separate the 
signal of the intracellular (bound) sodium and the extracellular (free) sodium. In 
particular, a hybrid technique combining diffusion and sodium imaging would 
aid in distinguishing the two pools of sodium molecules. Advanced model-
based diffusion imaging (i.e. neurite orientation dispersion and density imaging 
[NODDI] or VERDICT, discussed in chapters 2 and 3) could be used to 
calculate the compartmentalisation of tissue within each voxel (intracellular vs 
extracellular volume fraction) and in turn, this information could be combined 
with the total sodium concentration to disentangle the sodium concentration in 
the different compartments. 
The 23Na MRI acquisition was followed by conventional proton imaging 
including: 3D T2-weighted imaging (T2W; repetition time/echo time [TR/TE] 
2500/79 ms; 248 slices; slice thickness 1.2 mm; acquisition matrix 320 x 320; 
field of view [FOV] 240 x 240 mm), 2D T2W fluid-attenuated inversion recovery 
(T2W FLAIR; TR/TE 8000/126 ms; inversion time [TI] 2128 ms; slice thickness 6 
mm; acquisition matrix 384 x 224; FOV 240 x 240 mm) and Diffusion-Weighted 
Imaging (DWI, TR/TE 2841-3867/83.3-87.4 ms; slice thickness 5 mm; b-values 
0, 1000 s/mm2; matrix 128 x 128; FOV 240 x 240 mm). 3D T1-weighted Fast 
SPoiled GRadient echo (3D T1W FSPGR; 252 slices; 0.94 x 0.94 x1.5 mm 
reconstructed to 0.94 x 0.94 x 1 mm; TR/TE 8.2/3.2; slice thickness 1.5 mm; 
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matrix 256 x 256; FOV 240 x 240 mm) was performed before and after 
gadolinium-based contrast injection (Gadobutrol 1.0 mmol mL-1; Schering).  
4.1.3 Image processing and analysis 
The post processing was performed in Matlab (Matlab 2017a, the 
MathWorks, Natick, MA) using in-house scripts allowing for the automatic 
segmentation of the phantoms, including erosion of the voxels at the periphery 
of the phantoms to avoid partial volume due to intensity thresholding. Tissue 
sodium concentration (TSC) and intracellular-weighted sodium concentration 
maps were subsequently generated using Matlab as previously described by 
Inglese et al. (Inglese et al., 2010). Briefly, the signal intensity of the calibrants 
was used to create a two-point linear calibration curve that was then used to 
convert signal intensity to sodium concentration voxel-wise. Noise 
compensation was performed by subtracting the average signal intensities 
derived from regions of interest (ROIs) drawn within air inside the FOV. 
In order to facilitate image analysis and ROI drawing, the sodium images 
were registered to their corresponding T2WI and T1WI post-contrast images 
using SPM8 (The Wellcome Trust Centre for Neuroimaging, University College 
London, London, UK). Due to the different head positioning within the dual-
tuned 23Na/1H quadrature transmit/receive head coil and the 1H 12-channel 
head coil, the first step of the registration process involved the realignment of 
the 3D T2WI and the post gadolinium 3D T1W FSPGR to the sodium images. 
Firstly, the 3D T2W sequence was warped and realigned to the tissue sodium 
concentration maps. Those two sequences were chosen as pivotal for 
realignment, warping and, subsequently, co-registration due to the similar 
contrast intensity. The CSF contains the highest concentration of sodium in the 
head and is hyperintense on the maps and on the T2WI. Once the alignment 
and warping of the T2WI was deemed satisfactory, the 3D T2WI and the post 
gadolinium 3D T1W FSPGR were co-registered. Subsequently, the 3D T2WI and 
the tissue sodium concentration maps were registered propagating the 
translational parameters to the associated 3D T1W FSPGR and intracellular-
weighted sodium concentration. Re-alignment, warping and registration of the 
1H and 23Na images was an iterative process that required intensive 
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computation and carefully evaluation by a trained neuroradiologist to ensure the 
highest quality of registration. The choice of performing most of the re-
alignment, warping and registration on the 1H images was made to avoid 
excessive manipulation of the quantitative sodium maps to ensure that the 
measured values on the images corresponded to the acquired data and not 
biased by interpolation. 
A neuroradiologist with 7 years of experience in neuro-imaging outlined 
all the ROIs to generate the volumes of interest (VOIs) using OsiriX (V.8.5.2, 
Pixmeo SARL, Bernex, Switzerland). The unenhanced, registered, 3D T1W 
FSPGR acquired with the dual-tuned 23Na/1H coil and the registered 3D T2W 
acquired with the 1H coil were used to define the ROIs. The T2W hyperintense 
lesion was defined on the T2WI as the region including the lesion and the 
hyperintense peritumoral brain zone. The same sequence was used also for the 
normal-appearing white matter (NAWM) that was assessed in the contralateral 
corona radiata. The enhancing lesion and the non-enhancing core were 
evaluated on the post gadolinium 3D T1WI; as per conventional definition, the 
former was defined as the contrast enhancing component of the lesion whilst 
the latter was defined as the non-enhancing core tissue using the signal 
intensity on the T2WI as additional guidance.  
The normal-appearing grey matter (NAGM) was assessed in the 
contralateral basal ganglia on the post gadolinium 3D T1W FSPGR. Those 
structures were chosen, as opposed to the cortical white matter, to maximise 
the reliability of the analysis while minimizing the risk of partial volume from the 
CSF contained in the sulci. Automatic segmentation of white matter and grey 
matter is challenging in patients with large space-occupying lesions due to 
mass effect and distortion of the normal anatomy. Moreover, the cortex is 
usually thin measuring between 1 and 4.5 mm (Fischl and Dale, 2000). The 
nominal isotropic resolution of our sodium imaging is 3 mm, therefore the 
measured sodium concentration in the cortical grey matter would have been 
heavily influenced by the high sodium concentration in the CSF. However, the 
basal ganglia can be reliably identified on the post gadolinium 3D T1W images 
and segmented allowing for enough distance from the lateral ventricles to avoid 
any partial volume effect.  
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The generated VOIs were stored and applied to the corresponding 
registered tissue sodium concentration and intracellular-weighted sodium 
concentration maps using OsiriX. Mean, standard deviation, minimum and 
maximum values were extracted for every voxel using a custom plugin and 
recorded in dedicated spreadsheets.   
Due to the exploratory nature of this study, the inter-observer agreement 
was not tested, in line with the previously published data on this technique. 
4.1.4 Histopathology 
All the enrolled patients underwent surgery (either stereotactic burr hole 
biopsy or debulking resection) and tissue samples were analysed by a 
neuropathologist with 7 years of experience to determine tumour type and 
grade according to the WHO 2016 classification of tumours of the central 
nervous system (Louis et al., 2016). Patients enrolled before the new 
classification came into force were reassessed and re-classified according to 
the new classification. Accounting for the new WHO 2016 classification, the 
molecular biomarkers and the recent guidelines for management, gliomas were 
classified as lower-grade (LrGG) and high-grade (HGG) (Louis et al., 2016).  
Haematoxylin and eosin staining (H&E) was performed as per clinical 
standard. Analysis of the isocitrate dehydrogenase 1 (IDH1 R132H) and O6-
methylguanin-DNA-methyltransferase (MGMT) methylation status were 
performed in all cases. In addition, ATP-dependent helicase (ATRX), glial 
fibrillary acidic protein (GFAP), deletion of 1p36 and amplification of 19q13 
chromosomal locus were tested as determined by the pathologist according to 
the tumour grade and type or if the MDT deemed this necessary to better plan 
the treatment. The monoclonal antibody MIB-1 was used to measure the Ki-67 
expression which in turn determined the Ki-67 labelling index as a marker of 
proliferation. MIB-1 staining was assessed on tumour photomicrographs from a 
x600 FOV and a fixed matrix of 184x138 µm using a semi-automated software 
(Image-Pro Insight) and expressed in percentage.   
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4.1.5 Statistical Analysis 
All data were recorded in digital spreadsheets (Excel 16.16.7 for Mac 
OS; Microsoft Corporation, Redmond, WA, USA) and the statistical analysis 
was performed using a dedicated statistical analytical software (SPSS 18.0 
statistical package; SPSS Inc, Chicago, IL, USA). The Shapiro–Wilk test was 
used to test for normality of data. Continuous data are expressed as mean ± 
standard deviation [minimum – maximum] for normally distributed data and 
median [minimum - maximum] for non-parametric data; categorical data are 
expressed an n (%). 
Paired and unpaired t-test were used to compare the sodium 
concentration between LrGGs and HGGs and to assess differences in 
concentration among brain tumours and normal appearing brain parenchyma as 
appropriate according to the nature of the data. To determine the statistical 
significance of all the tests, a base set value of p = 0.05 was initially chosen and 
subsequently corrected for multiple comparison. The false discovery rate (FDR) 
method using the Benjamini-Hochberg procedure was applied to test 
significance (Benjamini and Hochberg, 1995). The FDR represents the 
proportion of significant results that are actually false positives. Carefully 
consideration has been given to which proportion of false positive we were 
willing to accept for this study.  An FDR of 5% is generally believed too low for 
many experiments having multiple correlations because this is applied on top of 
a p value which is usually already chosen as low as 0.05 lead to an over 
rejection rate (McDonald, 2014). However, considering the strong significance 
on the determined p values and deeming the n of this study ample enough to 
explore the relationship between sodium concentration in brain tumours and 
normal appearing tissue, we choose the strictest FDR (5%) to ensure that 
significant results of this study would be most likely to be significant in further 
following studies. Of note, the p values that are presented in this study are raw 
p values and only the significance is stated according to the Benjamini-
Hochberg procedure. No Benjamini-Hochberg adjusted p values have been 
provided to avoid the potential confusion that those modified p values could 
generate in readers not familiar with the procedure.  
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A survival analysis was performed to explore the prognostication 
capability of sodium imaging. IDH status and tumour grade after pathology were 
also analysed for prognostication to provide a comparison with current clinical 
reference standards and confirm the generalisability of the recruited cohort. The 
Kaplan-Meier survival analysis was used for each of the assessed parameters.  
A total of 20 imaging parameters derived from sodium imaging were 
chosen for the analysis: TSC and IW-SC for T2W hyperintense VOI, enhancing 
lesion, non-enhancing core, ratio between T2W hyperintense VOI and NAWM, 
ratio between enhancing lesion and NAWM, ratio between T2W hyperintense 
VOI and basal ganglia, ratio between enhancing lesion and basal ganglia and 
ratio between T2W hyperintense VOI and non-enhancing core; ratio between 
TSC and IW-SC and between IW-SC and TSC for both the T2W hyperintense 
VOI and the enhancing lesion. The optimal cut-offs to divide the cohort in two 
groups according to their survival was chosen performing a receiver operating 
characteristic (ROC) analysis and determining the best Youden’s index for 
each parameter. The Youden's index is a single statistic that captures the 
performance of a dichotomous diagnostic test (W. J. Youden, 1950). The index 
is designed to maximise the number of correctly classified results, either 
positive or negative, attributing equal weight to false positive and false negative 
results. In this context, the Youden’s index would maximise the chance of 
sodium imaging to predict prognosis either as survival or death. The index was 
computed with a custom SPSS script for all points of each ROC curves; the 
maximum value was used for selecting the optimum cut-off point to be the 
threshold for the Kaplan-Meier analysis in the following steps. Kaplan-Meier 
curves dividing patients according to the optimal threshold were generated to 
facilitate the visualization of the survival trend of the two populations. The 
curves with the most significant capability of predicting the survival status are 





Figure 4.1: Representative case of lower-grade glioma (LrGG). 
Axial T2-weighted images (T2W; axial post gadolinium 3D T1-weighted Fast SPoiled 
GRadient echo images (Post Gd T1W); axial post Gd T1W overlaid with tissue sodium 
concentration overlaid (TSC); and axial post Gd T1W overlaid with intracellular-weighted 
sodium concentration (IW-SC). A heterogenous T2-weighted hyperintense lesion in the right 
superior frontal gyrus is shown extending downwards towards the frontal pole; no contrast 
enhancement is seen after gadolinium injection. The lesion does not have mass effect on 
the adjacent parenchyma although there is sulcal effacement. On the proton images the 
corpus callosum appears spared. The TSC images demonstrates the lesion with similar 
conspicuity as on the T2W, however, the increase in sodium concentration is seen extending 
beyond the T2W hyperintensity, particularly downwards and within the corpus callosum. Of 
note, the high sodium concentration within the ventricles, sylvian fissures and eye globes 
confirming the accurate registration of sodium imaging with the conventional proton MRI. 
The IW-SC images show almost complete suppression of the sodium concentration within 
the T2W hyperintense lesion suggesting that the increase in sodium within the lesion is 
mostly due to an enlarged interstitial matrix. However, some foci of increased IW-SC could 
represent areas of potential higher grade cancer cells within the LrGG that might be targets 







Figure 4.2: Representative case of high-grade glioma (HGG). 
Axial T2-weigthed images (T2W); axial post gadolinium injection 3D T1-weighted Fast 
SPoiled GRadient echo images (Post Gd T1W); axial post Gd T1W overlaid with tissue 
sodium concentration overlaid (TSC); and axial post Gd T1W overlaid with intracellular-
weighted sodium concentration (IW-SC). Large heterogenous T2-weighted hyperintense 
lesion in the right middle and superior temporal lobe with mild peritumoral oedema. 
Gadolinium enhanced images demonstrate the presence of two round lesions with 
complete ring enhancement and hypointense central core in keeping with multifocal GBM. 
Adjacent sulci are effaced and there is mild expansion of the temporal lobe with mild 
compressive effects on the right insula. The TSC images demonstrates diffuse 
heterogeneity within the T2W hyperintense area with the posterior lesion exhibiting a 
higher tissue sodium concentration when compared with the anterior one. There is 
increased sodium concentration in the non-enhancing T2W hyperintense area between the 
smaller lesion and the sylvian fissure. Interestingly, on the IW-SC images the anterior 
lesion shows complete suppression whilst the larger one still has a discreet signal 
corresponding to increased intracellular sodium concentration. This could be due to the 
different content of the tissue with the anterior core being entirely necrotic (hence the 
suppression) and the core of the posterior lesion containing tumour and inflammatory 
cells. Of note, the discrepancy could be appreciated also on the T2W images showing 
higher signal intensity in the anterior lesion, and on the post Gd T1W images showing 
intermediate signal within the core of the larger signal. This case clearly demonstrates the 
potential of sodium imaging to detect necrosis and therefore therapy response. Moreover, 
the heterogenous sodium signal within the area of T2W hyperintensity and the discrepancy 
between the TSC and IW-SC could help in differentiating oedema from 





4.2.1 Characteristic of the cohort 
Of the sixty-five recruited patients, 2 patients were not able to tolerate the 
scan due to claustrophobia and in 3 cases the acquisition failed due to technical 
reasons, therefore 60 patients (34 male, 55.7%) successfully completed the 
research MRI. Mean age at diagnosis of the successfully scanned cohort was 
55.3 ± 17.2 (18 - 79) years; patients with LrGG were significantly younger (38.7 
± 15.9 vs 64 ± 9.9, p < 0.001). All the enrolled patients underwent surgery 
(either burr hole biopsy or debulking resection) and tissue was analysed 
according to the WHO 2016 classification of tumours of the central nervous 
system (Louis et al., 2016). At pathology, 36 patients were classified as higher-
grade (WHO grade IV) primary CNS tumours, 19 as lower-grade (Grade II and 
III) primary CNS tumours and 3 cases were classified as metastases (high-
grade serous carcinoma, renal cell carcinoma and lung cancer); 2 cases were 
reported as non-diagnostic from a consensus of neuro-pathologists and were 
excluded from the analysis. The 55 primary CNS tumours were: 32 (58.2%) 
glioblastoma IDH1 R132H wild type, 8 (14.5%) diffuse astrocytoma IDH mutant, 
5 (9.1%) anaplastic oligodendroglioma IDH-mutant and 1p/19q co-deleted, 3 
(5.5%) gliosarcoma, 1 (1.8%) anaplastic astrocytoma IDH-wildtype, 1 (1.8%) 
anaplastic astrocytoma IDH mutated, 1 (1.8%) anaplastic ependymoma, 1 
(1.8%)  oligodendroglioma non otherwise specified, 1 (1.8%)  Anaplastic 
pleomorphic xanthoastrocytoma, 1 (1.8%)  gangliocytoma and 1 (1.8%)  
anaplastic ganglioglioma. 
The tissue sodium concentration and the intracellular-weighted sodium 
concentration for the 3 metastases are reported separately; these 3 cases were 
not included in the survival analysis. Therefore, the survival analysis was 
performed in 55 patients with primary brain tumours. 
 
4.2.2 Tissue sodium concentration  
Figure 4.1 shows a representative case of LrGGs (patient GS-56, a 
diffuse astrocytoma IDH mutant) and figure 4.2 shows a representative case of 
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HGGs (patient MGS-09, Glioblastoma IDH1 R132H wild type). Detailed 
description of the imaging findings is provided in the respective captions of the 
two figures. 
The tissue sodium concentration in LrGGs, HGGs and metastases is 
shown in table 4.3. Briefly, the tissue sodium concentration in T2W hyperintense 
lesions was higher in the HGGs (58 ± 13 mmol L-1 vs 55 ± 1.5 mmol L-1 in the 
LrGGs). The tissue sodium concentration in the enhancing component and in 
the non-enhancing core were higher in the LrGGs than in the HGGs (66 ± 15 
mmol L-1 vs 62 ± 17 mmol L-1 and 84 ± 11 mmol L-1 vs 76 ± 21 mmol L-1 
respectively). However, there were no statistically significant differences 
between LrGGs and HGGs. The tissue sodium concentration in the basal 
ganglia and in the normal appearing white matter was not significantly different 
between the two groups (p = 0.45 and p = 0.97 respectively). 
Table 4.3 shows the comparison between the sodium concentration in 
the lesions and the normal appearing brain parenchyma. Both in LrGGs and in 
HGGs, the tissue sodium concentration in the T2W hyperintense lesion and in 
the enhancing lesion were significantly higher compared to basal ganglia (p 
values < 0.01) and normal appearing white matter (p values < 0.001).  
The metastases showed an average tissue sodium concentration of 62 ± 
30 mmol L-1 in the T2W hyperintense lesion and 76 ± 37 mmol L-1 in the 
enhancing lesion. Only a single case showed a non-enhancing core.  
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Region of interest 
Tissue Sodium Concentration (mmol L−1) Intracellular-weighted Sodium concentration (mmol L−1) Metastases (n = 3) 




lesion 55 ± 15 58 ± 13 0.54 21 ± 7 27 ± 15 0.04* 62 ± 30 17 ± 11 
Enhancing lesion 
66 ± 15 62 ± 17 0.60 18 ± 9 29 ± 15 0.03* 76 ± 37 25 ± 6 
Non-enhancing core 
84 ± 11 76 ± 21 0.35 10 ± 7 32 ± 17 0.01* 67‡ 25‡ 
Basal ganglia 
34 ± 5 33 ± 8 0.45 29 ± 10 32 ± 12 0.29 40 ± 8 29 ± 6 
Normal appearing 
white matter 32 ± 6 32 ± 8 0.97 26 ± 8 28 ± 12 0.61 33 ± 4 24 ± 5 
 
Table 4.2: Tissue sodium concentration and intracellular-weighted sodium concentration according to tumour grade (lower-grade 
glioma - LrGG and high-grade glioma - HGG).  
Concentration values are shown as mean ± standard deviation (minimum - maximum) and expressed in mmol L-1. The level of 
significance was assessed using unpaired sample t-tests and was set at 0.05. Correction for multiple comparison was performed 
using a false discovery rate method (FDR) according to the Benjamini-Hochberg procedure. Significant p values are indicated with 
*. ‡ non-enhancing core was present only in a single case of brain metastasis therefore no SD or range is given. 
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4.2.3 Intracellular-weighted sodium concentration  
The intra-cellular weighted sodium concentration in LrGGs, HGGs and 
metastases is shown in table 4.2. The intra-cellular weighted sodium 
concentration was significantly higher in all the three VOIs of the HGGs as 
compared to the LrGGs (p = 0.04 for the T2W hyperintense lesion, p = 0.03 for 
the enhancing lesion and p = 0.01 for the non-enhancing core). The intra-
cellular weighted sodium concentration in the normal appearing tissue did not 
significantly differ (p = 0.29 for the basal ganglia and p = 0.61 for the normal 
appearing white matter).  
  
p values for LrGG p values for HGG 
TSC IW-SC TSC IW-SC 
T2W hyperintense lesion vs basal 
ganglia 
< 0.001* < 0.001* < 0.0001** 0.01* 
T2W hyperintense lesion vs 
normal appearing white matter 
< 0.0001** < 0.0001** < 0.0001** 0.86 
Enhancing lesion vs basal 
ganglia 
0.01* 0.01* < 0.0001** 0.14 
Enhancing lesion vs normal 
appearing white matter 
< 0.001* 0.11 < 0.0001** 0.36 
	
Table 4.3: Comparison between sodium concentration in glioma and in normal tissue. 
The table shows the p values for the comparison between tissue sodium concentration (TSC) 
and intracellular-weighted sodium concentration (IW-SC) in gliomas (lower-grade gliomas - 
LrGG and high-grade glioma - HGG) and in the normal appearing tissue assessed at the level 
of the contralateral basal ganglia and contralateral corona radiata. The level of significance was 
assessed using unpaired sample t-tests and was set at 0.05. Correction for multiple comparison 
was performed using a false discovery rate method (FDR) according to the Benjamini-Hochberg 
procedure. 
 
As shown in Table 4.3, for the LrGGs, the intra-cellular weighted sodium 
concentration in the T2W hyperintense lesion and in the enhancing lesion were 
significantly lower compared to basal ganglia (p values < 0.001 and p = 0.01, 
respectively); but only the T2W hyperintense lesion was significantly lower than 
normal appearing white matter (p = 0.01). The intra-cellular weighted sodium 
concentration in the HGGs was significantly different only when comparing the 




Cut-off p value 
Tissue sodium concentration 
T2W hyperintense VOI 50.6 0.04* 
Enhancing lesion 56.2 0.87 
Non-enhancing core 74.5 0.81 
Ratio between T2W hyperintense VOI and NAWM 1.7 0.43 
Ratio between enhancing lesion and NAWM 1.4 0.60 
Ratio between T2W hyperintense VOI and basal 
ganglia 
1.6 0.03* 
Ratio between enhancing lesion and basal ganglia 1.4 0.58 
Ratio between T2W hyperintense VOI and Non-
enhancing core 
0.9 < 0.001** 
   
Intracellular-weighted sodium concentration 
T2W hyperintense VOI 74.5 0.27 
Enhancing lesion 24.8 < 0.01* 
Non-enhancing core 25.4 0.13 
Ratio between T2W hyperintense VOI and NAWM 0.9 0.02* 
Ratio between enhancing lesion and NAWM 1 < 0.01* 
Ratio between T2W hyperintense VOI and basal 
ganglia 
1.1 0.02* 
Ratio between enhancing lesion and basal ganglia 1.1 < 0.001** 
Ratio between T2W hyperintense VOI and Non-
enhancing core 
0.9 0.98 
   
T2W hyperintense VOI 
Ratio between TSC and IW-SC 2.9 0.11 
Ratio between IW-SC and TSC 0.45 0.12 
   
Enhancing lesion 
Ratio between TSC and IW-SC 7.4 0.09 
Ratio between IW-SC and TSC 0.3 < 0.01* 
 
Table 4.4: Optimal cut-offs obtained from the receiver operating characteristics curve analysis 
and Youden’s index assessment. 
The table shows the best cut-off obtained from the Youden’s index assessment, performed on 
the receiver operating characteristic curve analysis. The cut-offs shown here were used for the 
Kaplan-Meier survival analysis and the p values are relative to the survival analysis, i.e. if a p 
value is significant the corresponding cut-off is able to correctly predict survival status. The level 





Figure 4.3: Boxplot of intracellular-weighted sodium concentration (IW-SC) according to tumour grade. 
The boxplot show minimal overlap between the IW-SC of the T2W hyperintense lesion between lower-grade gliomas (LrGG) and high grade gliomas 
(HGG). Negligible overlap is demonstrated for the enhancing component of the lesion and for the necrotic core. The level of significance was assessed 
using unpaired sample t-tests and was set at 0.05. Correction for multiple comparison was performed using a false discovery rate method (FDR) 





The metastases showed an average intracellular weighted sodium 
concentration of 17 ± 11 mmol L-1 in the T2W hyperintense lesion and 25 ± 6 
mmol L-1 in the enhancing lesion. The intracellular weighted sodium 
concentration in the single case with central non-enhancing core was 25 mmol 
L-1. 
4.2.4 Survival analysis 
Table 4.4 shows the best cut-off obtained from the ROC analysis and 
subsequent Youden’s index assessment paired with the p values resulting from 
their use in the Kaplan-Meier analysis. Figures 4 to 6 show the Kaplan-Meier 
curves for: the current clinical reference standard (IDH and WHO 2016 grading; 
figure 4.4), tissue sodium concentration (figure 4.5) and intracellular-weighted 
sodium concentration (figure 4.6). 
As expected, higher-grade primary brain tumours according to the WHO 
2016 criteria and the absence of the IDH1 R132H mutation (IDH wildtype) are 
strong predictor of worse prognosis (p < 0.0001 for both the biomarkers).  
The tissue sodium concentration in the T2W hyperintense lesion is a 
significant prognostic predictor (figure 4.5), with sodium concentration values 
higher than 50.6 mmol L-1 predicting a shorter overall survival (p = 0.04). 
Similarly, a ratio between the tissue sodium concentration in the T2W 
hyperintense lesion and the basal ganglia greater than 1.6 was indicative of a 
worst prognosis (p = 0.03; figure 4.5). The strongest prognostic predictor based 
on the tissue sodium concentration was the ratio between the T2W hyperintense 
lesion and the necrotic component (threshold 0.9, p < 0.001; figure 4.5). 
The most representative Kaplan-Meier curves for the biomarkers derived 
from the intracellular-weighted sodium concentration are shown in figure 4.6. A 
ratio greater than 1 between the intracellular-weighted sodium concentration in 
the T2W hyperintense lesion and the basal ganglia was indicative of the worst 
prognosis (p = 0.02). The enhancing component was more strongly associated 
with survival. An intracellular-weighted sodium concentration greater than 24.8 
in the enhancing component was a strong predictor of survival both as an 
independent biomarker (p <0.01) and as ratio over the basal ganglia (threshold 
1.1; p < 0.001; figure 6).  
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4.3 Discussion  
This study aimed to explore the total tissue sodium concentration and the 
intracellular concentration as predictors of survival in patients with gliomas. 
Over the three-year recruitment window, we recruited the largest cohort of brain 
tumours patient in a sodium MRI study. Indeed, with a total cohort of 65 
recruited patients, we breached the current record of Weber et al. that recruited 
a cohort of 61 patients for their study (Weber et al., 2010). Of interest, in both 
the studies a small amount of lesions turned out to not be a glioma, highlighting 
how challenging can be the differential diagnosis if even in very selected and 
sophisticated studies there is a proportion of misdiagnosed cases. Moreover, 
	
Figure 4.4: Kaplan-Meier survival analysis according to grade and IDH status. 
The survival analysis comparing lower-grade gliomas (LrGG) to high grade gliomas 
(HGG) shows a significant longer survival for LrGG (p < 0.0001). As expected, the 
presence of IDH mutation is indicative of longer survival (p < 0.0001) irrespective of other 






we obtained clinical follow-up for the entire cohort, almost double the current 
largest published cohort (34 patients) with follow-up previously reported by Biller 
et al. (Biller et al., 2016). The size of the study allows important results to be 
derived and provides a basis for future work in this area. 
	
Figure 4.5: Kaplan-Meier survival analysis according to tissue sodium concentration. 
 





4.3.1 Sodium concentration in normal tissue and glioma 
grading  
The tissue sodium concentration in our cohort was consistent with 
published literature. Despite the wide ranges of estimated tissue sodium 
concentration previously reported for both white matter (20 - 60 mmol L-1) and 
grey matter / basal ganglia (30-70 mmol L-1), most published reports fall within a 
similar range to this study (Madelin and Regatte, 2013). Madelin et al. reported 
an overall average for combined white and grey matter of around 35 mmol L-1, 
whilst the most recent paper published by Neto et al. reported an average 
of 30.30 ± 3.53 mmol L-1 for white matter and 34.95 ± 4.16 mmol L-1 for the 
putamen (Madelin et al., 2014; Neto et al., 2018). In particular, the latter is very 
close to the 34 ± 5 mmol L-1 detected in the contralateral basal ganglia reported 
here. The similarity between published results in normal brain parenchyma 
highlights the robustness of the technique and the limited variance across 
different sites that we have recently estimated to be below 5% (Riemer et al., 
2019). Technical validation and reproducibility of the technique is a mandatory 
and key component of potential clinical implementation and translation. The 
current study did not include an ex vivo correlate for the sodium concentration. 
The possibility of ex vivo quantifying the sodium concentration from tumour 
biopsies was explored in depth with input from the Department of Chemistry 
and the MRC Nutritional Unit. However, this was not deemed feasible due to 
logistical and technical issues and therefore was not performed. The strict 
similarity between our results and previously published data would suggest that 
our measurements are accurate and reproducible, however future studies may 
correlate ex vivo measurements with imaging biomarkers to confirm the validity 
of the in vivo technique.   
In our cohort, the tissue sodium concentration was not able to 
differentiate lower-grade glioma and higher-grade glioma. However, the 
intracellular-weighted sodium concentration was significantly different in the 
T2W hyperintense lesion (p = 0.04), the enhancing component (p = 0.03) and 
the non-enhancing core (p = 0.01). This discrepancy is likely to be a 
consequence of the different contributions of the intracellular and extracellular 
compartments to the total sodium concentration in lower-grade glioma and 
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higher-grade glioma. The sodium concentration in the extracellular matrix is 
known to be an order of magnitude higher than the intracellular concentration 
and therefore an increase in the tissue sodium concentration may be due to 
both an increase in the intracellular concentration and/or an increase in the 
volume of the extracellular fluid relative to the volume of intracellular fluid (Leslie 
et al., 2019). In HGGs the sodium concentration is increased in both 
compartments. The larger cancer cells and the known increase in intracellular 
sodium concentration in malignant cancer cells paired with the necrotic core 
and the oedema in the peritumoral tumour zone produce a parallel increase in 
the total and intracellular sodium concentrations. This is supported by the lower 
degree of suppression of the sodium signal in the intracellular-weighted 
sequence in HGGs as opposed to the LrGG: lower-grade gliomas are less 
cellular than their higher-grade counterparts. This striking difference could 
potentially be used for early detection of LrGG malignant transformation in 
secondary GBMs where an increase in the IW-SC may be a biomarker for 
malignant transformation. Moreover, as sodium homeostasis dysregulation 
contributes to imbalance in metabolic activity, proliferation, migration and 
invasion, a shift in sodium concentration towards an increase in the intracellular 
compartment may affect the integrity of the blood-brain barrier resulting in 
gadolinium enhancement. A simple metric such as the ratio between the tissue 
sodium concentration and the intracellular-weighted sodium concentration of the 
T2W hyperintense lesion could represent a simple index to monitor LrGG over 
time. At present, the relative cerebral blood volume (rCBV) obtained from 
gadolinium-enhanced perfusion MRI is a valid indicator of tumour progression 
when it is at least 2.6-fold higher than the contralateral normal appearing tissue 
(Langen et al., 2017). This is particularly useful when there is an increase over 
time of the rCBV in patient under close surveillance. However, the lack of 
standardization of image acquisition and processing, the difficult in interpreting 
the results and the susceptibility to artifacts have somewhat limited a 
widespread use of the technique. An index based on sodium imaging could 
provide additional information to Dynamic Susceptibility Contrast perfusion 
imaging and could complement its assessment. The few published papers have 
shown similar ranges of sodium concentration in the normal grey and white 
matter proving the reproducibility and repeatability of the results. Once a 
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threshold for optimal progression prediction is established, this could be 
automatically analysed due to the high contrast-to-background ratio of sodium 
MR images. In this cohort, that threshold turned out to be 2.9, however, this is a 
report from a single institution study and, albeit this is the largest cohort of 
patients with both tissue sodium concentration and intracellular-weighted 
sodium concentration, further investigation on the optimal thresholds is 
warranted. 
Sodium imaging can also have a role in the detection of gliomas. Figure 
4.1 and 4.2 show a representative case of LrGG and HGG. In both the cases 
the conspicuity of the lesions over the background on the tissue sodium 
concentration images is clearly appreciated. On the intracellular-weighted 
sodium concentration, the contrast is mostly negative with the lesion appearing 
hypointense as compared to the background. Quantitatively, the lower-grade 
glioma tissue sodium concentration in the T2W hyperintense lesion and 
enhancing component were significantly different compared to the basal ganglia 
(p < 0.001 and p = 0.01, respectively) and to the normal appearing white matter 
(p < 0.0001 and p < 0.001, respectively). Interestingly, whilst the tissue sodium 
concentration of the HGGs was significantly different compared with both the 
basal ganglia and normal appearing white matter (p < 0.0001 for all the 
combinations), only the difference between the intracellular-weighted sodium 
concentration in the T2W hyperintense lesion and the basal ganglia was 
significantly different (p = 0.01). The comparison with the basal ganglia appears 
to be a reliable reference for comparison with the tumour to be chosen as 
biomarker in future larger studies. It is worth mentioning that age-related iron 
deposition in the basal ganglia is a known phenomenon. The presence of iron 
causes shortening of the T1 and T2 relaxation times on conventional 1H imaging, 
however, this does not affect sodium imaging as the gyromagnetic ratio for 
23Na, is approximately four times lower than that for 1H. 
4.3.2 Intralesional and peritumoral heterogeneity  
Gliomas are highly heterogenous with areas containing different gene 
expression profiles, hence different grades within the same lesion. 
Heterogeneity is particularly important in lower-grade gliomas, where foci of 
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higher-grade tumour can avoid detection through conventional imaging. 
Therefore stereotactic biopsies must be aimed at areas reflecting the biologic 
most active region of the tumour and thus of higher-grade (Jacobs et al., 2005). 
Imaging can play a significant role in selecting suitable targets for stereotactic 
biopsies exploiting the metabolic heterogeneity in vivo. Complex approaches 
combining a plethora of MRI and positron emission tomography (PET) 
techniques, such as diffusion, perfusion and spectroscopy with 18F-
fluorothymidine-PET have been evaluated. However, despite the improvement 
in grading assessment the incorporation of many of these advanced techniques 
in a clinical setting is not feasible (Weber et al., 2010). Sodium MRI could be a 
potential viable solution to this problem as it is relatively straightforward to 
implement. 
Comparing the tissue sodium concentration and the intracellular-
weighted sodium concentration maps with the corresponding T2WI and post-
gadolinium 3D T1WI in figure 4.1 and 4.2, it appears that the sodium signal is 
heterogenous with changes that do not correspond to the proton signal. In 
lower-grade gliomas, sodium imaging is able to highlights region of potential 
higher-grade that the post-gadolinium 3D T1WI, currently used in many centres 
as the reference sequence for intraoperative guidance, is not able to highlight. 
Indeed, only a minority of LrGGs enhance and when the enhancement is 
detected it often corresponds to an area which has already transformed to 
higher-grade tumour. Hence, it is too late to make a significant impact on the 
long-term survival. The tissue sodium concentration maps in all the LrGG 
recruited in this study were highly heterogenous, depicting several areas with 
different sodium concentration even within homogenously T2W hyperintense 
regions. As previously mentioned, those areas are likely to correspond to cells 
that are proliferating, migrating and actively consuming more ATP. Therefore, 
we could postulate that areas of higher TSC and IW-SC would be the best 
target for stereotactic biopsies in LrGG. Similarly, sodium imaging highlights 
greater heterogeneity within GBMs than found on conventional imaging. 
Contrast enhancement in GBMs is deemed to be secondary to gadolinium 
leakage through the damaged blood-brain barrier, and therefore may not 
entirely represent viable tissue. Comparing the TSC and the IW-SC, sodium 
offers the possibility to disentangle areas where there is loss of cellular integrity 
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(signal is suppressed on the IW-SC) from the viable tissue providing a better 
target for tissue biopsy and treatment.  
Furthermore, on the TSC maps there are areas of increased sodium 
concentration outside the tumour boundaries defined by the T2W hyperintensity 
both in LrGGs and in HGGs. The sodium concentration has been shown to be 
increased also in the presence of inflammation (Leslie et al., 2019). Although 
sodium concentration measurements have not yet been studied in tumour 
inflammation, it is reasonable to believe that this will also be associated with 
elevated sodium. Therefore, the areas of increased sodium concentration 
outside the tumour boundaries could either represent foci of migrated cancer 
cells or peritumoral inflammation and further histological assessment of those 
regions is warranted. Areas of increased TSC could be additional targets for 
more aggressive resection or radiotherapy treatment with potential survival 
benefit. 
Interestingly, sodium is also used intraoperatively as fluorescein sodium 
(FL) for real-time intraoperative guidance during microsurgery. Fluorescein 
sodium is a biosafe green-fluorescing dye that accumulates in areas of 
malignancy, vascular leakage, pooling defects or abnormal vasculature. This 
compound has been evaluated as an alternative to 5-aminolevulinic acid (5-
ALA) for several years although its precise mechanism of action is still 
unravelled (D’Amico et al., 2017). Fluorescein sodium is believed to passive 
stain the extracellular space in the presence of a disrupted blood-brain barrier 
(Chen et al., 2012; Höhne et al., 2019). However, recent studies have 
demonstrated that non-enhancing gliomas show fluorescence and this extends 
beyond the tumour margins (Neira et al., 2017; Bowden et al., 2018). The 
fluorescent regions can be shown to have a higher cell density and proliferative 
activity, similarly to what seen with sodium imaging (Bowden et al., 2018). 
However, despite the fact that the extent of resection is an independent 
predictor of prognosis in patients with gliomas and fluorescein sodium increases 
the extent of resection, the dose used to maximise the resection can induce an 
anaphylactic reaction and therefore the wide adoption of this technique is halted 
(Fan et al., 2018). Sodium MRI could complement fluorescein sodium: its non-
invasive nature, safety and high resolution (up to 2 mm isotropic) could be 
applied clinically. Sodium maps could be used in guidance systems fused with 
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other convectional images technique providing the same information of 
fluorescein sodium without the need of the injection. Moreover, if safety 
concerns are addressed, sodium imaging could be the natural complement for 
fluorescein sodium. Liu et al. demonstrated that combining advanced imaging 
and fluorescein sodium can increase the gross total resection rate, decrease 
surgical morbidity and improve quality of life (Liu et al., 2013). Sodium MRI 
could be the natural complement for this technique and the combination of the 
two may lead to the identification of more foci of cancer cells that are presently 
not identified.  
4.3.3 Therapy assessment and prognostication 
In the clinic, therapy assessment for brain tumours usually assesses size 
and contrast enhancement, but is limited by the fact that gliomas are highly 
heterogenous and lack of contrast enhancement may not represent complete 
response as enhancing tissue may not indicate recurrence/residual disease 
(Wen et al., 2010). A more accurate way of assessing therapy response could 
include evaluation of tissue viability and metabolic activity rather than 
morphology alone.  
Sodium MRI is particularly sensitive to necrosis due to the abundance of 
free sodium ions in the necrotic tissue. Moreover, the availability of intracellular-
weighted sequences can aid the identification of areas of loss of cellular 
integrity. In previous work on stroke, it has been demonstrated that an increase 
of tissue sodium concentration of ~50% greater than the contralateral tissue 
(corresponding to a threshold of 70mM), corresponds to infarct (Madelin and 
Regatte, 2013). In our group, the non-enhancing areas of both the LrGGs and 
the HGGs were above this threshold (84 ± 11 for the LrGG and 76 ± 21 for the 
HGG). Furthermore, we observed a suppression of sodium signal greater than 
50% on the IW-SC maps. The capability of detecting necrosis would be 
extremely effective in serial follow-up studies to monitor therapy efficacy and 
assess therapy response at an early stage. Indeed, an increase in the TSC with 
an associated decrease in IW-SC during treatment would be indicative of loss of 
cellular integrity and therefore potential therapy response. On the contrary, if the 
TSC remains stable and/or the IW-SC increases, the tumour may be still 
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proliferating and therefore a change of therapy would be warranted. Further 
studies are required to evaluate further. 
  Looking beyond therapy response assessment, the capability of 
predicting long term survival with a scan at baseline would be invaluable to 
better manage patients with glioma. Previously, Biller and colleagues 
demonstrated in a cohort of 34 patients that sodium imaging is able to predict 
IDH mutation status and tumour progression (Biller et al., 2016). IDH mutation is 
the strongest predictor of prognosis in glioma. Since the most recent update of 
the WHO classification of tumours of the central nervous system, IDH 
mutational status has been shown to play a key role in classifying and grading 
glioma. Unsurprisingly, in our cohort it was the strongest predictor of long-term 
survival with a significant shorter survival if no mutation was detected. Sodium 
imaging did not offer any additional prognostic information over IDH 
measurements. This was expected as IDH is currently the key determining 
biomarker for treatment and survival of patients with glioma. Nonetheless, 
tissue is required to test for the presence of the mutation and, given the high 
degree of heterogeneity present within gliomas, a wild-type result may not be 
accurate if the biopsy was taken in the highest-grade area of the lesion. 
Therefore, the role of sodium imaging could be as a potential aid for targeting 
biopsies or in selected cases in which a tissue biopsy is not deemed feasible. 
Sodium MRI is a potential candidate for non-invasive, in vivo, 
assessment of long-term prognosis. Several biomarkers were statistically 
significant predictor of survival: the tissue sodium concentration in the T2W 
hyperintense lesion (p = 0.04), the ratio between the tissue sodium 
concentration in the T2W hyperintense lesion and the basal ganglia (p = 0.03) 
and the ratio between he tissue sodium concentration in the T2W hyperintense 
lesion and the non-enhancing core (p < 0.001). The latter was the strongest 
predictor among the biomarkers derived from the tissue sodium concentration 
results. This may be explained considering that the higher the quantity of 
necrosis, the greater the aggressiveness of the tumour, growing so rapidly that 
it outpaces the neovascularization. The intracellular-weighted sodium 
concentration and the ratio between the enhancing tissue and the basal ganglia 
were the strongest predictors of survival (p < 0.01 and p < 0.001). Also, the ratio 
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between the sodium concentration in the T2W hyperintense lesion and the basal 
ganglia was a significant predictor, albeit weaker (p = 0.02). 
4.3.4 Support for drug discovery and assessment of 
experimental therapies 
  Primary brain tumours are challenging to treat due to heterogeneity 
(Aldape et al., 2019). Indeed, despite recent progress in the treatment of many 
other cancer types, the survival of patients with primary brain tumours remains 
poor. Sodium imaging can play a significant role in fostering drug research. The 
identification of new targets in primary brain tumours requires a deeper 
understanding of tumour biology. Ion channels are one of those novel targets 
that could be exploited as new therapeutic approach. 
  Several ions have been shown to be dysregulated in cancer cells and 
are involved in most of the hallmarks of cancer (Prevarskaya et al., 2010). 
Imaging can aid in determining if the channel is under- or over-expressed in a 
specific cancer, how specific is the dysregulation of the channel to the tumour 
as well as the functional significance of any change in expression. Sodium has 
been shown to be increased in malignancy and involved in several pathways, 
therefore direct or indirect manipulation of its concentration may either 
complement existing therapeutic approaches or be evaluated as primary 
therapy (Leslie et al., 2019). High-grade gliomas overexpress non-voltage-gated 
sodium channel of the degenerin superfamily that are commonly absent in 
normal astrocytes and in lower-grade tumours. Several studies have 
demonstrated that the inhibition of some of those channels, namely ASIC 1 and 
2, results in a decrease in growth and glioma cells migration (Vila-Carriles et al., 
2006; Kapoor et al., 2009). Sodium imaging can be instrumental in trials aimed 
at evaluating the efficacy of those drugs in vivo. The possibility of profiling the 
individual cancer before any intervention will allow the selection of patients who 
are most likely to benefit from a therapy, maximising the survival whilst also 
limiting the adverse effects. In this instance, on top of the above-mentioned key 
role in assessing therapy response to conventional therapies, evaluating the 
concentration of tissue sodium concentration and intracellular-weighted sodium 
concentration could aid in the selection of patients that are more likely to benefit 
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from the inhibition of non-voltage-gated sodium channels.  Moreover, sodium 
imaging of the ion concentration in the extracellular and intracellular 
compartments, can be used to provide an assessment of the efficacy of those 
drugs in inhibiting the sodium current through the channels. A more accurate 
means of evaluating the efficacy of treatment would also allow for therapy to be 
switched or modulated and therefore reducing adverse effects, improving 
quality of life and potentially maximising the survival. However, sodium 
channels are ubiquitous and therefore accurately targeting cancer cells is a 
challenge. Moreover, voltage-gated sodium channels play a significant role in 
regulating immune cell function, therefore there is a risk of impairing innate 
immunity by targeting these channels (Leslie et al., 2019). 
4.4 Conclusion 
Sodium homeostasis is disrupted in primary brain tumours. Here I have 
demonstrated that sodium MRI is a reliable technique to measure both the total 
sodium concentration and the concentration in the intracellular compartment. In 
particular, the quantification of the intracellular fraction could help in grading 
gliomas and in early detection of malignant transformation. Sodium imaging 
significantly correlates with survival and could be used as a novel imaging 
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Glioblastomas (GBMs) are the most common and aggressive adult-onset 
primary malignant brain tumours accounting for 16% of all primary brain 
tumours (Dolecek et al., 2013; Ostrom et al., 2015; Tamimi and Juweid, 2017). 
Prognosis for newly diagnosed GBMs remains dismal with a median survival of 
12-15 months despite the combination of maximal surgical resection, 
chemotherapy and targeted radiotherapy (or radiosurgery) (Ostrom et al., 2015; 
CRUK, 2019). Furthermore, the cumulative incidence rate of brain tumours in 
the UK increased by around 34% since the early 1990s, thus becoming a 
pressing health burden (CRUK, 2019). GBMs are extremely heterogeneous, 
both morphologically and biologically, which contributes to a very poor 
prognosis. The intralesional heterogeneity seen at pathology is characterized by 
foci of necrosis commonly surrounded by cellular pseudopalisades and areas of 
microvascular hyperplasia (Rong et al., 2006; Vartanian et al., 2014). Those 
characteristics of an aggressive growth pattern help in differentiating GBM from 
lower-grade gliomas (LrGG). Moreover, the heterogeneity extends beyond the 
boundaries of the lesion into the so-called peritumoral brain zone (PBZ). This is 
defined on Magnetic Resonance Imaging (MRI) as the area surrounding the 
lesion that does not show contrast enhancement after gadolinium (Gd) 
administration on the T1-weighted (T1W) images and it is commonly 
hyperintense in the T2-weighted (T2W) images (Lemée et al., 2015a). At 
pathology, this area contains a plethora of different cells, including reactive 
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astrocytes and inflammatory cells. Tumour cells are commonly identified in a 
third of biopsies from the PBZ that are considered as normal both on MRI and 
following surgical inspection; however, the histological characteristics of these 
invasive cell populations may differ from the cells isolated from the primary 
mass suggesting that only some clonal populations are able to migrate outside 
the boundaries of the lesion (Lemée et al., 2015a, b). According to the so-called 
“go or grow” hypothesis, subpopulations of GBM cells have different metabolic 
and biological behaviour, with some cells exhibiting a tendency to favour 
migration whilst in contrast, other subpopulations preferentially proliferate 
(Giese et al., 2003; Kathagen-Buhmann et al., 2016). Metabolic reprogramming 
is believed to be one of the major driving forces in determining this behaviour 
(Corbin et al., 2017). 
Otto Warburg was the first to describe aerobic glycolysis (termed the 
Warburg effect), the non-oxidative metabolism of glucose even in the presence 
of oxygen. Although his assumption that the switch away from the tricarboxylic 
acid (TCA) cycle was derived by defective mitochondria has been confirmed 
only in selective cases, such as in a subset of cancers in which succinate 
dehydrogenase (SDH) and/or fumarate hydratase (FH) are mutated, the 
Warburg effect still constitutes the foundation stone of metabolic reprogramming 
in cancer (Warburg, 1925, 1956; Corbin et al., 2017). Despite its metabolic 
inefficiency in terms of produced ATP molecules (aerobic glycolysis leads to the 
production of 2 molecules of ATP per pyruvate whilst the TCA produces up to 
38 molecules of ATP), aerobic glycolysis produces NADH, used to fuel energy 
production, and lactate, that contributes in acidifying the microenvironment 
promoting cells invasion (Vander et al., 2015; Strickland and Stoll, 2017). 
The pentose phosphate pathway (PPP) also plays a significant and 
complementary role to aerobic glycolysis in the metabolism of GBM. Enzymes 
of the PPP are upregulated in highly proliferative, non-migrating cells to 
generate ribose-5-phospate and NADPH for DNA, RNA and fatty acid 
synthesis, and are downregulated in the hypoxic cellular pseudopalisades 
(Kathagen et al., 2013; Kathagen-Buhmann et al., 2016). On contrast, glycolytic 
enzymes are downregulated in highly proliferative, non-migrating cells and 
upregulated in the cell clones that favour migration (Kaur et al., 2005; Kathagen 
et al., 2013; Kathagen-Buhmann et al., 2016). Moreover, glioma stem cells, 
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which may play a significant role in tumour recurrence, are less glycolytic when 
compared to differentiated cancer cells and this preservation of the 
mitochondrial capacity has been correlated to radio-resistance (Vlashi et al., 
2011; Strickland and Stoll, 2017). 
The metabolic alterations in glioblastoma have been shown to promote 
cancer growth and invasiveness whereas previously they were thought to be 
solely a consequence of tumour development (Vartanian et al., 2014; Corbin et 
al., 2017). Therefore, metabolic reprogramming could represent a target for 
novel therapeutic strategies aimed at disrupting cancer-specific metabolic 
pathways (Corbin et al., 2017; Strickland and Stoll, 2017). To date there have 
been several attempts to use pharmacological methods to alter tumour 
metabolism both in GBMs and other cancers and although some have shown 
initial promise, none are used routinely; examples include dichloroacetate which 
stimulates flux of pyruvate through pyruvate dehydrogenase within 
mitochondria. Exploring the intratumoral, peritumoral and intertumoral metabolic 
heterogeneity in vivo may help to identify why some patients are responding to 
these agents and may help with the discovery of novel therapeutic strategies 
(Michelakis et al., 2010; Marin-Valencia et al., 2012; Corbin et al., 2017). 
Hyperpolarised 13C Magnetic Resonance Spectroscopic Imaging (HP 13C MRSI; 
also commonly called Hyperpolarised 13C  Magnetic Resonance Imaging, HP 
13C MRI) is based on the principles of dynamic nuclear polarization (DNP) and 
is a novel technique that allows the in vivo non-invasive assessment of the 
metabolism of hyperpolarized (HP) 13C-labelled molecules (Zaccagna et al., 
2018).  The process of DNP involves polarizing the nuclear spin in the solid 
state at temperatures close to absolute zero and in a strong magnetic field: 
polarization is transferred from the electrons to the nuclear spins by microwave 
irradiation; this method can result in a >10,000-fold enhancement of the nuclear 
polarization with a significant increase of the signal-to-noise (SNR) ratio when 
measured with 13C MRS in the liquid-state (Ardenkjaer-Larsen et al., 2003). The 
technique allows the possibility of in vivo detection of tissue metabolism through 
imaging the spatial distribution on injected 13C-labelled cell substrates and their 
metabolites. The development of the method has spawned a new research area 
and several compounds have been evaluated in the pre-clinical setting 
(Kurhanewicz et al., 2011). Among all the potential compounds, [1-13C]pyruvate 
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(refered to simply as pyruvate here) has been the most studied due to technical 
reasons (relatively long polarization half-life, forms a glass suitable for 
polarisation when frozen, is at a high concentration in liquid form) and biological 
reasons (rapid distribution and uptake, ability to explore the Warburg effect in 
cancer) (Zaccagna et al., 2018; Kurhanewicz et al., 2019). Pyruvate sits at a 
metabolic crossroad and plays a major role in many metabolic pathways 
(Brindle et al., 2011; Lumata et al., 2015). While the first clinical study of the 
technique used a preclinical device modified for human use, a clinical polarizer 
for sterile use intent was developed in 2011 which allowed the technique to be 
	
Figure 5.1: Schematic diagrams for models and model-free methods. 
Schematic diagrams showing some of the models and model-free methods proposed for 
the analysis of HP 13C MRI data. In (a) interactions accounted for in the two-way 
differential/ integral models; kP is the forward reaction rate constant, kL is the backward 
reaction rate constants, ρ is the inverse of the effective spin–lattice relaxation. In (b) 
interactions for one-way integral model; kP is the forward reaction rate constant, ρ is the 
inverse of the effective spin–lattice relaxation. In (c) example metabolite time courses 
demonstrating the ratiometric model. (d) fall-minus-rise time at height α (FmR α) approach 
and L/P ratio method. (e) Lactate-to-pyruvate AUC ratio. (f) Lactate time to peak (TTP). 






translated more widely into the clinical arena (Ardenkjaer-Larsen et al., 2011). 
The work described here has utilised one of the early devices to study 
metabolism in glioma. 
Parallel to the development of hyperpolarised compounds, several 
methods to quantify the exchange between pyruvate and lactate have been 
proposed. Figure 5.1 illustrates the most widely used approaches to date. 
Kinetic models applied to spectroscopic data have been widely applied to 
derive the apparent build-up rate forward constant kPL which expresses the 
constant conversion rate between pyruvate and lactate catalysed by the 
enzyme lactate dehydrogenase (Day et al., 2007; Zierhut et al., 2010; Witney 
et al., 2011). Over the years, different approaches, based on simpler post-
processing techniques have also been proposed. For instance, model-free 
parameters as the area under the curve for each metabolite (Hill et al., 2013; 
Daniels et al., 2016) or ratios of the metabolite signal peaks (Schroeder et al., 
2008; Seth et al., 2011). Nevertheless, at present there is not a consensus on 
which method to use for the post-processing of HP [1-13C]pyruvate MRI data. 
Our group is using a kinetic modelling of the exchange between the labelled 
pyruvate and its products based on a two-site exchange kinetic modelling with 
a frequency-domain approach (Khegai et al., 2014) as represented in figure 
5.2. 
Translation, feasibility and safety of the technique in a clinical setting 
were achieved in 2013 with the first-in-man study in patients with prostate 
cancer by Nelson and colleagues (Nelson et al., 2013). Subsequently, images 
of the heart in healthy volunteers and the first-in-human renal cell carcinoma 
have been reported (Cunningham et al., 2016; Tran et al., 2019). Pyruvate has 
also been shown to cross the blood-brain barrier with the conversion of 
 
Figure 5.2: Schematic diagram of a two-site exchange model. 
The diagram shows the two-site exchange model of pyruvate metabolism adopted in this 
study.  





Linear least-squares, time-domain spectral fitting
Spectral fitting of metabolite amplitudes am can be considered as
the solution of the inverse problemdefined by thematrix equation
[1]. For the typical case ofmore FID samples than unknownmetab-
olite constituents, this describes an over-determined system that
can be solved in a weighted linear least-squares sense using the




with the superscript H the complex conjugate operator, andW an
optional, diagonal weighting matrix. In order to increase the
detectability of low amplitude signals next to a dominant pyruvate
peak (i.e. to reduce CS aliasing), the pyruvate resonance can also be
approximated by more than a single spectral component.
Two-site exchange kinetic modeling
The spectrally fitted metabolite time signals am were then used
to derive apparent rate constants characterizing metabolite ex-
change and signal decay. In the case of hyperpolarized pyruvate
the signal dynamics was described by a two-site exchange
model (8,13) including the pyruvate substrate (pyr) and a single
metabolic product (m). This model, illustrated in Figure 2, ac-
counts for forward (kpyr→m) and backward (km→pyr) conversion
and signal decay mechanisms due to T1 relaxation and repetitive











with Tk and αk the time increment and the effective flip angle of
the kth measurement point, respectively. It is important to note
that kpyr→m and km→pyr are the apparent build-up and deple-
tion rates, respectively, including enzymatically driven conver-
sion as well as transport effects. The apparent rate constants
were assumed to be constant during the experiment time pe-
riod. Summarizing the contributions proportional to am,k and
apyr,k and considering a constant repetition time (Tk=Δt) and flip
angle, the above equation was simplified to
Δam;k
Δt
¼ þ kpyr→mapyr;k " Reff;mam;k [4]
with the effective decay rate, Reff,m= 1/T1,m+ [1" cos(αk)]/Δt+
km→ pyr, accounting for the signal decay effects due to T1 relaxa-
tion, repetitive excitation, and backward conversion. This
equation was solved for the unknown apparent build-up rate
(kpyr→m) and the effective decay rate Reff,m using either time or
frequency domain analysis, as described in the following.
Time-domain fitting of kinetic model. Given time-resolved me-
tabolite signals, Equation [4] results in an over-determined sys-






















which can be solved using the Moore–Penrose pseudo-inverse,
similar to the case discussed in the context of Equation [2].
Figure 1. (a)–(d) Example schematic representation of spectral fitting
using the matching pursuit algorithm (power spectra are shown). (e)
Sparse representation of initial spectrum (red circles show obtained am-
plitudes and frequencies {ai,ωi}) together with expected metabolite CS
frequencies (blue lines) and predefined frequency intervals (green lines).
Figure 2. Schematic diagram of a two-site exchange model of pyruvate
metabolis .
O. KHEGAI ET AL.




pyruvate to [1-13C]lactate (termed lactate) demonstrated both in healthy 
subjects and in primary and secondary brain tumours (Miloushev et al., 2018; 
Park et al., 2018; Grist et al., 2019). Grist et al. demonstrated the conversion of 
hyperpolarized pyruvate to lactate and bicarbonate in the healthy human brain 
in the context of an intact blood-brain barrier (Grist et al., 2019). This first study 
of healthy volunteers also measured the peak of pyruvate and lactate at 12 s 
and 16 s respectively, whilst the peak of labelled-bicarbonate was seen at 26 s 
(Grist et al., 2019). Grist et al. also reported the first quantification of kPL and 
Inclusion criteria 
- 18 years or older; 
- Be scheduled for biopsy or resection of a presumed glioma of any grade (based on 
imaging features consisting with glioma); 
- Be aware of, and understand the diagnosis; 
- Be able to provide written informed consent according to ICH/GCP, national and local 
regulations; 
- Be willing and able to comply with scheduled visits, laboratory tests, imaging and 
other study procedure; 
- Patients of childbearing potential must have a negative urinary or blood pregnancy 
test prior to enrolment if there is a possibility they could be pregnant. 
 
Exclusion Criteria 
Clinical contraindications to MR imaging will apply to each patient and include, but are 
not limited to: 
- Pacemakers, non-MR compatible heart valves or cardiac stent or other vascular stent; 
- Renal impairment; 
- Known allergic reactions to Gd contrast agent; 
- Intracranial aneurysm clips that are not MR safe; 
- Intracranial programmable shunt; 
- History of intra-orbital metal fragments that have not been removed; 
- Inner ear implants; 
- Artificial joint/limb prosthesis not MR safe; 
- Neuro-stimulator or other under the skin devices; 
- False eye; 
- Claustrophobia; 
- Inability to give informed consent; 
- Diabetes or glucose deranging conditions. 
 




kPB from the whole brain of healthy subjects; in that cohort, the kPL was 0.012 
± 0.006 s-1 and the kPB 0.02 ± 0.002 s-1. Park et al. have reported 8 cases of 
previously diagnosed gliomas (grade II to IV) undergoing MRI follow-up using a 
2D echo-planar spectroscopic sequence and paddle coils (Park et al., 2018). 
They observed 13C signal in all the cases but the experimental setup centred 
on a custom-built surface coil, as opposed to the dual-tuned birdcage coil used 
in this study, resulted in a 3- to 4- fold reduction of the signal intensity in the 
centre of the image with an almost complete lack of signal from the deep brain 
nuclei observed in those cases which is problematic for quantifying the 
metabolism of deep; the lactate peak was observed between 6 and 9 seconds 
after the pyruvate peak, potentially due to impaired exchange in the cancer 
cells (Park et al., 2018). Miloushev et al. observed pyruvate conversion to 
lactate in 2 primary and secondary brain tumours; they also assessed 
repeatability in 1 patient (Miloushev et al., 2018). Most of the published 
literature to date has demonstrated the feasibility and the safety of the 









Patient 1 Male 66 
GBM IDH-
Wildtype 
Lost 22 209 
Patient 2 Female 53 
GBM IDH-
Wildtype 
Retained 26 alive 
Patient 3 Male 73 
GBM IDH-
Wildtype 
Lost 38 257 
Patient 4 Female 49 
GBM IDH-
Wildtype 
Retained 18 alive 
Patient 5 Male 48 
GBM IDH-
Wildtype 
Retained 18 alive 
Patient 6 Male 57 
GBM IDH-
Wildtype 
Retained 19 alive 
Patient 7 Male 74 
GBM IDH-
Wildtype 
Lost 31 132 
Table 5.2: Clinical characteristics 
The monoclonal antibody MIB-1 was used to measure the Ki-67 expression which in turn 
determined the Ki-67 labelling index as a marker of proliferation as the clinical standard. 




exchange between the different metabolites. The work has shown that HP [1-
13C]pyruvate MRI is feasible and safe to use in humans with signal from the 
13C-labelled molecules clearly detectable in the human brain. This technique is 
extremely promising for the in vivo assessment of cellular metabolism in 
healthy and disease brain. Thus, the purpose of this study was to explore 
metabolic reprogramming in glioblastoma and in the surrounding 
microenvironment using. Moreover, this study explored the potential correlation 
between HP 13C MRI and conventional, invasive, tissue biomarkers to increase 
our understanding of the underpinning metabolic changes of GBM. 
5.1 Methods and materials 
5.1.1 Patient selection, enrolment and clinical monitoring 
This prospective study was approved by our local Research Ethics 
Committee (East of England, Cambridge South Research Ethics Committee, 
REC reference number 16/EE/0184). Between November 2016 and October 
2018 eight treatment-naïve patients (6 males, 2 females; 60 ± 10.98 years) with 
a presumed diagnosis of GBM were recruited from the weekly Multidisciplinary 
Team (MDT) Meeting and/or from the Neuro-oncology clinic. Only patients 
scheduled for stereotactic biopsy or resection of a glioblastoma (based on 
consisting imaging features and MDT review) were screened to assess eligibility 
according to our inclusion and exclusion criteria (table 5.1). Considering the 
paucity of data relative to pyruvate injection in humans, a strictly conservative 
approach was chosen towards any disorder that may adversely affect by the 
injections of a high concentration of pyruvate (such as diabetes) or in presence 
of medications that may affect levels of pyruvate in the blood stream and, 
consequently, jeopardise the success of the scan. Clinical characteristics are 
displayed in table 5.2. During the Neuro-oncology clinic appointment, all the 
eligible patients received a detailed participant information sheet, describing the 
study rationale and procedure, and had a dedicated encounter with a member 
of the research team to discuss the study rationale, potential involvement and 
expected outcome. Written informed consent was signed by all the participants 
before enrolling in the study.  
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On the day of the scan, vital signs and laboratory tests were collected 
before and after the scan to ensure the wellbeing of the patient and confirm the 
safety of the study. Blood pressure, pulse and saturation were recorded before 
and after the scan and monitored during the entire procedure; temperature and 
weight were collected before and after the scan. Blood tests included: Aspartate 
transaminase, Lactate dehydrogenase, Lactate, Serum Glucose, Urea, 
Albumin, Bicarbonate, Sodium, Potassium and Creatinine; those were 
performed before and after the scan. Vital signs and laboratory investigations 
were performed to ensure patient suitability for the study.  
5.1.2 Pyruvate synthesis and hyperpolarization 
MRI examinations were performed using a 3.0 T clinical scanner and a 
12-channel head coil (Discovery MR750; GE Healthcare). Imaging included: 3D 
T2-weighted imaging (T2W; repetition time/echo time [TR/TE] 2500/79 ms; 248 
slices; slice thickness 1.2 mm; acquisition matrix 320x320; field of view [FOV] 
240x240 mm), 2D T2W fluid-attenuated inversion recovery (FLAIR; TR/TE 
8000/126ms; inversion time [TI] 2128 ms; slice thickness 6 mm; acquisition 
matrix 384x224; FOV 240x240 mm) and DWI (TR/TE 2841-3867/83.3-87.4 ms; 
slice thickness 5mm; b-values 0,1000 s/mm2; matrix 128x128; FOV 240x240 
mm). 3D T1-weighted Fast SPoiled GRadient echo (T1W FSPGR; 252 slices; 
0.94x0.94x1.5 mm reconstructed to 0.94x0.94x1 mm; TR/TE 8.2/3.2; slice 
thickness 1.5 mm; matrix 256x256; FOV 240x240 mm) was performed before 
and after gadolinium-based contrast injection (Gadobutrol 1.0 mmol/mL; 
Schering). ADC maps were generated as per clinical standard.  
5.1.3 1H and HP 13C MRI acquisitions 
Patients were imaged on a 3 T clinical scanner (Discovery MR750, GE 
Healthcare, Waukesha, WI, U.S.A.) using a dual-tuned 13C/1H quadrature 
transmit/receive head coil (Rapid Biomedical, Rimpar, Germany) for the HP 13C 




The HP 13C MRI acquisition was performed using a dynamic Iterative 
Decomposition with Echo Asymmetry and Least squares estimation (IDEAL) 
spiral chemical shift imaging (CSI) sequence (FOV 240 x 240 mm, TR 500 ms, 
Flip angle 15°, acquisition time 60 s, temporal resolution 4 s, acquisition matrix 
40 x 40, reconstruction matrix 128 x 128, slice thickness 30 mm). (Wiesinger et 
al., 2012) A reference 3D T1W Fast SPoiled GRadient echo (FSPGR; field of 
view [FOV] 240 x 240 mm, TR/TE 8.6/3.2 ms, acquisition matrix 256 x 224, 
reconstruction matrix 256 x 256; slice thickness 2mm) was acquired with the 
dual-tuned 13C/1H quadrature head coil within the same geometrical space to 
facilitate image registration for quantitative analysis.  
The HP 13C MRI acquisition was followed by conventional proton imaging 
including: 3D T2W (repetition time/echo time [TR/TE] 2500/79 ms; 248 slices; 
slice thickness 1.2 mm; acquisition matrix 320 x 320; FOV 240 x 240 mm), 2D 
T2W fluid-attenuated inversion recovery (T2W FLAIR; TR/TE 8000/126 ms; 
inversion time [TI] 2128 ms; slice thickness 6 mm; acquisition matrix 384 x 224; 
FOV 240 x 240 mm) and Diffusion-Weighted Imaging (DWI, TR/TE 2841-
3867/83.3-87.4 ms; slice thickness 5 mm; b-values 0, 1000 s/mm2; matrix 128 x 
128; FOV 240 x 240 mm). A 3D T1W FSPGR (252 slices; 0.94 x 0.94 x1.5 mm 
reconstructed to 0.94 x 0.94 x 1 mm; TR/TE 8.2/3.2; slice thickness 1.5 mm; 
matrix 256 x 256; FOV 240 x 240 mm) was performed before and after 
gadolinium-based contrast injection (Gadobutrol 1.0 mmol/mL; Bayer AG, 
Leverkusen, Germany).  
	
Figure 5.3: Representative spectra. 





5.1.4 Image processing and analysis 
The post processing was performed in Matlab (Matlab 2017a, the 
MathWorks, Natick, MA, U.S.A.) using in-house scripts allowing for the sum of 
the metabolites over the time course, iterative adjustment of a threshold for 
masking and estimation of noise-corrected ratio maps (lactate to 
pyruvate, bicarbonate to pyruvate and bicarbonate to lactate ratios). The kinetic 
modelling of the exchange between the labelled pyruvate and its products was 
estimated using a two-site exchange kinetic modelling with a frequency-domain 
approach (Khegai et al., 2014). This fitting utilizes the entire acquired signal, 
from the pyruvate arrival until the polarization is decayed, avoiding an explicit 
time differentiation that could result in noise amplification. The apparent build-up 
rate forward constant kPL, derived through the kinetic modelling, expresses the 
constant conversion rate between pyruvate and lactate catalysed by the 
enzyme lactate dehydrogenase (LDH) but also incorporates inflow and transport 
and hence is an apparent rate constant rather than a true rate constant. For the 
modelling, the backward conversion (expressed by the constant kLP) and the 
spin lattice relaxation effects were combined as an effective relaxation term. 
Similarly, kPB was defined as the apparent forward rate constant representing 
the conversion of pyruvate to carbon dioxide catalysed by the enzyme pyruvate 
dehydrogenase (PDH) and followed by exchange with bicarbonate, catalysed 
by the enzyme carbonic anhydrase (CA). Figure 5.4 shows the interplay 
between pyruvate, lactate and bicarbonate; a more comprehensive depiction of 
pyruvate metabolic fate is shown in Figure 2.2 in chapter 2. 
	
Figure 5.4: Diagram showing the conversion of pyruvate into lactate and bicarbonate. 
Abbreviations: LDH - lactate dehydrogenase, PDH - pyruvate dehydrogenase, CA - 




A neuroradiologist with 7 years of experience in neuro-imaging outlined 
all the ROIs on the unenhanced 3D T1W FSPGR sequence, acquired with the 
dual-tuned coil, using OsiriX (V.8.5.2, Pixmeo SARL, Bernex, Switzerland). The 
post gadolinium injection 3D T1W FSPGR, the T2W and the T2W FLAIR images 
were used as additional guidance to define the different lesion components. 
Enhancing tumour was defined on the post-gadolinium T1WI compared to pre-
contrast T1WI and excluding any area of haemorrhage. The necrotic 
components were defined as regions within the tumour that did not enhance 
and had a hyperintense signal on the corresponding T2WI. ROIs were obtained 
for the whole tumour and the peritumoral region. To further assess the spatial 
heterogeneity within the lesion, a regional sub-analysis was performed selecting 
multiple circular ROIs in the medial, lateral, anterior and posterior aspects of the 
lesion; those ROIs were of the same area (1 cm2) to avoid any potential 
confounding effects due to different volume of the ROIs. For comparison, the 
non-tumour bearing brain parenchyma (NTBP) was assessed in each 
hemisphere, each lobe and at the level of the basal ganglia. Furthermore, the 
lesion ROIs were mirrored on the contralateral side. Lastly, individual circular 
ROIs, identical to the ones drawn for the GBMs, were obtained in the lobes that 
were deemed normal at conventional imaging. The intra-patient heterogeneity 
was assessed computing histograms and scatter plots of metabolite 
concentrations and constants value in the GBMs and in the contralateral NTBP 
using in-house scripts in Matlab.  
Apparent diffusion coefficient (ADC) maps were reconstructed from the 
DWI data. To ensure perfect matching of the ROIs, the ADC maps were 
registered to the unenhanced 3D T1W FSPGR and the T2W sequences using 
an in-house pipeline using FLIRT (FMRIB's Linear Image Registration Tool) as 
registration tool (Jenkinson and Smith, 2001; Jenkinson et al., 2002). To 
account for the different slice thickness, the 6 ADC slices corresponding to the 
13C MRI slice were averaged. The ROIs drawn on the 3D T1W FSPGR and the 
T2W sequences, as detailed in the previous paragraph, were used to 
extrapolate the ADC values from the lesion and the mirrored contralateral 
region. 
The same neuroradiologist performed a 3D manual segmentation of the 
GBMs using an open source dedicated software (ITK-SNAP v. 3.6; 
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www.itksnap.org) to obtain lesion volumes (Yushkevich et al., 2006). As per the 
previously mentioned classification of the tumour components, the volume of 
the enhancing tissue and of the necrotic components were separately drawn 
and recorded. The total volume of the lesion was also computed as the sum of 
the two volumes. An example of segmented volume is shown in figure 5.1. 
5.1.5 Histopathology, immunohistochemistry and western blot 
5.1.5.1 Image-guided biopsy targeting and correlation with pathology  
All the patients enrolled in this study were scheduled for maximal 
resection of their previously identified GBM. To explore the intratumoral 
heterogeneity of the lesions, several target areas for biopsies were identified 
prior to surgery for each patient with the aim of correlating imaging biomarkers 
with tissue-derived biomarkers. Identification of target areas was performed by 
the neuroradiologist in charge of the project on HP 13C MR images and 
discussed with the operating neurosurgeon prior to surgery. For consistency, 
the same three sequences were used in all the cases: summed pyruvate, 
	
 
Figure 5.5: Example of volume segmentation. 
Software used for the volumetric segmentation (ITK-SNAP v. 3.6; www.itksnap.org). Axial, 
sagittal and coronal images are reformatted from the 3D T1W Fast SPoiled GRadient-echo 
(FSPGR). The segmentation is manually performed using the three planes to ensure 
maximum accuracy. The software also shows a 3D volume rendering of the lesion. 




summed lactate and lactate to pyruvate (LP) ratio. Those sequences were 
overlaid on the corresponding unenhanced axial T1W FSPGR slice obtained 
with the dual-tuned coil. Targets were defined by a mismatch between summed 
pyruvate, summed lactate and LP ratio accounting also for eloquence of the 
adjacent tissue. If a potential target was deemed to be too close to a functional 
area of the brain (i.e. the motor cortex or the calcarine cortex) the location was 
discarded, and another suitable target identified. After the sampling plan was 
finalised; the proposed biopsy targets were recorded on the unenhanced and 
enhanced axial T1W FSPGR. The neuroradiologist in charge of the study then 
discussed the sampling plan with the operating neurosurgeon prior to surgery, 
using both the annotated images and the full set of acquired images. Digital and 
printed copy of the annotated images were provided to the operating 
neurosurgeon to be used in the operating theatre. A member of the research 
team was present in theatre during surgery with a further copy of the sampling 
plan to assist with the targeted sampling. Tissue sampling was adapted during 
surgery if deemed necessary by the operating neurosurgery in consensus with 
the member of the research team present in the operating room. Screenshots of 
the neuronavigation system depicting the exact location of each biopsy were 
taken and stored for further image registration. After surgery, the exact areas 
from where the samples were taken were recorded on printed MRI images and 
on each sample to ensure future localization. 
The direct comparison between imaging, pathological analysis and 
results from the western blots was performed by drawing circular ROIs of 1 cm2 
on the registered T1WI, on areas corresponding to the biopsies location from 
which the tissue was obtained during surgery. Those ROIs were then 
transferred on the metabolic maps to obtain the concentration of the metabolites 
directly matched with the corresponding sample. 
5.1.5.2 Histopathology and immunohistochemistry  
A board-certified neuropathologist with 7 years of experience determined 
the tumour grade and type using the WHO-2016 classification (Louis et al., 
2016). Haematoxylin and eosin staining (H&E) was performed as per clinical 
standard; isocitrate dehydrogenase isozymes 1 (IDH1) mutation status and 
O[6]-methylguanine-DNA methyltransferase (MGMT) methylation status were 
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checked in all cases. As per standard of care, the antibody MIB-1, directed 
against the protein Ki-67 produced by the gene MKI67, was assessed on 
tumour photomicrographs from a x600 FOV and a fixed matrix of 184x138 µm 
using a semi-automated software (Image-Pro Insight, Media Cybernetics Inc, 
Maryland, U.S.A.) and expressed in percentage as a proliferation marker.   
Tissue samples collected at surgery under image-guidance were fresh-
frozen and stored in the Human Research Tissue Bank (HRTB) at -80 °C to 
allow for a subsequent quantitative and semi-quantitative analysis as per the 
research protocol. Additional Immunohistochemical (IHC) staining for research 
purposes was obtained for monocarboxylate transporter 1 (MCT1), 
monocarboxylate transporter 4 (MCT4), hypoxia-inducible factor 1-alpha (HIF1-
a), carbonic anhydrase IX (CA IX), cluster of differentiation 31 (CD31), cluster of 
differentiation 4 (CD4), cluster of differentiation 8 (CD8), cluster of differentiation 
68 (CD68), the antigen Ki67 and the antigen mast cell tryptase 1 (MCT). 
Samples were formalin-fixed and paraffin embedded (FFPE) after defrosting. 
Subsequently, de-waxing and re-hydration (as standard) prior to IHC were 
performed using an automated Leica ST5020 (Leica Biosystems Newcastle Ltd, 
Newcastle Upon Tyne, United Kingdom); 4 µm sections were obtained with a 
microtome. 
The staining was done with a BOND-III fully automated 
immunohistochemistry (IHC) and in situ hybridization (ISH) stainer system 
(Leica Microsystems UK Ltd, Milton Keynes, United Kingdom). Pre-treatment of 
the formalin-fixed, paraffin-embedded tissue sections with heat-induced epitope 
retrieval (HIER) was performed for each monoclonal antibody for 20 minutes; 
Tris EDTA prepared at different pHs (6 to 9) was used in all the IHC procedures 
except for HIF1-α and CA IX (sodium citrate was used) and ki67 (no pre-
treatment was performed). Endogenous peroxidase activity was blocked using 
3-4% (v/v) hydrogen peroxide. Since all of the primary antibodies (listed in the 
following paragraph) are raised in rabbit, for antigen localisation all the slides 
were then incubated with a polymer anti-rabbit Poly-HRP-IgG (<25 µg/ml) 
containing 10% (v/v) animal serum in tris-buffered saline/0.09% ProClinTM 950 
(Sigma-Aldrich, St. Louis, MO, U.S.A.). Diaminobenzidine tetrahydrochloride 
hydrate enhancer (DAB; AR9432; Leica Biosystems Newcastle Ltd, Newcastle 
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Upon Tyne, United Kingdom) was used for all the antibodies. The post-staining 
de-hydration and clearing were done on the automated Leica ST5020 (Leica 
Biosystems Newcastle Ltd, Newcastle Upon Tyne, United Kingdom). Finally, 
sections were mounted on a fully automated glass cover slipper CV5030 (Leica 
Biosystems Newcastle Ltd, Newcastle Upon Tyne, United Kingdom). 
The antibodies used for staining were: HPA003324 (Atlas Antibodies, 
Bromma, Sweden) at a dilution of 1:500 for MCT1, HPA021451 (Atlas 
Antibodies, Bromma, Sweden) at a dilution of 1:500 for MCT4, ab51608 
(Abcam, Cambridge, United Kingdom) at a concentration of 23.36 µg/ml for 
HIF1-α, NCL-L-CA IX (Leica Biosystems Newcastle Ltd, Newcastle Upon Tyne, 
United Kingdom) at a dilution of 1:100 for CA IX, M 0823 (Dako Denmark A/S, 
Glostrup, Denmark) at a dilution of 1:20 for CD31, PA0427-4B12 (Leica 
Biosystems Newcastle Ltd, Newcastle Upon Tyne, United Kingdom) for CD4 
(no dilution required as this antibody is optimally diluted for use on the BOND 
systems), PA0183-4B11 (Leica Biosystems Newcastle Ltd, Newcastle Upon 
Tyne, United Kingdom) for CD8 (no dilution required as this antibody is 
optimally diluted for use on the BOND systems), M 0876 (Dako Denmark A/S, 
Glostrup, Denmark)  at a dilution of 1:50 for CD68, M 7240 (Dako Denmark A/S, 
Glostrup, Denmark) at a dilution of 1:75 for Ki67 and PA0019-10D11 (Leica 
Biosystems Newcastle Ltd, Newcastle Upon Tyne, United Kingdom) and 
PA0019-10D11 (Leica Biosystems Newcastle Ltd, Newcastle Upon Tyne, 
United Kingdom) for MCT (no dilution required as this antibody is optimally 
diluted for use on the BOND systems).  
After staining, brightfield scanning was performed to allow the high-
resolution digitalised images to be quantitatively analysed using a dedicated 
image analysis platform for quantitative tissue analysis in digital pathology 
(HALO v2.2.1870.15; Indica Labs, Albuquerque, New Mexico, U.S.A).  
The digital analysis of the slides was performed using dedicated 
algorithms able to quantify areas of staining according to their intensity (weak, 
moderate or strong). To facilitate the comparison across multiple samples and 
multiple staining the intensity was converted in percentage of staining relative to 
the whole area of the slide.  The minimum optical densities used to cluster the 
voxels in weak, moderate and strong are as follow: MCT 1 0.482, 0.487 and 
0.540; MCT 4 0.424, 0.487 and 0.54; CA IX 0.240, 0.319 and 0.478; CD31 
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0.244, 0.319 and 0.478. For CD4, CD8, CD68 and Ki67, cells were firstly 
identified and then classified as positive/negative stained; subsequently, the 
percentage of stained cells was computed. Mast cell tryptase 1 was not further 
analysed due to the complete lack of staining. A total of 290 individual slides 
from the 7 patients were analysed. 
Biomarker Role and rationale for inclusion 
MCT-1 
Monocarboxylate transporter 1 is a membrane transporter with high affinity for 
pyruvate and responsible for its uptake and lactate import. Overexpression of 
MCT-1 in glioblastoma has been linked to worse survival. 
MCT-4 
Monocarboxylate transporter 4 is a membrane transporter with lactate as 
preferred substrate and mostly responsible for lactate export. MCT-4 is 
hypothesised to be overexpressed in hypoxic glioblastomas. 
HIF1-α  
Hypoxia Inducible Factor-1 alpha is involved in the induction of stem-like 
phenotype under hypoxia. Expression of HIF1-α is thought to be regulated by 
MCT-4 in glioblastoma.  
CA IX 
Carbonic anhydrase IX is a marker of hypoxia. CA IX is overexpressed in 
glioblastoma and associated with poor survival. 
CD31 
Cluster of differentiation 31, also known as Platelet endothelial cell adhesion 
molecule (PECAM-1), is expressed on platelets, inflammatory cells and 
endothelial cells. CD31 is overexpressed in glioblastomas and its expression 
correlates with HIF1-α. 
CD4 
Cluster of differentiation 4 is found on immune cells and dendritic cells. 
Tumour-infiltrating lymphocytes express CD4 and CD8, thus their quantification 
can inform on inflammation. 
CD8 
Cluster of differentiation 8 is found on immune cells (predominantly cytotoxic T 
cells), thymocytes and dendritic cells. Tumour-infiltrating lymphocytes express 
CD4 and CD8, thus their quantification can inform on inflammation. 
CD68 
Cluster of Differentiation 68 is expressed by monocytes and macrophages 
(including microglia). CD68 is a marker of inflammation. 
Ki67 Ki67 is a cellular marker of proliferation.  
LDH-A 
Lactate dehydrogenase A is a key enzyme for the conversion of pyruvate into 
lactate. In glioblastoma, LDH-A has been shown to positively correlate with 
GBM development. 
c-Myc 
c-Myc is a transcription factor which expression is correlated with glioma grade 
and increases the expression of glycolytic enzymes.  
Table 5.3: Tissue biomarkers 
The table shows the tissue biomarkers assessed with immunohistochemistry and western 




Western blotting was performed as described in Mair et al (Mair et al., 
2018). Briefly, proteins were extracted from tissue samples in Pierce RIPA 
buffer, containing protease inhibitor and EDTA (Thermo Fisher Scientific). 
Proteins were separated using gel electrophoresis in NuPage Bis-Tris precast 
gels (Thermo Fisher Scientific) and dry-blotted onto polyvinylidene difluoride 
(PVDF) membranes using an iBlot transfer stack (Thermo Fisher Scientific). 
Subsequent analysis was performed using an Odyssey Licor near-infrared 
digital fluorescence imaging system (LI-COR Biotechnology). Samples (n = 23) 
were analyzed in duplicate or triplicate and data from technical replicates were 
averaged. The antibodies for LDH-A and c-Myc were used at the dilution 
recommended by the manufacturer: LDHA–Cell Signaling Technology #3582 
1:1,000 and c-Myc–Abcam ab32072 1:10,000, respectively. 
5.1.6 Statistical Analysis 
Anonymised data were recorded into multiple electronic spreadsheets 
(Microsoft Excel for Macintosh V. 16; Microsoft Corporation, Redmond, 
Washington, U.S.A.) for easy storage and analysis. The statistical analysis was 
performed using a mathematical analytical software (Matlab Statistics and 
Machine Learning Toolbox, Matlab 2017a; MathWorks, Natick, MA, United 
States), and two statistical dedicated packages, SPSS (SPSS 18.0 statistical 
package; SPSS Inc, Chicago, IL, USA) and RStudio version 1.1.463 (Rstudio 
Inc., Boston, MA, USA) for Macintosh based on R version 3.5.1 (The R 
Foundation for Statistical Computing Platform) as appropriate for the specific 
analysis to be undertaken. The Shapiro–Wilk test was used to test for normality 
of data. Continuous data are expressed as mean ± standard deviation 
[minimum – maximum] for normally distributed data and median ± median 
absolute deviation [minimum – maximum] for non-parametric data; categorical 
data are expressed an n (%). 
Paired t-test, unpaired t-test and Wilcoxon signed rank test were used to 
compare the lactate to pyruvate ratio and kinetic values derived from the GBM 
and the NTBP as appropriate according to the distribution of the data. To further 
explore heterogeneity, in house developed scripts were used to generate 
histograms using the metabolites values and/or ADC to determine the bin width 
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and the number of voxels to determine the bin height. Values of pyruvate, 
lactate and bicarbonate were normalised for the contralateral non-tumour 
bearing brain parenchyma to account for inter-patient heterogeneity. 
Normalisation was not deemed necessary for the ratios (as ratios are 
intrinsically normalised) and for the modelled values (as they are 
mathematically derived using the same equations and thus the effects of the 
different SNRs is eliminated). In house scripts were also used to generate 
scatter plots of ADC and labelled metabolites both as per-voxel and per-patient. 
Volume of the entire lesion, the enhancing and the necrotic components were 
correlated with the LP and BP ratio using the Spearman’s rho correlation 
coefficient and represented graphically using scatter plots. If present, all the fits 
have been obtained using a binomial derivate (linear fit). In-house scripts for the 
analysis are provided in the supplementary material at the end of the chapter.  
To determine the statistical significance of all the tests, a base set value 
of p = 0.05 was initially chosen and subsequently corrected for multiple 
comparison. The false discovery rate (FDR) method using the Benjamini-
Hochberg procedure was applied to test significance (Benjamini and Hochberg, 
1995). The FDR represents the proportion of significant results that are actually 
false positives. Carefully consideration has been given to which proportion of 
false positive we were willing to accept for this study.  An FDR of 5% is 
generally believed too low for many experiments having multiple correlations 
because this will be on top of a p value which is usually already chosen as low 
as 0.05 lead to an over rejection rate (McDonald, 2014). 
Moreover, this is the first study correlating biological biomarkers with HP 
13C MRI in an exploratory fashion, thus, avoiding potential false negatives was 
deemed more important than the risk of including some false positives that 
might be disputed in future works. At the same time, the potential cost of 
disproving a too high number of false positive findings due to the expensive 
technique used in this study and the logistical difficulties in replicating the same 
setup, was considered when setting the FDR. All those considerations lead to a 
chosen value of 10%, however, we also decided to show the results of the 
analysis performed with a FDR of 5% as those results would be most likely to 
be significant in a confirmatory study. Of note, the p values that are presented in 
this study are raw p values and only the significance is stated according to the 
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Benjamini-Hochberg procedure. No Benjamini-Hochberg adjusted p values 
have been provided to avoid the potential confusion that those modified p 
values could generate when interposed with non-adjusted p values relating to 
other statistical procedures. 
5.2 Results 
5.2.1 Feasibility and technical success 
Dynamic signal from hyperpolarized pyruvate, lactate, and bicarbonate 
was observed in the brain following intravenous injection of [1-13C]pyruvate and 
	
Figure 5.6: Hyperpolarised 13C MRI of the entire cohort. 
The first three rows show the 3D T1W Fast SPoiled GRadient-echo (FSPGR), axial unenhanced 
T1W overlaid with the lactate to pyruvate ratio and axial unenhanced T1W overlaid with the 
bicarbonate to pyruvate ratio through the centre of the lesion for each patient. The last two rows 
show the histograms relative to the lactate to pyruvate ratio and bicarbonate to pyruvate ratio 
values for each voxel from the same slice; glioblastoma is shown in light blue, non-tumour 
bearing brain parenchyma is shown in light red. 
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no adverse events were observed in the entire cohort. In 1 case the FoV was 
incorrectly acquired compared to the other cases and therefore this patient was 
excluded from the subsequent analysis to ensure homogeneity of the scans. 
Figure 5.2 shows LP and bicarbonate to pyruvate (BP) ratio maps for all the 
subjects. 
Results from the QC report are shown in table 5.3. Briefly, the average 
polarization was 22.3 ± 3.9 % [16.3 – 28.0]; the pyruvate concentration was 256 
± 12 mmol/L [232 - 268] and pH was 7.7 ± 0.2 [7.3 – 8.0]. The time delay 




















Patient 1 22.6 232 0.6 7.9 35 34 39 
Patient 2 16.3 243 0.8 8 34 34 40 
Patient 3 22.1 259 1 7.8 32.8 34 32 
Patient 4 20.3 268 1.3 7.5 33.5 36 34.3 
Patient 5 27.5 264 2 7.3 35.9 34 33.3 
Patient 6 19.2 263 1.2 7.6 35.9 35 35 
Patient 7 28 263 0.6 7.9 34.6 38 32.4 
        
Entire cohort 
22.3 ± 3.9 
(16.3 - 28) 
256 ± 12.3 
(232 - 268) 
1.1 ± 0.4 
(0.6 - 2) 
7.7 ± 0.2 
(7.3 - 8) 
34.5 ± 1.1 
(32.8 - 35.9) 
35 ± 1.4 
(34 - 38) 
35.1 ± 2.9 
(32 - 40) 
 
Table 5.4: Quality control of the hyperpolarized pyruvate. 
The table shows the results from the quality control analyses of the hyperpolarized pyruvate obtained with the quality control (QC) monitor immediately after 
dissolution for each patient and as average ± standard deviation (minimum - maximum) for the entire cohort. Polarization is expressed in percentage of increase 
from the baseline, pyruvate concentration in the solution as mmol/L, the EPA concentration in μM/L, temperature in Celsius degree (C), the QC module refers to 
the time after dissolution when the door of the QC unlocks and is expressed in seconds, the injected volume of pyruvate is expressed in mL.
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5.2.2 Pyruvate dynamics and metabolic heterogeneity 
5.2.2.1 Comparison between the GBM and the contralateral side 
The kinetic analysis of the GBMs demonstrated a high degree of 
variability in the concentrations of summed pyruvate, lactate and bicarbonate 
ranging, respectively, from 5.5 to 34.0 (average 18.6 ± 11.1), 1.7 to 10.6 (6.1 ± 
3.6) and 0.28 to 2.74 (1.03 ± 0.84). This heterogeneity is best appreciated in the 
histograms shown in figures 5.5 and 5.6. Pyruvate and lactate summed over the 
entire time course were significantly higher in the GBM compared to the 
contralateral non-tumour bearing brain parenchyma, assessed using a mirrored 
ROI of the lesion (p = 0.010 and p = 0.036 respectively, paired samples t-test); 
table 5.4. However, the bicarbonate concentration summed over the time 
course was significantly lower in the tumour compared to contralateral non-
tumour bearing brain parenchyma (p = 0.004, paired samples t-test); table 5.4. 
	
Figure 5.7: Hyperpolarised 13C MRI metabolites in the entire cohort. 
Histograms showing the pooled values in the entire cohort for lactate to pyruvate ratio, 
bicarbonate to pyruvate ratio, normalized pyruvate, normalized lactate and normalized 
bicarbonate. Normalisation is according to the non-tumour bearing brain parenchyma. 






The same trends were confirmed comparing the metabolic values of the GBMs 
with the metabolites obtained from multiple ROIs in the NTBP and from the 
entire contralateral hemisphere; tables 5.5 and 5.6. 
As there are many experimental factors that may influence the summed 
pyruvate, lactate and bicarbonate signal, kinetic analysis was performed which 
corrects for these factors to generate more comparable data between patients. 
The kinetic analysis of the conversion between pyruvate and lactate showed a 
slightly lower LP ratio in the GBM compared with the corresponding area of the 
contralateral side; however, the difference was not statistically significant (p = 
0.382, paired samples t-test); table 5.4. Similarly, there was not a statistically 
significant difference in the kPL between the tumour and the contralateral side (p 
= 0.730, paired samples t-test); table 5.4. The lack of significant differences 
between the GBM and the NTBP was confirmed in the subanalyses with 
multiple ROIs and with the entire contralateral hemisphere; tables 5.5 and 5.6.  
The assessment of the exchange between pyruvate and bicarbonate, 
revealed a BP ratio significantly lower in the GBM than in the contralateral side 
in all the subanalyses and unlike the LP ratio, this was significant (same region 
p = 0.002, paired samples t-test; multiple ROIs p = 0.0002, paired samples t-
test; entire hemisphere p = 0.016, Wilcoxon signed rank test); tables 5.4, 5.5 
and 5.6. The kPB was lower in the GBM in all the sub analyses, however, the 
difference was significant only comparing the GBMs with multiple ROIs from the 
same contralateral region (p = 0.0006, paired sample t-test) and with the entire 
contralateral hemisphere (p = 0.031, Wilcoxon signed rank test); tables 5.5 and 
5.6. 
5.2.2.2 Intralesional heterogeneity 
Visual inspection of the metabolic maps revealed intralesional 
heterogeneity in all the cases for all the analysed metabolites. In particular, LP 
and BP ratios show a high degree of intralesional heterogeneity. In all the 7 
cases, areas of low LP ratio were demonstrated (representing high uptake of 
pyruvate in the GBM with slow exchange to lactate) as well as areas showing a 
high LP ratio (representing low pyruvate uptake and high lactate conversion). 
Similarly, tumour regions of both low BP ratio (representing high uptake of 
pyruvate with low exchange to bicarbonate) and high BP ratio (representing low 
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uptake of pyruvate and high exchange to bicarbonate) coexisted in all the 
cases. The intralesional heterogeneity is demonstrated in Figure 5.2; visually 
with the LP and BP ratio maps of all the 7 patients and quantitatively with the 
histograms showing the voxel intensity values for the two ratios. 
The intralesional heterogeneity was assessed comparing the medial and 
the lateral side of the lesion. Pyruvate, lactate, bicarbonate and the BP ratio 
were significantly different across the lesion (p = 0.108, paired samples t-test; p 
= 0.028, Wilcoxon signed rank test; p = 0.034, Wilcoxon signed rank test; p = 
0.0007, Wilcoxon signed rank test; respectively), table 5.7. There was no 
statistically significant difference in LP ratio (p = 0.774, paired sample t-test), kPL 
(p = 0.497, paired sample t-test) or kPB between the medial and lateral areas of 
the tumour (p = 0.055, Wilcoxon signed rank test). 
5.2.2.3 Metabolic activity of the non-tumour bearing brain parenchyma  
The comparison between the NTBP ipsilateral to the GBM and the 
contralateral NTBP demonstrated no statistically significant differences in 
pyruvate uptake (p = 0.119, paired sample t-test), lactate production (p = 0.100, 
paired sample t-test), LP ratio (p = 0.945, paired sample t-test) or kPL (p = 
0.772, paired sample t-test). Summed bicarbonate (p = 0.016, Wilcoxon signed 
rank test), BP ratio (p = 0.012, paired sample t-test) and kPB (p = 0.029, paired 
sample t-test) were significantly lower in the ipsilateral side; table 5.9. 
The kinetic analysis of the entire hemisphere confirmed significant 
differences in the exchange between pyruvate and bicarbonate, as 
 
Figure 5.8: ADC values in the entire cohort. 
Histograms showing the pooled ADC values in the entire cohort. Glioblastoma is shown in 
light blue, non-tumour bearing brain parenchyma is shown in light red. 
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demonstrated by the summed bicarbonate signal (p = 0.001, Wilcoxon signed 
rank test), BP ratio (p < 0.001, Wilcoxon signed rank test) and kPB (p = 0.044, 
Wilcoxon signed rank test). There was also a statistically significant difference 
in summed pyruvate signal (p = 0.030, paired sample t-test) and lactate signal 
(p = 0.040, paired sample t-test); table 5.10. 
5.2.3 GBM cellularity, size and metabolic activity  
The average tumour ADC was 1105.6 ± 282.3 x 10-6 mm2/s (409.3 – 
2483.9) for the GBMs and 1049.7 ± 348.4 x 10-6 mm2/s (182.7 – 2782.5) for the 
contralateral area; there was no statistically significant difference between the 
two regions (p = 0.310; Wilcoxon signed rank test). Figure 5.7 shows the 
overlay between the histogram of ADC values in the tumour and those of the 
contralateral NTBP. 
The scatter plots in figure 5.5 depict the distribution of ADC with LP and 
BP ratios. In the GBM, the ADC showed a slightly upward trend with increasing 
ADC values associated with an increase in both LP and BP ratios (r = 0.06, p < 
0.001 and r = 0.18, p < 0.001, respectively), opposite to the trend showed by 
normal tissue that showed a decrease of ADC values with decrease of LP and 
BP ratios (LP ratio r = 0.15, p < 0.001 and BP ratio r = 0.1, p < 0.001). Higher r 
	
Figure 5.9: Relationship between ADC and hyperpolarized 13C MRI. 
The scatterplots show the relationship between ADC and lactate to pyruvate ratio (first 
column) and bicarbonate to pyruvate ratio (second column). Glioblastoma is shown in light 




values were found using a quadratic fit for both LP ratio (GBM r = 0.21, p < 
0.001 and NTBP r = 0.23, p < 0.001) and BP ratio (GBM r = 0.2, p < 0.001 and 
NTBP r = 0.18, p < 0.001). 
Figure 5.6 shows the relationship between the tumour volume and the LP and 
BP ratio. The average volume of the lesions was 43.4 ± 32.6 cm3 (14.9 – 
120.6), of which 27.6 ± 19.3 % (0.4 – 52.0) was frankly necrotic. A regression 
analysis demonstrated no statistically significant relationship between the LP 
ratio and: the entire lesion volume, the volume of the enhancing tissue, the 
volume of the necrosis and the percentage of the necrosis and (p = 0.770, p = 
0.685, p = 0.503 and p = 0.356 respectively). This finding was corroborated by 
the Spearman’s correlation coefficient analysis that showed no statistically 
significant correlation between the LP ratio and the tumour volume (p = 0.148 
for the entire volume, p = 0.148 for the enhancing tissue, p = 0.819 for the 
necrosis and p = 0.819 for the percentage of necrosis).  
The BP ratio showed a significant relationship with the entire lesion 
volume (r = 0.78, p = 0.038), the enhancing component (r = 0.84, p = 0.018) 
and the percentage of necrosis (r = 0.78, p = 0.038); there was no statistically 
significant relationship with the volume of necrosis (p = 0.138); figure 5.6. The 
Spearman’s correlation coefficient analysis demonstrated a statistically 
significant correlation between BP ratio and necrosis both as volume (rho = 
0.857, p = 0.014) and as a percentage (rho = 0.857, p = 0.014). 
5.2.4 Relationship between HP 13C MRI and tissue biomarkers 
The concentration of LDH-A, as quantified by Western Blot, exhibited a 
linear positive relationship with the LP ratio (r = 0.43, p = 0.042; figure 5.7) 
which was statistically signficant (p = 0.0433; Spearman’s correlation 
coefficient; figure 5.8). There were no statistically significant relationship nor 
correlation between LDH-A and the other HP 13C MRI biomarkers; figure 5.7 
and 5.8. The concentration of c-Myc did not show any statistically significant 
relationship or correlation with HP 13C MRI biomarkers, figure 5.7 and 5.8.  
Figure 5.9 and figure 5.10 show the scatter plot, with the corresponding linear 
regressions, and the correlation matrix between IHC and the HP 13C MRI. The 




Figure 5.10: Relationship between the volume of the lesion and the hyperpolarized 13C MRI. 
The scatterplots show the relationship between the volume of the different components of the lesions and lactate to pyruvate ratio (first column), 
bicarbonate to pyruvate ratio (second column) and bicarbonate to lactate ratio (third column). Each marker represents a patient. The R and p for each 





Figure 5.11: Relationship between the results of the western blots and the hyperpolarized 13C MRI. 
The scatterplots show the relationship between cMyc and LDH-A expression and lactate to pyruvate ratio 
(first column), bicarbonate to pyruvate ratio (second column) and bicarbonate to lactate ratio (third 
column). Each marker represents a tissue sample. The R and p for each regression are given in the 
figure. Level of significance was set at 0.05. 
	
Figure 5.12: Correlation matrix between the results of the western blots and the hyperpolarized 13C MRI. 
Correlation matrix between LDH-A and cMyc expression and summed pyruvate, summed lactate, 
summed bicarbonate, lactate to pyruvate ratio (LP_Ratio), bicarbonate to pyruvate ratio (BP_Ratio) and 
bicarbonate to lactate ratio (BL_Ratio). The numbers shown in each square represent the Spearman’s 
correlation coefficient. Level of significance was set at 0.05 and corrected with the false discovery rate 
(FDR) method using the Benjamini-Hochberg procedure as described in the text. Significant differences, 




immunohistochemical markers and the metabolites derived from the HP 13C 
MRI. There was a significant linear positive relationship between CA IX and the 
BP ratio (r = 0.5, p = 0.005) and CD68 and BL ratio (r = 0.38, p = 0.043). The 
Spearman’s correlation coefficient demonstrated several statistically significant 
correlations after correction with FDR at 10%. CA IX was significantly correlated 
with summed pyruvate (rho = - 0.59, p = 0.0007), summed lactate (rho = - 0.54, 
p = 0.003), BP ratio (rho = 0.51, p = 0.005) and BL ratio (rho = 0.48, p = 0.008). 
CD8 was significantly correlated with summed pyruvate (rho = -0.46, p = 0.011), 
summed lactate (rho = -0.43, p = 0.020), BP ratio (rho = 0.6, p = 0.0006) and BL 
ratio (rho = 0.59, p = 0.0007). CD68 was significantly correlated with BP ratio 
(rho = 0.55, p = 0.002) and BL ratio (rho = 0.53, p = 0.003). Lastly, MIB-1 was 
significantly correlated with LP ratio (rho = - 0.46, p = 0.013). With the FDR at 
5%, CA IX was significantly correlated: with summed pyruvate, summed lactate 
and BP ratio; CD8 was correlated with BP ratio and BL ratio; and CD68 






Figure 5.13: Relationship between the the results of the immunohistochemistry staining 
and the hyperpolarized 13C MRI. 
On the y axis: monocarboxylate transporter 1 (MCT1), monocarboxylate transporter 4 
(MCT4), index of proliferation (MIB-1), cluster of differentiation 4 (CD4), cluster of 
differentiation 8 (CD8), cluster of differentiation 68 (CD68),  cluster of differentiation 31 
(CD31), hypoxia-inducible factor 1-alpha (HIF1-a) and carbonic anhydrase IX (CA IX). 
On the x axis: lactate to pyruvate ratio (first column), bicarbonate to pyruvate ratio 
(second column) and bicarbonate to lactate ratio (third column). Each marker represents a 
tissue sample. The R and p for each regression are given in the figure. Level of 







Figure 5.14: Correlation matrix between the results of the immunohistochemistry staining 
and the hyperpolarized 13C MRI. 
Immunohistochemistry staining are: monocarboxylate transporter 1 (MCT1), 
monocarboxylate transporter 4 (MCT4), cluster of differentiation 4 (CD4), cluster of 
differentiation 8 (CD8), cluster of differentiation 68 (CD68), cluster of differentiation 31 
(CD31), hypoxia-inducible factor 1-alpha (HIF1-a) and carbonic anhydrase IX (CA IX). 
Hyperepolarised 13C MRI biomarkers are: summed pyruvate, summed lactate, summed 
bicarbonate, lactate to pyruvate ratio (LP_Ratio), bicarbonate to pyruvate ratio (BP_Ratio) 
and bicarbonate to lactate ratio (BL_Ratio). The numbers shown in each square represent 
the Spearman’s correlation coefficient. Level of significance was set at 0.05 and corrected 
with the false discovery rate (FDR) method using the Benjamini-Hochberg procedure as 




5.3 Discussion  
5.3.1 A novel tool for in vivo assessment of metabolic activity 
This study has demonstrated the feasibility of imaging the conversion of 
hyperpolarized 13C-labelled pyruvate to both lactate and bicarbonate in the 
human brain and in glioblastoma. Moreover, this study is the first of its kind 
correlating tissue biomarkers obtained through immunohistochemistry and 
western blots to the metabolic biomarkers obtained in vivo using HP 13C MRI in 
patients with GBM.  
There are only a small number of papers describing the use of HP 13C 
MRI in the human brain. The initial reports in patients with brain tumours have 
focused on demonstrating its feasibility rather than attempting to correlate the 
signal with other measures of the metabolic activity of brain tumours. A total of 
five patients with GBM have been reported to date; however, the clinical history 
and characteristics are too varied to infer any significant conclusions (Miloushev 
et al., 2018; Park et al., 2018). More recently, Grist et al. demonstrated the 
feasibility of using HP 13C MRI to acquire quantitative non-invasive 
measurements of pyruvate metabolism in a case series of 4 healthy volunteers 
applying the possibility of using these methods to study the diseased brain 
(Grist et al., 2019). In this present study, we have confirmed the feasibility of the 
technique in the largest cohort of GBM patients to date with patients who are 
treatment naïve and have the same mutation profile (WHO 2016 GBM IDH-
wildtype). The genetic and histological homogeneity of our cohort allows for 
interlesional comparison that has not been possible previously. Moreover, I 
assessed the correlation between HP 13C MRI and the underlined biological 
features of GBMs. Confirming the biological correlates of the detected signal is 
key to understand how the technique may be used in clinical practice. MRI is 
already a key technique for the diagnosis, stratification and therapy assessment 
in GBM: however, the information that conventional imaging provides is 
insufficiently sensitive and specific and improved imaging techniques are 
required. Exploiting in vivo metabolic pathways with HP 13C MRI may have a 
significant role in the future management of GBM if it could provide additional 
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biological and clinical information not accessible by other methods 
(Kurhanewicz et al., 2019). 
Together with Park et al. (Park et al., 2018), this is the largest cohort of 
brain HP 13C MRI scans reported so far. The technical success in all but one 
patient demonstrates that this technique is feasible in a clinical research setting. 
The single unsuccessful case reported here was due to a manual error during 
the set-up of the acquisition protocol and is accounted for by human error. The 
polarization levels of pyruvate were acceptable with values close to those 
reported previously (Grist et al., 2019) and slightly lower when compared to the 
other reports on brain tumours imaging (Miloushev et al., 2018; Park et al., 
2018). It is worthy to mention that the use of a birdcage coil, as opposed to a 
clamshell or pad coils, allows for a higher homogeneity of the acquired signal 
and resulting in better imaging.  
5.3.2 Intra- and inter- lesional heterogeneity 
Tumour heterogeneity, defined as the presence of different cancer cells 
within the same neoplasm, has been recognised as a distinctive characteristic 
of cancer (Dexter et al., 1978; Heppner, 1984). The heterogeneity in gliomas 
was first described in the middle of the past century when Scherer noted 
different growing behaviours shown by different gliomas although at that time 
the term “heterogeneity” had not been ascribed to this (Scherer, 1940). Since 
then, mounting evidence has proved that malignant gliomas show a striking 
heterogeneity both at the cellular and molecular level, with authors claiming that 
a patient with glioblastoma may represent several distinct tumour subtypes 
within the same tumour (Aum et al., 2014; Patel et al., 2014). Indeed, several 
subclones with different genetic mutations and phenotypic characteristics 
(including different morphologies, proliferative properties, infiltrative capabilities 
and sensitivity to therapy) have been demonstrated (Stieber et al., 2014; Soeda 
et al., 2015). Interestingly, analysis of biopsies obtained from different locations 
within the same lesions have been classified into different glioblastoma 
molecular subgroups (Eder and Kalman, 2014). The high degree of intratumoral 
and intertumoral heterogeneity has been considered one of the key factors in 
determining a lack of effective therapeutic options for glioblastoma (Sottoriva et 
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al., 2013). This high degree of heterogeneity can jeopardise an accurate 
profiling of patients and contribute to a biased selection for single target 
therapies with consequent treatment failure or development of drug resistance. 
Therefore, a biomarker able to non-invasively characterize the metabolic 
phenotype of glioblastoma would be a significant contributor in the path to 
discover novel personalized therapies (Grande et al., 2018). 
Conventional imaging technique are limited in visualizing both the 
intratumoral and intertumoral heterogeneity in GBMs. Imaging the metabolic 
heterogeneity with HP 13C MRI could represent a turning point for glioma 
imaging. At a visual inspection of the lactate to pyruvate and bicarbonate-to-
pyruvate maps presented in this study (figure 5.2), the intralesional 
heterogeneity is immediately evident. Comparing those maps with the 
corresponding post-gadolinium T1WI (figure 5.2), the capability of HP 13C MRI in 
assessing the heterogeneity is even more striking. Indeed, whilst the post-
gadolinium images show the extravasation of gadolinium in the lesion mostly 
due to the breakdown of the blood brain barrier, the carbon-13 images show the 
different metabolic activity in different clusters of the lesion, allegedly composed 
by different cellular populations. Of interest, the lactate-to-pyruvate and 
bicarbonate-to-pyruvate maps show a different distribution of clusters producing 
more lactate and/or more bicarbonate highlighting the capability of this 
technique to explore intralesional heterogeneity. Comparing the metabolic maps 
across patients, it is evident that some lesions are more metabolically active 
whilst other lesions are less metabolically active. This heterogenetiy is 
particularly significant for the lactate-to-pyruvate ratio.  
A more quantitative assessment of the intralesional heterogeneity comes 
from the quantitative analysis of the metabolism within the lesions. The 
histogram in figure 5.2 shows both the intralesional and intrapatient 
heterogeneity. Comparing the distribution of the lactate-to-pyruvate across the 
patients, the different histogram patterns is notable. In some cases, GBMs 
exhibit lower LP values than the contralateral non-tumour bearing brain 
parenchyma; in other cases, the opposite is true. Also, the kurtosis of the 
histograms and the number of bins (representing how many voxels had the 
same LP or BP ratio) greatly vary between patients as did the number of voxels 
clustered in each bin. In contrast to the LP ratio, the bicarbonate-to-pyruvate 
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ratio showed a constant trend with values in the GBMs significantly lower than 
in the contralateral non-tumour bearing brain parenchyma, nonetheless, 
although once again, there was a high degree of heterogeneity within and 
between the lesions. 
The lactate-to-pyruvate ratio and bicarbonate-to-pyruvate ratio maps 
showed a common pattern with one side of the lesion seemingly more 
metabolic active than the contralateral side. Although the biological explanation 
for this is not clear, it might relate to the grow or go theory described above 
(Giese et al., 2003), I decided to arbitrarily compare the two sides to quantify 
this unusual intralesional heterogeneity. Interestingly, summed pyruvate, 
summed lactate, summed bicarbonate and the bicarbonate-to-pyruvate ratio 
were significantly different when the two sides were compared using evenly 
spaced and volumetrically identical region-of-interests (table 5.7). This result 
could be related to different perfusion characteristics of the medial and lateral 
component of the GBMs, for example a high number of perforating arteries 
and/or lenticulo-striate arteries adjacent to the lesion can determine a higher 
blood flow in the medial aspect of the lesion partially determining this behaviour. 
However, as this study was designed as a first, proof-of-concept study we do 
not have perfusion data available to disentangle a potential effect of the 
cerebral blood flow on the delivery of pyruvate and its subsequent metabolism. 
The information provided by the post-gadolinium T1W images lack the dynamic 
component therefore they could not provide any more insights on this issue.     
The correlation between LDH-A, c-Myc and the several 
immunohistochemistry staining we obtained from the tissue analysis 
unsurprisingly also highlighted the heterogeneity within the lesions. Indeed, both 
the correlation matrix for the western blots biomarkers and the 
immunohistochemistry staining included a series of correlations between the HP 
13C MRI metabolites. Due to the limited quantity of tissue available for each 
biopsy, the tissue samples used for the western blots and for the 
immunohistochemistry were different in almost all the cases.  
The capability of HP 13C MRI to detect intertumoral heterogeneity has 
significant implications for the management of patients with glioblastoma. 
Indeed, the ability to highlight regions with different metabolic activity and 
different metabolite concentrations, could be used to generate metabolic 
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habitats within the same lesion. Those topographic maps could be used in 
theatre to either guide needle biopsies in the areas with the presumed higher 
grade or to plan debulking and resection of lesions with a higher degree of 
confidence that the malignant tissue has been resected. In the context of 
lesions in close proximity to eloquent areas, the metabolic information could be 
used to study the potential aggressiveness of the tissue adjacent to the area in 
question, which could provide invaluable information to the surgeon to either 
push the boundaries of the resection to the highest possible safest margin or 
decide for a more conservative approach relying on other therapy approaches. 
Moreover, in the era of advanced image-guided targeting for radiotherapy 
treatment, a topographic map displaying the areas of higher metabolic activity 
could significantly alter the therapeutic plan (Burnet et al., 2014). 
5.3.3 The Warburg effect  
The quantitative analysis of pyruvate, lactate and bicarbonate 
concentrations revealed a different behaviour of the GBMs as compared to the 
NTBP. Pyruvate and lactate were significantly higher in terms of absolute 
concentration; however, this did not translate into a significant increase in the  
lactate to pyruvate ratio nor the apparent forward rate constant kPL, a modelled 
parameter expressing the conversion rate between pyruvate and lactate 
catalysed by the enzyme lactate dehydrogenase (LDH). The higher 
concentration of the two metabolites may reflect the known increase of 
perfusion in malignant gliomas or in the inflammation in the peritumoral brain 
zone (Lemée et al., 2015a). Pyruvate concentration is influenced by blood 
perfusion and if more pyruvate is brought to the lesion, a concordant increase of 
lactate concentration is to be expected. Therefore, the increase in the absolute 
values of the two metabolites could potentially be partially attributed to the 
perfusion effect rather than an increase in aerobic glycolysis and GBMs have a 
high perfusion rate. This hypothesis is supported by the lactate to pyruvate ratio 
which partially corrects for perfusion effects and showed similar values in the 
tumour as compared to the contralateral side (0.34 ± 0.06 for the GBM versus 
0.36 ± 0.10 for the contralateral side). The data here suggests that the aerobic 
glycolysis in GBMs is similar if not lower than in the non-tumour bearing brain 
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parenchyma. However, this agrees with the few clinical cases published to date: 
Park et al. showed lower aerobic glycolysis in patients with GBMs, 
whilst Miloushev et al. observed similar signal compared to the background in 
the sole GBM enrolled in their study (Miloushev et al., 2018; Park et al., 2018). 
These human results are somewhat surprising given the pre-clinical data in this 
area obtained from rats with orthotopic human glioblastoma xenografts : 
previous studies have shown an increased conversion of pyruvate in lactate in 
tumours as opposed to a lack of lactate production in normal brain parenchyma 
(Park et al., 2010, 2013a, 2014). However, other pre-clinical reports have 
demonstrated a significant lactate production in the normal brain; these 
differences may represent interspecies variation or effects of anaesthesia on 
blood-brain barrier transport (Butt et al., 2012; Park et al., 2013b, 2016).  
Our study confirmed, as previously shown by Grist et al., that non-tumour 
bearing brain parenchyma has a significant conversion of pyruvate to lactate 
(Grist et al., 2019). In the early nineties Magistretti et al. proposed the 
production of lactate in the normal brain as a key part in neurotransmission, with 
astrocytes being more glycolytic producing lactate and neurons being 
predominately oxidative and consuming lactate (Luc et al., 1994; Bittar et al., 
1996; Magistretti et al., 1999). Lactate shuttles the energy between astrocytes 
and neurons so that the latter can benefit from the high production rate of the 
former. More recently, MCT4 has been demonstrated in astrocytes and 
tanycytes (Pellerin et al., 2005; Cortés-Campos et al., 2011). Although 
tanycytes are only present in the fourth ventricle and hypothalamus, astrocytes 
are ubiquitous in the brain parenchyma, highlighting the importance of pyruvate 
and lactate metabolism in the normal brain. According to recent literature, MCTs 
have a key roles in several functions such as control the delivery of astrocyte-
produced lactate to neurons, controlling the exchange of lactate and other 
monocarboxylates between several cells and promote angiogenesis (Pérez-
Escuredo et al., 2016). Indeed, alterations of MCT expression have been shown 
in a variety of diseases involving the central or the peripheral nervous systems 
such as neurodegenerative diseases or epilepsy (Pérez-Escuredo et al., 2016). 
A reduction in MCTs expression, with consequent reduction in the lactate used 
to foster the metabolic activity of oligodendrocytes and neurons in general has 
been shown in animal models of Alzheimer’s disease, multiple sclerosis and 
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Parkinson’s disease (Puchades et al., 2013; Nijland et al., 2014; Lu et al., 
2015). 
Despite promising pre-clinical evidence that lactate labelling correlates 
with expression of LDH-A and c-Myc, in our cohort only the lactate-to-pyruvate 
ratio correlated with the expression of LDH-A (Mair et al., 2018). The conversion 
from pyruvate to lactate is catalysed by LDH-A, therefore it was expected that 
the expression of LDH-A in cancer cells should directly correlate with the 
lactate-to-pyruvate ratio.  
c-Myc is a promising biomarker for prognosis prediction and assessment 
of the metabolic activity in glioblastoma. In glioma, this proto-oncogene is 
involved in stem cell transformation and maintenance (Orian et al., 1992; H. 
ZHENG, H. YING, H. YAN et al., 2008). Moreover, c-Myc is deemed to drive the 
expression of key enzymes for the glycolytic pathway such as LDH-A. 
Overexpression of c-Myc has been strongly correlated with glioma grading and 
survival (Orian et al., 1992; Chattopadhyay et al., 1995; Herms et al., 1999). 
Interestingly, c-Myc expression is also associated with mutant IDH1 expression 
known to be the most accurate predictor of survival and therapeutic response 
(Odia et al., 2013). Besides its role as a potential biomarker, c-Myc is a potential 
therapeutic target in glioblastoma (Dang et al., 2009). Preliminary data showed 
that c-Myc inhibition reduces proliferation, increases apoptosis and induces the 
formation of multinucleated cells that undergoes mitotic catastrophe (Annibali et 
al., 2014). The increased glycolysis induced by c-Myc can also be a direct 
target. For instance, inhibition of the rate-limiting enzyme NAD+ salvage 
pathway nicotinamide phosphoribosyl-transferase (NAMPT) induce cytotoxicity 
(Tateishi et al., 2016). Therefore, c-Myc is of particular interest in glioblastoma 
and a non-invasive correlate of its expression would be desirable. Mair et al. 
demonstrated a positive correlation between lactate-to-pyruvate ratio and c-Myc 
(Mair et al., 2018). Two of the patient-derived animal models exhibited a higher 
concentration of c-Myc and LDH-A, in those tumours the lactate-to-pyruvate 
ratio was significantly higher compared to the tumours with lower expression of 
c-Myc and LDH-A. Furthermore, to confirm that c-Myc was the driver of the 
lactate-to-pyruvate ratio increase, Mair et al. (Mair et al., 2018) knocked down c-
Myc expression in one of the models. This led to a reduction in expression of 
LDHA and subsequent decrease in lactate labelling. However, in our cohort 
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there was no correlation between c-Myc and any of the HP 13C MRI biomarkers. 
An explanation for this could be that the pre-clinical studies were performed with 
either immortalized, commercially available single cell lines or PDX derived from 
single cell lines resulting in identical phenotypic and genotypic profiles. In our 
study biopsies were taken from different regions within the same cancer 
showing different metabolic behaviour. As glioblastomas are known to be 
extremely heterogenous and our samples have been obtained from different 
areas with different phenotypic characteristics, the lack of significance may be 
the result of the higher heterogeneity in our cohort. The locations for the 
biopsies were chosen according to their different metabolic behaviour with the 
aim of exploring the expression profile to further characterise those regions. 
Therefore, we can postulate that the lack of correlation could be ascribed to the 
heterogeneity of the clinical data or the homogeneity of the animal models. 
Potential future studies and mitigations strategies will be described in the 
section “limitations and future work”. 
Immunohistochemistry was used to assess the drivers behind the 
metabolic phenotype in each case. Figure 5.9 shows the scatterplots for the 
immunohistochemistry biomarkers and the metabolic ratios. Pyruvate and 
lactate were significantly correlated with CA IX which is upregulated in hypoxia 
and can explain the increased lactate formation. The relationship between 
lactate and hypoxia highlights the potential role of HP 13C MRI as a tool to study 
hypoxia in GBM. Pyruvate and lactate were significantly correlated also and 
CD8 which may reflect cytotoxic T cell immune infiltration, whilst the lactate-to-
pyruvate ratio was significantly correlated with MIB-1. A positive linear 
relationship was observed between CA IX and the bicarbonate-to-pyruvate ratio 
and between CD68 on macrophages/microglia the and bicarbonate-to-lactate 
ratio but this was not present for the lactate to pyruvate ratio.  
5.3.4 Reduced bicarbonate in GBM 
A very consistent finding from these results is a reduced tumour 
bicarbonate signal which was unexpected. Bicarbonate has a key role in 
bioenergetics; it is produced by mitochondrial oxidative metabolism, through a 
reaction catalysed by PDH, and is a biomarker of inflammation and 
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mitochondrial dysfunction. Grist et al. recently demonstrated the presence of [1-
13C]bicarbonate throughout the brain in healthy subjects that underwent HP 13C 
MRI (Grist et al., 2019).  
In this study the concentration of [1-13C]bicarbonate and of the 
bicarbonate-to-pyruvate ratio were consistently lower in the GBMs when 
compared to the contralateral non-tumour bearing brain parenchyma. The lack 
of bicarbonate in the GBMs was also seen by Park et al. (Park et al., 2018). A 
reduction in mitochondrial activity could be secondary to mitochondrial 
impairment in the cancer cells, an alteration in intracellular signalling pathways, 
or a consequence of local inflammation in the peritumoral microenvironment 
(Grist et al., 2019).  
The bicarbonate-to-pyruvate ratio is more informative than the absolute 
concentration of bicarbonate as the latter is affected by confounding factors 
such as the polarisation of the pyruvate or blood flow. Therefore, I assessed the 
relationship between bicarbonate-to-pyruvate ratio and other biomarkers to gain 
more insight on what is driving the downregulation of mitochondrial oxidative 
metabolism in the GBMs. Interestingly, the bicarbonate-to-pyruvate ratio 
showed an inverse relationship with the lesion volume and the volume of the 
enhancing tissue, whilst it showed a positive relationship with the percentage of 
necrosis. The data seems to suggest that an increase in necrosis is either the 
driving force of mitochondrial impairment or is secondary to it. CA IX, a known 
marker of hypoxia, was positively correlated with the BP ratio confirming that 
there is a relationship between hypoxia (or hypoxia-induced necrosis) and the 
production of bicarbonate. However, the bicarbonate-to-pyruvate ratio was also 
correlated with CD8 and CD68; know markers of inflammatory cells (the former 
is expressed by cytotoxic T cells and the latter by cells in the monocyte lineage 
and macrophages) The production of bicarbonate by inflammatory cells could 
explain the lack of bicarbonate observed in the GBMs as typically, the 
peritumoral region is where the inflammatory cells accumulate as a reaction to 
the pro-inflammatory status caused by the cancer, whilst there are rew 
inflammatory cells in the core. Moreover, both normal white and grey matter are 
producing bicarbonate, therefore the destruction of the normal microstructure in 
the GBM leads to the lack of neurons and astrocytes that are replaced by 
cancer cells with the consequent drop in bicarbonate production. 
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Although the actual reason for the lack of bicarbonate is still 
undetermined, in this study we demonstrated that bicarbonate production is 
clearly impaired in GBMs suggesting a reduction in mitochondrial function. 
5.3.5 Lesion size and cellularity 
We explored potential correlations between lesion size, cellularity and 
metabolic biomarkers to assess the relationship between tumour size and 
metabolism.  The lactate-to-pyruvate ratio did not show any correlation with any 
volumetric measurements showing that size alone does not dictate metabolism. 
The metabolic phenotype in glioblastoma is the result of a highly heterogeneous 
environment with several habitats expressing different DNA mutations, having 
different protein expression profiles and therefore exhibiting different metabolic 
behaviour: therefore, heterogeneity is a greater driver of metabolism rather than 
the simple size of the lesion. The information provided by studying lactate 
dynamics are independent from what could be obtained with a conventional 
morphologic scan.  
In this study, we observed a negative linear relationship between the 
bicarbonate-to-pyruvate ratio, the volume of the entire lesion and the volume of 
the enhancing component. In contrast, there was a positive linear relationship 
between bicarbonate-to-pyruvate ratio and necrosis both as volume and 
percentage, although the former was just a trend. This is in keeping with the 
assumption that larger lesions are more necrotic, due to the growth outpacing 
the angiogenesis, and more hypoxic, due to the lack of oxygenation. The 
correlation between the bicarbonate-to-pyruvate ratio and CA IX seems to 
support this hypothesis. However, despite an increase in pyruvate concentration 
and a reduction in bicarbonate production, there was not an increase in lactate-
to-pyruvate ratio that remains unexplained.  
The presence of diffuse and marked necrosis is one of the defining 
characteristics of Glioblastomas in the WHO classification of brain tumours. 
Cellularity is another key characteristic that also informs on prognosis and can 
be non-invasively explored with DWI. The utility of DWI in grading gliomas or 
assessing prognosis has been a matter of debate for more than two decades 
(Kono et al., 2001; Zhang et al., 2017). Here we used the ADC as a measure of 
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cellularity and compared it with HP 13C MRI biomarkers to explore the presence 
of a direct relationship between cell density in the GBM and metabolism of 
pyruvate. There were correlations between ADC values, lactate-to-pyruvate and 
bicarbonate-to-pyruvate ratios. Of interest, we found a discrepancy between the 
linear regression and the correlation between lactate-to-pyruvate and 
bicarbonate-to-pyruvate ratio and ADC which points toward a non-linear 
relationship between HP 13C MRI biomarkers and cellularity. This may be 
related to the complex GBM microenvironment which contains a wide variety of 
cell types. We envisage that the lactate concentration may be driven by cancer 
cells whilst bicarbonate concentration should be primarily due to inflammatory 
cells. A quadratic regression model was slightly better in predicting lactate-to-
pyruvate and bicarbonate-to-pyruvate ratios given the ADC value of a certain 
voxel. In our cohort, the R values for the association between lactate-to-
pyruvate and bicarbonate-to-pyruvate ratios with ADC were all in the lower 
spectrum suggesting a weak direct correlation between cellularity and metabolic 
activity.  
In the GBM both the lactate-to-pyruvate and the bicarbonate-to-pyruvate 
ratios tend to increase as cellularity increases whilst the opposite is true in the 
non-tumour bearing white matter. The increase in cellularity in the GBM is given 
by a number of different factors including proliferation of cancer cells but 
inflammatory cells may also play a role. In particular, inflammation is significant 
at the boundaries of the lesion where cancer cells are spreading within the fibre 
bundles and the host is trying to resist to the invasion. In the non-tumour 
bearing brain parenchyma, lactate is predominantly produced within astrocytes 
and internalised in neurons for the back conversion to pyruvate. The 
bicarbonate-to-pyruvate ratio showed a difference when fit with a linear or 
quadratic model. With the quadratic model, the ratio decreases with increasing 
ADC values up to around 1000 x 10-6 mm2/s, thereafter, it starts to steadily 
increase with cellularity.  
5.3.6 Limitations and future work 
This study has several limitations, mostly due to the preliminary 
exploratory nature of the study. First of all, only 8 patients were recruited and 
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only 7 successfully scanned. HP 13C MRI is a very challenging technique and it 
is still at a very early stage with limited resources and lack of clinical-grade 
consumables. In particular, the production of the labelled pyruvate has to be 
undertaken manually by trained personnel in a sterile environment and the 
compound stored in a dedicated fluid path. The latter has been a hindrance to 
the recruitment because of limited availability, high failure rate and cost. During 
the course of this research project, more patients would have been eligible and 
willing to participate; however, the lack of fluid path halted the recruitment. This 
issue is partially been resolved by the vendor (GE) but the technique is some 
way from routine use. The availability of reliable fluid paths could significantly 
boost recruitment; indeed, my experience with recruiting patients with glioma 
into imaging study clearly demonstrated that the vast majority are willing to 
participate in research studies. A future study can aim to recruit a substantially 
higher number of patients to achieve numbers more fit for statistical analysis of 
results. Moreover, in this study I recruited only WHO 2016 GBM IDH-wildtype. 
Although this is the most common and most aggressive type of glioma, 
recruiting other subtypes would foster out understanding of glioma metabolic 
activity potentially discovering differences between grades not yet 
demonstrated. 
Analysis-wise, the correlation with pathology is one of the strongest 
features of this study, however, at the same time, it is also a weak point. To 
explore the diverse aspects of metabolic activity and the tumour 
microenvironment, we collected data on expression of 1 enzyme, 1 proto-
oncogene and stained for 9 protein markers. Despite the high number of 
biopsies collected from the 7 patients as part of the analysis, testing such a 
large set of biomarkers required a strict statistical correction of the results that 
may have led us to reject existing correlations and/or relationships. However, 
the results of this study may inform future studies to look into specific pathway 
in a focused fashion reducing the risk of false negative and increasing the 
power of the statistical analysis. Moreover, during the course of this study, 
liaising with neurosurgeons, the Department of Pathology, the Brain Tissue 
Bank and the histopathology core facility, I streamlined a procedure for target 
identification, tissue collection, storage, processing and analysis that can be the 
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platform around which build future studies to investigate the relationship 
between HP 13C MRI and tissue biomarkers. 
Variation in pyruvate signal are due to a combination of factors including 
delivery of pyruvate to the brain which may vary across patients and across 
brain regions. Perfusion-weighted MRI (PWI), including dynamic susceptibility-
weighted contrast-enhanced imaging (DSC), dynamic contrast-enhanced 
imaging (DCE) and arterial spin labelling (ASL), is an established technique to 
assess perfusion in the brain. Glioblastomas are known to show an increase in 
the cerebral blood volume (Salama et al., 2018); therefore, part of the 
increased pyruvate signal compared to non-tumour bearing brain parenchyma 
may be due to this increase in perfusion. The lack of a perfusion sequence in 
the present study is a limitation that could be rectified in future studies. Indeed, 
the information provided by perfusion maps could aid in disentangling the effect 
of pyruvate delivery from a true increased metabolic activity in glioblastomas.  
Future studies may also explore more metabolites such as the 
bicarbonate-to-lactate ratio that was only partially explored in the current study. 
Indeed, the hyperpolarisation and delivery of pyruvate is a strong determinant of 
the concentration of lactate and bicarbonate. According to the fact that 
polarization is highly variable, as blood flow and volume are as well, pyruvate, 
lactate and bicarbonate concertation are unreliable as raw data. However, 
during the course of the study a reliable and easy pipeline to normalise the 
values with the contralateral non-tumour bearing brain parenchyma has been 
developed allowing for comparable data. Moreover, the addition of a perfusion 
sequence, with or without gadolinium, to the scan protocol would be beneficial 
in assessing the importance of the perfusion effect and to correct for it. 
In summary, despite the limitations of the current study, I firmly believe 
that this preliminary project set the scene for a more comprehensive work to be 
carried out elucidating the relationship between HP 13C-MRI, glioma 
heterogeneity and metabolism. 
5.4 Conclusion 
This study is the first comprehensive report to assess HP 13C-MRI in 
glioma correlating imaging biomarkers with pathology to explore metabolic 
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activity in glioma. The results here presented demonstrate that HP 13C-MRI can 
probe the metabolic activity of GBM in vivo and investigate both intratumoral 
and intertumoral heterogeneity. These results could deepen our understanding 
of metabolic reprogramming in GBM and the surrounding brain in vivo, which 
may enable improved stratification, tumour staging, and better monitoring of 













18.58 ± 11.12 
(5.53 - 33.96) 
13.65 ± 8.58 
(4.40 - 27.34) 
0.010‡ 
Summed lactate 
6.14 ± 3.55 
(1.72 - 10.60) 
4.30 ± 2.04 
(1.53 - 7.01) 
0.036‡ 
Summed bicarbonate 
1.03 ± 0.84 
(0.28 - 2.74) 
1.44 ± 1.00 
(0.53 - 3.51) 
0.004‡ 
Corrected Lactate to 
Pyruvate ratio 
0.34 ± 0.06 
(0.24 - 0.46) 
0.36 ± 0.10 
(0.25 - 0.53) 
0.382 
Corrected Bicarbonate 
to Pyruvate ratio 
0.06 ± 0.03 
(0.02 - 0.08) 
0.10 ± 0.04 
(0.05 - 0.16) 
0.002‡ 
kPL 
0.0161 ± 0.0057 
(0.0094 - 0.0277) 
0.0165 ± 0.0073 
(0.0078 - 0.0317) 
0.730 
kPB 
0.0017  ± 0.0013 
( 0.0003 - 0.0044) 
0.0024 ± 0.0010 
(0.0010 - 0.0044) 
0.122 
Table 5.5: Hyperpolarised 13C MRI metabolites in the glioblastoma and in the 
contralateral non-tumour bearing parenchyma - Mirrored ROI. 
The table shows the hyperpolarised 13C MRI metabolites within the glioblastoma 
and in a specular region of interest in the contralateral non-tumour bearing brain 
parenchyma. 
Normally-distributed continuous values are shown as mean ± standard deviation 
(minimum - maximum), non-parametric continuous values are shown as median ± 
median absolute dispersion (minimum - maximum). The level of significance 
between the glioblastoma and the contralateral non-tumour bearing parenchyma 
has been assessed with paired sample t-test (*) for normally distributed data and 
with the Wilcoxon signed rank test (★) for non-normally distributed figures. Level of 
significance was set at 0.05 and corrected with the false discovery rate (FDR) 
method using the Benjamini-Hochberg procedure as described in the text. 






























Summed pyruvate 18.34 ± 11.42  (3.86 - 33.96) 
12.83 ± 7.58 
(4.40 - 23.18) 0.017
‡
 
Summed lactate 6.01 ± 3.70 (1.60 - 10.60) 
4.11 ± 1.99 
(1.44 - 6.72) 0.048
‡
 
Summed bicarbonate 1.00 ± 0.86 (0.28 - 2.74) 
1.52 ± 1.10 
(0.52 - 3.86) 0.004
‡
 
Corrected Lactate to 
Pyruvate ratio 
0.33 ± 0.05 
(0.24 - 0.42) 
0.35 ± 0.07 
(0.25 - 0.44) 0.449 
Corrected Bicarbonate 
to Pyruvate ratio 
0.05 ± 0.02 
(0.02 - 0.08) 
0.12 ± 0.03 
(0.06 - 0.16) 0.0002
‡
 
kPL  0.0152 ± 0.0041  (0.0094 - 0.0213) 
 0.0156 ± 0.0053 
(0.0061 - 0.0226) 0.71 
kPB 0.0014  ± 0.0008 ( 0.0003 - 0.0025) 
0.0030 ± 0.0008  
(0.0016 - 0.0044) 0.0006
‡
 
Table 5.6: Hyperpolarised 13C MRI metabolites in the glioblastoma and in the 
contralateral non-tumour bearing parenchyma - Multiple ROIs. 
The table shows the hyperpolarised 13C MRI metabolites within the glioblastoma 
and in a multiple circular region of interests of the same size drawn in the 
contralateral non-tumour bearing brain parenchyma. 
Normally-distributed continuous values are shown as mean ± standard deviation 
(minimum - maximum), non-parametric continuous values are shown as median ± 
median absolute dispersion (minimum - maximum). The level of significance 
between the glioblastoma and the contralateral non-tumour bearing parenchyma has 
been assessed with paired sample t-test (*) for normally distributed data and with the 
Wilcoxon signed rank test (★) for non-normally distributed figures. Level of 
significance was set at 0.05 and corrected with the false discovery rate (FDR) 
method using the Benjamini-Hochberg procedure as described in the text. Significant 





























Summed pyruvate 18.58 ± 11.12  (5.53 - 33.96) 
13.64 ± 7.25 
(5.16 - 22.96) 0.044
‡
 
Summed lactate 6.14 ± 3.55 (1.72 - 10.60) 
4.09 ± 1.84 
(1.58 - 6.16) 0.036
‡
 
Summed bicarbonate 1.03 ± 0.84 (0.28 - 2.74) 
1.50 ± 1.13 
(0.49 - 3.88) 0.013
‡
 
Corrected Lactate to 
Pyruvate ratio 
0.34 ± 0.06 
(0.24 - 0.46) 
0.33 ± 0.05 
(0.27 - 0.42) 0.704 
Corrected Bicarbonate 
to Pyruvate ratio 
0.06 ± 0.03 
(0.02 - 0.08) 
0.08 ± 0.03 
(0.06 - 1.04) 0.016
★‡
 
kPL  0.0161 ± 0.0057  (0.0094 - 0.0277) 
 0.0152 ± 0.0045 
(0.0071 - 0.0212) 0.600 
kPB 0.0022  ± 0.0009 ( 0.0003 - 0.0044) 
0.0028 ± 0.0013  
(0.0014 - 0.2940) 0.031
★‡
 
Table 5.7: Hyperpolarised 13C MRI metabolites in the glioblastoma and in the contralateral 
non-tumour bearing parenchyma – Hemisphere. 
The table shows the hyperpolarised 13C MRI metabolites within the glioblastoma and in the 
contralateral hemisphere. 
Normally-distributed continuous values are shown as mean ± standard deviation (minimum - 
maximum), non-parametric continuous values are shown as median ± median absolute 
dispersion (minimum - maximum). The level of significance between the glioblastoma and the 
contralateral non-tumour bearing parenchyma has been assessed with paired sample t-test 
(*) for normally distributed data and with the Wilcoxon signed rank test (★) for non-normally 
distributed figures. Level of significance was set at 0.05 and corrected with the false 
discovery rate (FDR) method using the Benjamini-Hochberg procedure as described in the 










Lateral Medial p values 
Summed pyruvate 19.81 ± 12.14  (3.15 - 50.57) 
17.27 ± 13.42 
(4.17 - 49.01) 0.108
‡
 
Summed lactate 5.77 ± 1.91 (1.44 - 10.64) 
3.51 ± 1.87 
(1.82 - 18.64) 0.028
★‡
 
Summed bicarbonate 0.86 ± 0.78 (0.22 - 1.43) 
1.13 ± 1.14 
(0.41 - 1.09) 0.034
★‡
 
Corrected Lactate to 
Pyruvate ratio 
0.32 ± 0.08 
(0.18 - 0.40) 
0.31 ± 0.09 
(0.35 - 0.47) 0.774 
Corrected Bicarbonate 
to Pyruvate ratio 
0.03 ± 0.02 
(0.02 - 0.06) 
0.06 ± 0.04 
(0.01 - 0.09) 0.0007
★‡
 
kPL  0.0141 ± 0.0045  (0.0083 - 0.0230) 
 0.0150 ± 0.0081 
(0.0201 - 0.0320) 0.497 
kPB 0.0011  ± 0.0006 (0.0002 - 0.0026) 
0.0020 ± 0.0015  
(0.0001 - 0.0048) 0.055
★
 
Table 5.8: Hyperpolarised 13C MRI metabolites in the glioblastoma. 
The table shows the hyperpolarised 13C MRI metabolites within the glioblastoma comparing 
ROIs obtained from the lateral and medial part of the lesion. Normally-distributed continuous 
values are shown as mean ± standard deviation (minimum - maximum), non-parametric 
continuous values are shown as median ± median absolute dispersion (minimum - 
maximum). The level of significance between the glioblastoma and the contralateral non-
tumour bearing parenchyma has been assessed with paired sample t-test (*) for normally 
distributed data and with the Wilcoxon signed rank test (★) for non-normally distributed 
figures. Level of significance was set at 0.05 and corrected with the false discovery rate 
(FDR) method using the Benjamini-Hochberg procedure as described in the text. Significant 














Summed pyruvate 14.84 ± 8.89  (5.15 - 30.81) 
12.83 ± 6.63 
(5.16 - 22.96) 0.119 
Summed lactate 4.76 ± 2.50 (1.57 - 8.39) 
4.09 ± 1.83 
(1.58 - 6.16) 0.100 
Summed bicarbonate 1.09 ± 0.60 (0.43 - 3.40) 
1.25 ± 0.53 
(0.49 - 3.88) 0.016
★‡
 
Corrected Lactate to 
Pyruvate ratio 
0.34 ± 0.05 
(0.28 - 0.40) 
0.34 ± 0.06 
(0.27 - 0.42) 0.945 
Corrected Bicarbonate 
to Pyruvate ratio 
0.08 ± 0.02 
(0.05 - 0.11) 
0.10 ± 0.03 
(0.06 - 0.16) 0.012
‡
 
kPL  0.0158 ± 0.0045  (0.0076 - 0.0228) 
 0.0156 ± 0.0046 
(0.0071 - 0.0212) 0.772 
kPB 0.0022  ± 0.0008 ( 0.0012 - 0.0038) 
0.0027 ± 0.0008  
(0.0014 - 0.0042) 0.029
‡
 
Table 5.9: Hyperpolarised 13C MRI metabolites in the non-tumour bearing brain parenchyma - 
cancer slice. 
The table shows the hyperpolarised 13C MRI metabolites in the non-tumour bearing brain 
parenchyma assessed in the slice containing the glioblastoma. Normally-distributed 
continuous values are shown as mean ± standard deviation (minimum - maximum), non-
parametric continuous values are shown as median ± median absolute dispersion (minimum - 
maximum). The level of significance between the glioblastoma and the contralateral non-
tumour bearing parenchyma has been assessed with paired sample t-test (*) for normally 
distributed data and with the Wilcoxon signed rank test (★) for non-normally distributed 
figures. Level of significance was set at 0.05 and corrected with the false discovery rate 
(FDR) method using the Benjamini-Hochberg procedure as described in the text. Significant 












Summed pyruvate 14.50 ± 7.15  (4.12 - 30.81) 
13.37 ± 5.70  
(3.71 - 22.96) 0.030
‡
 
Summed lactate 4.49 ± 2.14  (1.57 - 8.39) 
4.19 ± 1.76  
(1.58 - 6.94) 0.040
‡
 
Summed bicarbonate 1.17 ± 0.55  (0.43 - 3.40) 
1.25 ± 0.53  
(0.46 - 3.88) 0.001
★‡
 
Corrected Lactate to 
Pyruvate ratio 
0.33 ± 0.08  
(0.15 - 0.51) 
0.34 ± 0.08  
(0.18 - 0.52) 0.427 
Corrected Bicarbonate 
to Pyruvate ratio 
0.09 ± 0.03  
(0.04 - 1.00) 
0.10 ± 0.03  
(0.05 - 1.04) 0.000002
★‡
 
kPL 0.0153 ± 0.0052  (0.0074 - 0.0305) 
0.0154 ± 0.0051  
(0.0071 - 0.0305) 0.669 
kPB 0.0022 ± 0.0006  (0.0012 - 0.3266) 
0.0027 ± 0.0005  
(0.0014 - 0.2940) 0.044
★‡
 
Table 5.10: Hyperpolarised 13C MRI metabolites in the ipsilateral and contralateral 
hemisphere. 
The table shows the hyperpolarised 13C MRI metabolites in the non-tumour bearing brain 
parenchyma assessed in the slice containing the glioblastoma. Normally-distributed 
continuous values are shown as mean ± standard deviation (minimum - maximum), non-
parametric continuous values are shown as median ± median absolute dispersion (minimum - 
maximum). The level of significance between the glioblastoma and the contralateral non-
tumour bearing parenchyma has been assessed with paired sample t-test (*) for normally 
distributed data and with the Wilcoxon signed rank test (★) for non-normally distributed 
figures. Level of significance was set at 0.05 and corrected with the false discovery rate 
(FDR) method using the Benjamini-Hochberg procedure as described in the text. Significant 
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The work presented in this thesis is a selection of the projects I 
conducted in Cambridge studying towards my PhD under the phenomenal 
supervision and tutelage of Dr Ferdia A. Gallagher. Having the chance of 
working under Dr Gallagher guidance has been instrumental for my 
development as a researcher in molecular imaging, as a clinician and as a 
person. I choose to build my academic career in imaging because I strongly 
believe that novel imaging techniques have an unparalleled potential in neuro-
oncology and will significantly shape this field. Currently, conventional proton 
MRI is a requisite for glioma detection, grading, assessment of tumour 
extension, monitoring and assessment of response to treatment. Moreover, 
image guidance is routinely used for biopsy, resection and radiotherapy 
targeting. However, MRI has significant limitations, for example in assessing 
response to treatment or monitoring disease progression. Novel techniques 
have the potential of overcoming such limitations providing functional, 
metabolic and micro-architectural information that can further exploit the 
underlying tumour biology. A new generation of superior imaging biomarkers 
could radically change the management of both lower-grade and high-grade 
tumours. In these final remarks I will summarise some of the content from the 
previous chapters to highlight how this thesis could foster a new generation of 
non-invasive biomarkers. 
6.1 Grading, extension and tumour microenvironment 
Current grading of glioma is largely based on tissue analysis which is 
invasive and can delay the diagnosis for several weeks. The time window 
Chapter 6   
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between the baseline MRI and subsequent surgery is very variable. Lesions 
can grow over this period of time, sometimes requiring a complete change in 
treatment plan; for example, a resection might be transformed following a 
stereotactic biopsy if the lesion grows to infiltrate eloquent areas. Also, the 
wait for surgery can be emotionally and psychologically devasting for patients 
and families. The three techniques presented in this thesis could all play a 
significant role in non-invasive detection, grading and assessment of 
infiltration of the surrounding tissue. 
VERDICT MRI probes the tumour microstructure in an unprecedented 
way. The quantification of the intracellular and the combined 
extracellular/vascular volume is important on both a biological and a clinical 
level. I have shown that high-grade gliomas exhibit a higher intracellular 
volume fraction compared to lower-grade glioma and a corresponding smaller 
extracellular/vascular volume fraction. Also, cancer cells in high-grade glioma 
are larger than in lower-grade lesions and VERDICT is able to non-invasively 
assess the average size of cells in a given voxel. Combining this information 
in the future could be used to determine the area expressing the highest 
grade within the lesion, to predict the grade and to guide either biopsy and 
treatment.  
I have demonstrated that tissue sodium concentration is increased in 
both lower-grade glioma and high-grade glioma but the ion is present in 
different compartments in the two. The development of a sequence to quantify 
the intracellular sodium concentration has demonstrated that the intracellular 
sodium concertation is significantly different between different grades, 
allowing for a quantitative tool to infer grading from imaging. Moreover, 
sodium MRI can assess the peritumoral zone highlighting foci of altered 
metabolism beyond the boundaries defined by conventional proton imaging. 
Hyperpolarised carbon-13 MRI is the most challenging of the 
techniques presented in this thesis. Despite the challenges, it has been used 
to directly assess metabolic activity in cancer cells. In our cohort, the lack of a 
significant increase of the lactate to pyruvate ratio, the currently most used 
biomarker, challenged the concept that malignant cells are glycolytic. My data 
suggested that the aerobic glycolysis in glioblastoma is similar if not lower 
than in the normal appearing brain parenchyma which is surprising. Similarly, 
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I demonstrated a lack of bicarbonate production in the lesions. However, there 
was a high degree of heterogeneity both within and between the tumours: the 
heterogeneity can reflect different clusters of cells having a different metabolic 
behaviour, again opening up the possibility of improving the localization of the 
most malignant focus (or foci) for a more refined image guidance. Similarly to 
sodium MRI, hyperpolarised carbon-13 MRI provides metabolic information 
from the peritumoral zone facilitating the localization of cancer cells outside 
the conventional boundaries. Despite the small number of patients recruited 
for this study, we were able to demonstrate the presence of cancer cells in an 
area of normal signal intensity on proton imaging outside the tumour in one 
patient. 
Ideally, a multiparametric MRI combining advanced proton imaging 
(such as DTI and perfusion imaging) with the above described techniques, 
could achieve better performance in the diagnosis of gliomas. 
6.2 Treatment response and prognostication  
The assessment of response to therapy is currently based on the 
revised RANO criteria using the assessment of post-gadolinium T1-weighted 
imaging and T2-weighted or FLAIR imaging. Relying on two-dimensional 
measurements in an era where volumetric analysis is increasingly automated 
seems anachronistic and prone to errors due to inter- and intra-operator 
variability. Nevertheless, the biggest limit of the RANO criteria is that the 
definition of true progression requires the follow-up to be undertaken 3 
months following completion of chemoradiation unless the progression is 
outside the field of radiation of there is pathological confirmation. This time 
window is long considering that the survival for patients with glioblastoma is 
often below 12 months. Novel biomarkers are required to assess response 
earlier than this and in more reliable ways, potentially measuring the effects of 
the treatment directly.  
Cytoreductive therapies induce necrosis in the target tissue. 
Notwithstanding the relative proportion of intracellular and extracellular 
volume at baseline, an increase in necrosis will lead to a decrease in the 
former and an increase in the latter. VERDICT MRI can reliable observe this 
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shift in relative volumes and could be used to detect necrosis as soon as it 
develops  
An increase in necrosis could be easily and quickly detected by an 
increase in the tissue sodium concentration with a simultaneous decrease of 
the intracellular sodium concentration. Serial sodium scans can monitor the 
ion concentration and detect changes as early as a few hours after cells start 
to die. Moreover, this is a quantitative biomarker and semiautomatic software 
can be incorporated to obtain a numeric result at the time of the imaging test. 
In this thesis, sodium MRI has also been tested as a prognostic tool. Several 
biomarkers have been shown to successfully predict survival at baseline 
providing a useful information for treatment selection and modulation.  
Hyperpolarised carbon-13 MRI may also play a significant role in 
assessing therapy response. Indeed, preclinical studies showed a decrease of 
metabolic activity, measured with the lactate to pyruvate ratio, within a few 
hours after starting treatment. This could be a very early imaging biomarker of 
response to therapy and could allow for immediate cessation of a non-
responsive therapy and a switch to another approach within days rather than 
months.  
6.3 The future of HP 13C MRI 
Hyperpolarised carbon-13 MRI has been the major focus of my 
research over the past 4 years. Many limitations have been overcome during 
that time, and a vast body of knowledge has been produced by the centres 
currently spearheading this technique. However, many open issues remain 
outstanding. I personally gained a fair amount of insight about this fascinating 
new tool that could potentially revolutionize the way we look at metabolic 
reprogramming in cancer and beyond. Therefore, a more detailed discussion 
of the future of the technique is provided below with some reflections made 
during my PhD. 	
6.3.1 MRI hardware developments for hyperpolarisation 
Despite the large increase in signal-to-noise that is generated by DNP, 
both the hardware and acquisition sequences required have to be optimised 
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to avail of this increased signal. Dedicated 13C coils are needed for the 
technology: current research being undertaken aims to optimize coil design 
and pulse sequences to maximize the signal acquired. For example, the use 
of multiple-channel coil arrays can enable parallel imaging techniques to 
accelerate acquisition while retaining sensitivity (Tropp et al., 2011). 
Calibrationless methods have been shown to overcome the limitations of the 
short-lived hyperpolarized species in this context (Feng et al., 2016). 
There have been several different imaging schemes proposed for the 
acquisition of hyperpolarized 13C data (Schmidt et al., 2008; Durst et al., 2015; 
Gordon et al., 2017). A key component of most sequences is the use of single 
shot, multiple time point acquisition to acquire dynamic, metabolite-specific 
data (Gordon et al., 2017). The differences mainly involve encoding efficiency, 
gradient demand and artefact behaviour: non-Cartesian trajectories are more 
efficient but are prone to artefacts (Durst et al., 2015). The choice of the 
optimal sequence depends on the spatial and temporal resolution desired and 
the number of different chemical species to be resolved. Future developments 
in this area will involve assessing and improving intersite reproducibility of the 
data acquisition methods.  
6.3.2 Pharmacy requirements and developments in 
formulation 
The current approach for the consumables for the clinical polariser 
requires a local sterile production facility to fill pharmacy kits which can be 
costly to establish. A more practical approach may be the development of a 
large, centralised, filling facility where pharmacy kits could be frozen and 
transported to other sites. There are a number of country-specific regulatory 
issues that need to be addressed for the production and transport of these 
filled pharmacy kits at each site which needs to be considered before 
developing a programme of research locally.  
If hyperpolarized 13C-MRI is to be more widely used, it needs to be 
accessible for non-specialist centres. To improve availability, there is ongoing 
research in the area of long-lived polarised states and transport of pre-
polarised molecules. Although this area is still in the early stages of 
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development and some way from clinical translation, it could potentially open 
up the possibility of hyperpolarizing molecules centrally and transporting them 
to the imaging site without the need for a local polariser.  
6.3.3 New hyperpolarized tracers 
Hyperpolarized 13C-labelled tracers offer unique opportunities to probe 
many metabolic pathways. Although many hyperpolarized tracers have been 
developed, very few have the necessary biological, chemical and physical 
properties required for successful translation into human imaging. Table 6.1 
summaries some of the tracers which have clinical potential and provide 
biologically useful information. As discussed above, [1-13C]pyruvate has been 
used to probe LDH and PDH activity and similarly, [1-13C]lactate can be used 
to probe LDH; however [1-13C]pyruvate cannot be used to probe the 
tricarboxylic acid (TCA) cycle as the label is not incorporated into acetyl CoA 
(Chen et al., 2008): [1-13C]pyruvate oxidation mediated by PDH releases the 
hyperpolarized 13C as 13CO2 and therefore the production of acetyl CoA and 
incorporation into the Krebs cycle cannot be studied. In contrast, [2-
13C]pyruvate allows downstream metabolites such as acetyl carnitine, citrate 
and glutamate to be detected (Schroeder et al., 2009, 2013) [2-13C]pyruvate 
can assess metabolism in tissues where PDH activity is high such as the 
heart, by probing oxidative metabolism through the Krebs cycle rather than 
anaerobic glycolysis and lactate formation (Schroeder et al., 2009). 
13C-Urea has been utilised to probe tissue perfusion but unlike 
conventional perfusion tracers, is a small endogenous molecule (Svensson, 
2003; Svensson et al., 2003). A number of potential issues has been identified 
with gadolinium-based contrast agents recently such as accumulation in the 
brain with repeated use (Kanda et al., 2015; McDonald et al., 2015); 
consequently, hyperpolarized urea may provide an alternative method to 
image tissue perfusion with a physiologically relevant molecule (Chen et al., 
2008). 13C-Urea could also be used to study tissue oxygenation as has been 
shown in both the healthy and diabetic rat kidney (Reed et al., 2014; Laustsen 




Tracer Name Biological Relevance 
[1-13C]Pyruvate LDH and PDH activity 
[2-13C]Pyruvate LDH, PDH, TCA activity 
[1-13C]Lactate LDH activity 
[1-13C]Acetate TCA activity and fatty acid oxidation 
[1-13C]Glutamine Glutaminolysis 
[13C]Urea Tissue perfusion 
[1,4-13C2]Fumarate Cellular necrosis 
	
Table 6.1: Some of the tracers currently being investigated and their biological relevance. 
 
Hyperpolarized [1,4-13C2]fumarate has been proposed as a positive 
contrast agent for detecting successful treatment response and tissue 
necrosis. [1,4-13C2]fumarate is exchanged to [1,4-13C2]malate in the presence 
of the enzyme fumarase. The intracellular enzyme is released into the 
extracellular space following necrosis allowing enzymatic conversion of 
fumarate to malate (Gallagher et al., 2009b) This has been demonstrated in 
tumours and in acute kidney injury (Nielsen et al., 2017). 
One important advantage of HP 13C-MRI over PET imaging is that it 
allows multiple probes to be injected either sequentially or simultaneously so 
that several metabolic pathways can be studied at a single time point. 
Although dual PET probe injection has also been undertaken, the modelling  
required to differentiate these probes is complicated by perfusion, metabolism 
and excretion and is often impractical; furthermore, conversion into metabolic 
products cannot be detected (Ho et al., 2007). In comparison, HP 13C-MRI 
has the advantage of discriminating probes and their metabolites by virtue of 
differences in chemical shift: therefore, metabolism of molecules injected 
simultaneously can be directly compared. This has been demonstrated in 
several pre-clinical models and has the potential to be applied to humans in 
the future (Witney et al., 2010). 
6.3.4 Image analysis and quantification 
Robust quantification of HP 13C-MRI will be important for the 
repeatability and reproducibility of the technique. Given that the technique 
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probes exchange or flux between two metabolic pools, there are many 
analogies between the approaches taken for HP 13C-MRI and those used in 
PET and DCE-MRI. Several methods have been proposed to reliably and 
reproducibly quantify the pyruvate-lactate exchange reaction: kinetic 
parameters can be fitted to model-based approaches such as the two-site 
exchange model which are the most accurate; simpler model-free approaches 
such as the area under the curve (AUC) of the lactate-to-pyruvate ratio and 
the lactate time-to-peak may adequately represent the reaction and may be 
more suitable for widespread clinical use (Day et al., 2007; Daniels et al., 
2016; Siddiqui et al., 2016). Further challenges of the technique include the 
segmentation of tumour from normal tissue which is compounded by the low 
resolution and SNR of the data. However, by fully utilising the 5-dimensional 
nature of HP 13C MRI – including spatial, temporal and spectral information – 
segmenting areas of high metabolic exchange from low exchange can be 
greatly facilitated and these approaches could be used for automated and 
reproducible delineation of tumour regions in the future (Gallagher and 
Daniels, 2017).  
6.3.5 Hyperpolarized 13C-MRI with PET/MRI  
Since its introduction in clinical practice, PET/CT has found many 
clinical applications due to the combination of metabolic (PET) and anatomical 
(CT) information (De Galiza Barbosa et al., 2016). 18F-FDG PET/CT is a 
powerful tool for staging and treatment response monitoring in a wide range of 
cancers such as lung cancer and lymphoma (Czernin et al., 2013; Parodi, 
2015). The recent creation of hybrid systems combining PET and MRI have 
capitalized on the inherent advantages of MRI over CT such as the lack of 
ionizing radiation, functional imaging capabilities, spectroscopy and improved 
soft-tissue contrast (Sotoudeh et al., 2016; Ehman et al., 2017). Several 
clinical applications have been proposed for PET/MRI (Nensa et al., 2014; 
Fraum et al., 2016): in oncology, examples include head and neck cancers, 
liver tumours and pelvic malignancies which may significantly benefit from the 
hybrid approach due to improvements in co-registration and reduction in 
movement artefact (Blechacz et al., 2011; Cheung et al., 2013; Lee et al., 
	
 195 
2014; Kang et al., 2016; Schaarschmidt et al., 2016) PET/MRI has also 
demonstrated potential in organs such as the lung where traditionally MRI has 
only had a limited role, highlighting the potential of the combination of those 
two techniques (Schmidt et al., 2013; Fraioli et al., 2014; Schaarschmidt et al., 
2017). 
PET/MRI could provide a powerful tool for imaging tumour metabolism. 
While 18F-FDG is a highly sensitive measure of metabolism and has many 
applications, it simply measures glucose uptake and phosphorylation and 
therefore provides only an indirect measure of the Warburg effect (Gambhir, 
2002; Vaupel and Mayer, 2007; Binderup et al., 2010). In contrast, 
hyperpolarized 13C-MRSI is capable of monitoring the uptake of 13C-pyruvate 
and its conversion into 13C-lactate (or 13C-alanine and 13C-bicarbonate) 
enabling real-time in vivo imaging of metabolism and a more direct measure 
of the Warburg effect (Golman et al., 2006; Kurhanewicz et al., 2008; 
Gallagher et al., 2009a). Combining PET/MRI with 13C-MRI provides the 
opportunity to study cancer metabolism in conjunction with other MR 
measures of tumour structure, function and heterogeneity (Gutte et al., 
2015b). A recent study reported the simultaneous acquisition of 18F-FDG PET 
and 13C-MRI using a PET/MRI system in 10 dogs (Gutte et al., 2015c). This 
demonstrated that, although there is a strong correlation between uptake of 
FDG and pyruvate conversion to lactate, there are areas of mismatch 
between the two techniques confirming the potential added value of 
combining the two techniques (Gutte et al., 2015c, a). For instance, increased 
accumulation of 18F-FDG with low lactate production would indicate oxidative 
metabolism, while increased accumulation of 18F-FDG and high lactate 
production would indicate aerobic glycolysis secondary to the Warburg effect. 
Therefore, by combining the data of the two techniques the accuracy in 
disentangling oxidative inflammatory cell metabolism from reductive 
metabolism in cancer cells would be improved. 
Simultaneous acquisition also provides the possibility of using data 
from one technique to improve the other. For instance, the use of MRI data 
has already been proven to enhance the spatial resolution of PET 
reconstructions (Bailey et al., 2018) and the use of integrated PET/MR system 
has been proven to achieve better image registration, resulting in more 
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accurate anatomical localization (Sotoudeh et al., 2016). In the clinical setting, 
PET is often used as a simple static scan to assess the steady state uptake of 
a target tissue e.g. by using the maximum standardised uptake value of a 
lesion. However, dynamic image acquisitions are feasible and provide 
additional information on the metabolic activity of the target tissue or lesion. 
Complex kinetic models are frequently used to estimate the wash in, 
metabolism, and wash out of the tracer, which may require dynamic blood 
sampling to quantify the concentration of the tracer in the blood; these 
approaches may cause discomfort and lack of compliance (La Fougère et al., 
2011). Perfusion MRI, with or without the intravenous administration of a 
gadolinium-based contrast agent, is a non-invasive technique to assess the 
perfusion dynamics of the normal brain and of gliomas. For instance, 
perfusion MRI can aid in differentiating true progression, pseudoprogression, 
pseudoresponse and radionecrosis (Suh et al., 2018a), with the potential of 
being used as a decision-making tool in the clinical management of patients 
with glioblastoma (Suh et al., 2018b). Acquiring a perfusion-weighted 
sequence shortly before the injection of the radiotracer provides valuable 
information on the blood flow reaching the lesion, the time the flow reaches its 
peak (time-to-peak) and the amount of blood volume contained within the 
lesion. This information could be used to model the kinetic of the radiotracer 
and of the hyperpolarised pyruvate improving the quantitative nature of those 
techniques and tailoring the models to the specific target tissue. Moreover, the 
simultaneous acquisition of PET and HP 13C-MRI, and the potential use of a 
single MR perfusion acquisition to model the delivery of both probes could 
ensure that the metabolic state is unchanged between the two acquisition 
ensuring comparability. Glioblastomas for instance grow rapidly and have a 
high degree of hypoxia that influences the metabolic state and may change 
day-by-day. A hybrid acquisition ensures that PET and MRI information is 
obtained simultaneously, and would there is no potential bias due to changing 
metabolic states of the lesion. 
Technically, acquiring HP 13C-MRI simultaneously during the PET 
acquisition does not have any significant effect on the PET signal. A phantom 
study demonstrated that using a flip angle of 29º, the error estimation of PET 
quantitative data is < 2% (Hansen et al., 2016). This flip angle corresponds to 
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the Ernst angle and was deliberately chosen as far larger than the flip angles 
actually used in the clinical studies. Our group have used flip angles between 
10º and 15º for all the clinical studies and therefore the error is likely to be 
lower in a real clinical scenario.  
Beside 18F-FDG, a wide range of tracers could be used with this 
combined hyperpolarized 13C-MRI/PET approach such as the amino acid 
analogues 11C-methyl-L-methionine (MET) and O-(2-[18F]fluoroethyl)-L-
tyrosine (FET) in brain tumours for diagnosis and therapy assessment 
(Galldiks et al., 2017). This combination could be important in the 
management of some cancers and certain population groups where 
longitudinal monitoring is required or where dose reduction is important such 
as children or women of reproductive age (Gutte et al., 2015c). Combined 
hyperpolarized 13C-MRI/PET studies are currently being undertaken at a 
number of sites. 
As HP 13C-MRI is in its infancy and rapidly evolving, the projected long-
term costs of the technology are difficult to accurately evaluate. Hardware 
costs will reduce in time if there is increased demand for hyperpolarisation 
approaches. The author believes that in the future the costs for undertaking 
such studies could be similar to those currently for PET imaging. These costs 
could be defrayed by the clinical benefits and treatment cost savings if the 
technique is shown to have unique applications, particularly if ineffective but 
expensive therapies can be discontinued. Given that MRI is more widely 
available than PET in most hospitals, HP 13C-MRI could become an important 
additional clinical tool if unique applications are revealed.  
6.4 To infinity and beyond 
 Advances in imaging will pave the way for better outcomes from 
personalised care and identification of new targets. In particular, sodium MRI 
and hyperpolarised carbon-13 MRI can exploit the metabolic activity of 
tumours in ways that were not feasible previously. This can lead to the 
identification of overexpressed ion channels, that could be selectively target. 
Understanding in vivo tumour biology may become a new role for the imaging 
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of tomorrow, especially in cancers such as glioblastomas in which animal 
models are failing to represent the heterogeneity of the in human disease.  
6.5 Future work 
 There is an urgent need for adoption of novel techniques into clinical 
trial design, to avoid under- or overestimation of response to treatment and to 
develop new drugs. The novel techniques presented here are exceptionally 
promising but more data is required for validation before a wider adoption 
could be promoted. Developing new techniques is technically challenging but I 
believe that the work conducted over the past 4 years has lead to a point 
where these techniques can be reliable used in a research setting. The 
sequences have been developed, tested and perfected over multiple 
iterations; similarly, the pipeline for post-processing and image analysis have 
been streamlined and it is now quite robust and reliable. Therefore, the next 
step must be trial setup with higher recruitment targets, a comprehensive 
pathological assessment and collection of follow-up data to confirm the 
preliminary findings of this thesis and validate the techniques.  
Moreover, over the course of my PhD I come to realise that many other 
neurological and neurosurgical conditions would be ideal candidates for one 
or a combination of these techniques. Now that acquisition, post-processing 
and image analysis are robust enough, new areas of research should be 
explored. For instance, over the course of my PhD I assessed both sodium 
MRI and VERDICT MRI in other primary and secondary brain tumours as a 
proof of concept or simply because some presumed glioblastomas turned out 
to be metastases. Therefore, trials assessing brain metastases or other 
primary tumours of the central nervous system would be easy to implement. 
Over the next few years I aim to continue working in molecular imaging 
both in neuro-oncology than in other neurological application. A pilot project 
on secondary brain tumours is pending ethics approval in my current 
institution and, hopefully, will start by the end of the year. Moreover, I hope to 
continue to oversee with Dr Gallagher the recruitment of high-grade glioma 
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into the MISSION:GliomaS study that has been developed in the first year of 
my PhD and allows for multinuclear imaging of patients with gliomas.  
6.6 Concluding remarks 
My PhD has been a long journey from the writing of the research 
protocol and submission to the Ethical Review Board to the final draft of this 
thesis, through development, validation and initial translation of novel MRI 
techniques for the assessment of patients with gliomas. The data presented in 
this thesis are a proof of that long journey from the first sodium MRI we 
undertook in Cambridge in 2015 to the 65th patient recruited in October 2018. 
I also explored other novel techniques in a very limited number of patients; 
those data are not featured in this thesis due to the limited nature of these 
proof of concept studies. Nevertheless, the three main pillar of my work 
presented in this thesis are the finish line of my PhD but also, and more 
importantly, the starting point of a new chapter for imaging research in glioma 
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understanding of gliomas and win the fight against one of the most aggressive 
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